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Abstract
With the spread of drug-resistant bacteria, existing antibiotics are losing their
potency. Antimicrobial peptides (AmPs) represent an exciting class of drug candidates,
particularly because their mechanism of action is unlikely to induce drug resistance. If
resistance to AmPs were also slower to emerge in the clinic, they would have longer
useful lifetimes than existing antibiotics. Nevertheless, a number of limitations exist for
AmPs in the clinic. The high cost of peptide manufacture requires that highly potent
sequences are created. Additionally, AmP selectivity must be improved if effective
systemic doses are to be given without hemolytic activity or other toxicity. Improved
high-throughput methods for AmP design or discovery could enable the achievement of
both of these goals. To this end, we developed an approach based on the discovery of
semi-conserved motifs across natural AmPs, which we demonstrated are associated with
antimicrobial activity. Additionally, we created novel AmP formulations that may
bypass some of these clinical limitations.
In order to evaluate AmP design approaches, a high-throughput production and
assay platform was created using in vitro translation. This technology may produce
peptides that would be toxic to recombinant hosts and synthesize peptides of arbitrary
length. The cost per peptide was minimized through a series of process improvements.
First, we created methods to construct oligonucleotides that mimicked our motif-based
design of AmPs. This approach allowed the reuse of primers for many peptides, reducing
cost and enabling the study of pattern synergy. Additionally, we found peptide
translation was enhanced by co-translating a fusion partner in frame with the AmP. The
AmP could be freed from the fusion partner after translation using enterokinase digestion.
Further, we increased yield 3-fold by optimizing the length of fusion partner. The partner
was made as short as possible to limit the translational resources required to synthesize
the fusion partner, while being long enough to ensure stability from proteases. The
solubility of the fusion partner-AmP construct was also improved through the selection of
a highly soluble partner of the optimal length. Finally, we developed a purification
scheme to ensure that the in vitro translation extract would not impact measurement of
antimicrobial activity.
We also developed and evaluated the design of AmPs using semi-conserved
motifs. We used a database of over 500 natural AmPs as a training set for pattern
discovery. The resulting motifs were exhaustively recombined to create all 20 amino
acid sequences that were entirely covered by these patterns. These sequences were
clustered, and 42 diverse members selected for characterization using representative
Gram negative and Gram positive bacteria. Approximately 50% of the designed AmPs
were active against at least one of the bacteria at 256 ug/ml. Control peptides were
created in which the amino acids in the designed peptides were rearranged such that they
were not homologous to any antimicrobial motifs. Thus, these controls had the same
bulk physiochemical properties frequently associated with antimicrobial activity as the
designed sequences, but we hypothesized they would not be active because they did not
match the antimicrobial motifs. In fact, only 5% of the control sequences had activity at
256 ug/ml, indicating that the antimicrobial motifs give a 10-fold enrichment in activity.
Further, two highly active designed peptides had MICs of 16 ug/ml against Bacillus
cereus and 64 ug/ml against Escherichia coli. Additionally, AmPs active against B.
cereus were all active against the hospital pathogen Staphylococcus aureus, and the
bioterror agent, Bacillus anthracis.
Our motif-based design may be most effective as the first stage of a two-stage
design tool. In the first stage, highly diverse leads with novel profiles are created and
evaluated. Promising leads could then be optimized using a variety of techniques. By
creating just 44 variants of one lead, we designed an AmP with broad spectrum activity
that had MICs of 16 ug/ml against E. coli and 8 ug/ml against B. cereus and 4 ug/ml
against S. aureus. Another approach to build on our design tool would be to incorporate
activity and toxicity characteristics of members of the training set into the design or
scoring of new sequences. In order to begin assembling this data using a standardized
method, a representative set of 100 natural, linear AmPs was chosen through clustering.
Their antimicrobial activity against E. coli, S. epidennidis, and S. aureus were evaluated,
along with hemolytic activity. When further supplemented, this information may enable
an improved scoring metric to be created. Additionally, we systematically demonstrated
that amidating the c-terminus of natural AmPs improves both antimicrobial activity and
therapeutic index.
Finally, we recognized that AmP's mechanism of action would allow activity to
be retained when they are permanently tethered to medical device surfaces. Unlike
existing coatings which rely on the slow release of silver or other antibiotics, a
permanently tethered approach could have a longer lifetime and reduced systemic
toxicity concerns. A versatile chemistry was developed to create immobilized AmP
coatings. These formulations had broad spectrum antimicrobial activity without
significant hemolytic activity. Further, the coatings were effective through multiple
bacterial challenges. The combination of the AmP design tool along with localized
formulations represent a significant advance in the process of moving AmPs to the clinic
to combat drug-resistant infections.
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Chapter 1
Introduction
1.1 Motivation
The discovery of penicillin in 1928 marked the beginning of the antibiotic era, in
which an array of life-saving drugs have been developed. Nevertheless, no new classes
of antibiotics were produced between 1962 and 2000, with only one created since (Coates,
Hu et al. 2002). In fact, many researchers suggest that the number of intracellular targets
for antibiotic discovery are being exhausted (Schmid 2006). Improved methods are
needed for the design or discovery of antibiotics with novel mechanisms of action.
The emergence of drug-resistant bacteria has heightened the urgency of antibiotic
discovery. The incidence of methicillin-resistant Staphylococcus aureus (MRSA)
infections, frequently responsible for hospital infections, increased from 32% to 45%
over just 3 years starting in 1994 (Lowy 2003). These infections raise hospital costs and
increase patient mortality. For example, in a study of orthopedic surgery patients,
hospital time increased from 11 days to 88 days if a patient carried MRSA (Tai, Nirvani
et al. 2004). Additionally, MRSA is now spreading in community settings (Hisata,
Kuwahara-Arai et al. 2005). The threat from hospital infection increases as strains
emerge which are resistant to the antibiotics that are our last line of defense.
With the waning efficacy of existing antibiotics, there is a critical need for new
drugs that kill bacteria through alternate mechanisms. Antimicrobial peptides (AmPs) are
a particularly attractive class of molecules because they work through a unique
membrane-targeting approach. Further, because this killing mechanism non-specifically
targets bacterial membranes, drug resistance is unlikely (Boman 2003). For this reason,
if AmPs with suitable clinical properties were developed, they would represent a more
sustainable approach to battling infection, with a longer useful lifetime than traditional
antibiotics. Significant challenges remain in the commercialization of AmPs, with
improvements required in antimicrobial activity, safety, and stability. Novel design
approaches, coupled with innovations in delivery or formulation, will be critical for
clinical success.
Antimicrobial peptide discovery has largely been carried out by screening
organisms for new sequences, or optimizing existing natural peptides (Hilpert, Volkmer-
Engert et al. 2005; Mygind, Fischer et al. 2005). These approaches only search a narrow
portion of sequence space that is tightly constrained around the set of natural AmPs.
They ignore the overwhelming majority of the space comprised of active antimicrobial
sequences, which may contain AmPs that have superior properties. We sought to create a
method to efficiently search this broader space. In order to accomplish this, we created a
design tool that would discover semi-conserved motifs across natural AmPs. We then
used these motifs to design novel peptides with limited homology to known sequences.
We sought to optimize leads generated through this search and develop applications.
1.2 Objectives and approach
At the outset of this work, two objectives were proposed:
1. Create an in vitro translation production scheme for AmPs. Due to the
high cost of chemical synthesis of peptides at the start of this work, we sought
to create an automatable, high-throughput production and assay system for
AmPs. Our goal was to develop a robust system that would produce sufficient
material to test antimicrobial activity against 2 bacteria at up to 16 ug/ml. In
order to accomplish this, a platform using in vitro translation was created.
Through a series of improvements including creating a combinatorial DNA
design approach, optimizing co-translated fusion partners, and improving
solubility, the system became cost-effective.
2. Develop a pattern-based design approach for AmPs. In order to explore a
region of sequence space that is diverse relative to the set of natural AmPs, we
desired a design method that used semi-conserved rules derived from natural
sequences. We sought to evaluate these designs against a series of clinically-
relevant bacteria. To accomplish this, a pattern discovery tool was applied to
the set of natural AmPs. The patterns discovered were used to design new
sequences through an exhaustive combinatorial method. Predicted sequences
were validated against representative gram-negative and gram-positive
bacteria before testing against Staphylococcus aureus and Bacillus anthracis.
Leads were optimized to demonstrate the utility of the pattern-based approach
as the first stage of a two-stage design tool.
Since this work commenced, two additional objectives have been developed:
3. Enable improved design through database characterization. For the
designs carried out in Objective 2, we used a database of natural AmPs as a
training set. This database had no information about the activity spectrum or
toxicity of these AmPs, limiting the activity and selectivity of our designs. To
provide more informative data, we clustered the set of linear natural AmPs
and selected approximately 100 for characterization. Their antimicrobial
activities against 3 bacteria and hemolytic activity were evaluated. Further,
we demonstrated that amidating the C-terminus of AmPs systematically
improved antimicrobial activities and therapeutic indices.
4. Develop medical device applications for AmPs. Through interactions with
members of the Boston hospital community, we found that catheters and
implants are frequently associated with hospital infections. Unlike existing
antimicrobials which must be released to reach their targets inside of bacteria,
AmPs target the bacterial membrane. Thus, AmPs could be active when
permanently tethered on a medical device surface. We demonstrated the
broad spectrum activity of AmPs permanently attached to medical devices
surfaces through a flexible chemistry. Additionally, the surface was shown to
kill through repeated bacterial challenges and was not significantly hemolytic.
The specific activity of the surface was enhanced by controlling the
orientation of peptides during immobilization. A team was assembled and a
company formed to exploit the opportunities created by this research.
1.3 Thesis organization
An overview of antimicrobial peptides, along with their role in innate immunity,
is given in Chapter 2. Additionally, existing methods for discovering and designing
AmPs are presented, along with their clinical application. Chapter 3 describes a high-
throughput method for synthesizing and assaying AmPs. The development and
optimization of a platform based on in vitro translation is given. A pattern-based
approach to design AmPs with significant diversity relative to natural AmPs is detailed in
Chapter 4. Further, Chapter 5 demonstrates that this design tool may serve as the first
stage of a two-stage design tool, in which heuristic methods are used to optimize lead
sequences in the second stage. Also, the groundwork is laid for improvement of the
design tools by characterizing the antimicrobial activity and toxicity of natural AmPs,
which could be used in an enhanced scoring system during design. Chapter 6 describes
applications of AmPs in medical device coatings, with preliminary formulations given.
Finally, Chapter 7 suggests future work for improving AmP activity through an iterative
design approach.
Chapter 2
Antimicrobial Peptide Overview
Although the first antimicrobial peptide, nicin, was discovered in 1928, the
majority of our knowledge about the diversity and mechanisms of action of AmPs has
emerged in the last 30 years (McPhee, Scott et al. 2005). Antimicrobial peptides
represent an exciting class of antibiotic candidates, particularly because their method of
attack is unlikely to induce drug-resistant bacteria. First, the role of AmPs in innate
immunity is described. Next, the classes of AmPs and their mechanism of action are
presented. Finally, an overview of existing methods for AmP discovery and challenges
remaining in the development of AmPs as antibiotics are given.
2.1 Antimicrobial peptides in nature
AmPs are ubiquitous among multicellular eukaryotes and are found in diverse
contexts including frog skin, scorpion venom, and human sweat. AmPs act as a first line
of defense against bacterial invaders. In the following sections, the natural properties of
AmPs are described to give background on their clinical potential. These properties
include the AmP's native role in immunity, structures, mechanism of action, and
susceptibility to drug-resistance.
2.1.1 AmPs in innate immunity
AmPs play a variety of protective roles in host defense. First, AmP may directly
kill microbial invaders (Papagianni 2003). This defense mechanism is particularly
important in protecting the crypts of the intestine from infection (Lehrer 2004). Recent
studies show that some AmPs have activity against pathogens that are resistant to
traditional antibiotics including penicillin, tetracycline, and vancomycin (Tiozzo, Rocco
et al. 1998). AmPs may also be useful in treating certain cancers (Ellerby, Arap et al.
1999; Kim, Kim et al. 2003) or preventing viral infection (Zhang, Yu et al. 2002; Owen,
Rudolph et al. 2004).
A common technique to study the roles of AmPs in immunity is to examine
organisms deficient in AmP activity. The loss of AmP function has been reported to lead
to a number of disorders in animals and humans. For instance, the inactivation of AmP
protection in the altered lung ion concentrations in cystic fibrosis patients leads to
increased bacterial infection (Goldman, Anderson et al. 1997). Additionally, mice
deficient in cathelicidins suffer necrotic skin infections (Nizet, Ohtake et al. 2001). The
lack of the human cathelicidin has also been implicated in Morbus Kostmann syndrome,
which typically leads to lethal infections in childhood (Putsep, Carlsson et al. 2002).
Susceptibility created by the breakdown of AmP defenses implicates their role in the
protection of a variety of tissues.
Recently, the opportunity to use antimicrobial peptides to modulate the immune
system has been investigated (Finlay and Hancock 2004; Brown and Hancock 2006). For
example, AmPs can lead to histamine and cytokine release (Befus, Mowat et al. 1999;
Zaiou 2007). Additionally, natural peptides may play a role in lipopolysaccharide
neutralization, preventing sepsis (Ciornei, Sigurdardottir et al. 2005). Neuropeptides
have also been suspected to be both message transmitters for immune response and
directly antimicrobial agents (Metz-Boutigue, Kieffer et al. 2003; Brogden, Guthmiller et
al. 2005). As research continues, it is clear that short cationic peptides play a variety of
roles in host defense, with direct killing representing just one mode of action. This has
lead to the concept that AmP may be used clinically as immune adjuvants or treatments
for sepsis.
2.1.2 Classes of AmPs
Natural AmPs occur in a great variety of plants, animals, and bacteria. Because
of the sequence diversity that exists within AmPs, they are often classified based on
structure, which is often linked to evolutionary relatedness. Broadly, they can be
classified as alpha-helical, beta-sheet, extended, looped, single-disulfide, multiple-
disulfide, and rich in unusual amino acids, such as proline or histadine (Andreu and Rivas
1998; Jenssen, Hamill et al. 2006). Natural AmPs may also contain alterations including
glycosylation, disulfide bonds, and unnatural amino acids. The spectra of antimicrobial
activity overlap heavily between classes, with peptides from disparate classes playing
similar roles in host defense. A number of classes have been investigated as leads for
drug design, with the ease of manufacture and stability being key criteria that
differentiate the classes. Structures of representative antimicrobial peptides from a
number of these classes are given in Figure 2.1.
(A)
(D)
(B) (C)
(E)
J
(F)
Figure 2.1: Structures of representative AmPs of different structural classes. A.
Multiple-disulfide, human beta-defensin-2; B. Looped, thanatin; C. Beta-sheet,
polyphemusin; D. Multiple-disulfide, rabbit kidney defensin- 1; E. Alpha-helical,
magainin-2; F. Extended, indolicidin. Figures reproduced from (Jenssen, Hamill et al.
2006).
2.1.3 Mechanism of action
The many disease-relevant behaviors of antimicrobial peptides are a consequence
of their ability to broadly distinguish eukaryotic cells from pathogenic invaders. In
general, AmPs have a net positive charge and an amphipathic 3-D structure that gives the
peptides an electrostatic affinity to the outer-leaflet of the microbial membrane
(Giangaspero, Sandri et al. 2001). This affinity leads to binding, disruption of the
membrane, and ultimately microbial cell death (Shai 2002). Studies with model
membranes, coupled with computational simulations have yielded insights on subtle
differences in the way the disruption occurs (Drin, Cottin et al. 2003; Leontiadou, Mark
et al. 2006). Model mechanisms include the barrel-stave model, in which multiple
peptide form an aqueous pore, the toroidal pore model in which lipids may partially line
the pore, and the carpet mechanism, in which a high local density of AmPs destabilizes
the membrane without pore construction (Yeaman and Yount 2003). The mechanism of
action of alpha-helical peptides is depicted in Figure 2.2.
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Figure 2.2: Alpha-helical AmP structure and mechanism of action. Illustration of an
alpha-helical peptide (left) which segregates hydrophobic residues on one side of the
helix and positively charged residues on the other side. Cartoon of the proposed
membrane disruption mechanism of AmPs. First, the positively charged residues are
attracted to the negatively charged bacterial membrane surface. Next, the hydrophobic
residues allow the peptide to penetrate and destabilize the membrane. Cell death may
result directly from loss of membrane integrity, or secondary internal target for the AmP
may be involved in killing. Figure designed by JF Moxley.
Further analysis of the interaction of AmPs and bacteria has revealed a variety of
killing mechanisms. In addition to membrane disruption, a variety of AmPs have
revealed internal targets. One peptide, buforin II, kills through binding to DNA without
lysing the membrane (Park, Kim et al. 1998). The lantibiotic, mersacidin, inhibits lipid II
formation in biosynthesis, a similar mechanism to vancomycin (Brotz, Bierbaum et al.
1998). Additional mechanisms have been reported for individual peptides, including
flocculation of intracellular contents, blockage of septum formation, inhibiting protein or
DNA synthesis, or inhibiting enzyme activity (Brogden 2005). Nevertheless, the
majority of killing activity is thought to arise through membrane disruption. This
bactericidal attack has attractive characteristics for drug development.
Additional activities have been reported for AmPs that stem from their ability to
discriminate between the cell surfaces of different classes of cells. Antifungal activity is
largely thought to occur through similar mechanisms as antimicrobial activity, including
membrane permeabilization and lysis (Tytler, Anantharamaiah et al. 1995; Lee, Hahm et
al. 2004). Antiviral activity is less well understood than antimicrobial action, but may
occur through direct envelope disruption (Jenssen, Hamill et al. 2006). For instance,
indolicidin directly inactivates HIV by targeting its envelope (Robinson, McDougall et al.
1998). Among other antiviral mechanisms suggested are AmPs ability to bind heparin
sulfate on mammalian cell surfaces and block viral interaction with specific cellular
receptors (Tamamura, Ishihara et al. 1996; Jenssen, Andersen et al. 2004). Anti-tumour
activity may result from increased surface concentration of phosphatidylserine, which
AmPs may target (Utsugi, Schroit et al. 1991). The mechanism is known not to be
specific because D-amino acid peptides have equivalent efficacy (Kamysz, Okroj et al.
2003). Since membrane recognition is a critical steps in all of these mechanisms, it may
be possible to adapt an AmP design tool to a variety of targets.
2.1.4 Antibiotic resistance
AmPs and bacteria have been in contact for hundreds of millions of years.
Detailed analysis of the modest mechanisms of resistance that have developed indicates
that AmP's nonspecific attack on a range of low-specificity targets imposes a significant
evolutionary cost for making changes that reduce susceptibility (Peschel and Sahl 2006).
In fact, hundreds of passages at sub-inhibitory concentrations of pexiganan, an alpha-
helical AmP, were required to induce resistance in a clinical resistance evolution assay
(Perron, Zasloff et al. 2006). Under identical conditions, 30 passages of sub-inhibitory
passages increased the MIC of an AmP only 2-4 fold, whereas the MIC of gentamicin, an
aminoglycoside, increased 190 fold (Marr, Gooderham et al. 2006). If a mixture of
peptides are delivered together, experts believe resistance is highly unlikely (Boman
2003). If the development of resistance to AmPs in the clinic is also slow relative to that
of traditional antibiotics, a given AmP therapeutic may have a longer useful lifetime.
2.2 Screening for AmPs
The potential of AmPs as antibiotics has been recognized by researchers over the
last 30 years. One approach to exploit this potential is through the development of
activity screens for AmPs. In the following sections, both screens of natural organisms,
as well as evaluations of random amino acid sequences will be described.
2.2.1 Screening of natural organisms
Through the screening of natural organisms for the presence of antimicrobial
peptides, a database of more than 500 natural sequences has been developed (Wang and
Wang 2004). One insight that improved the effectiveness of screening was to identify
organisms or tissues that are frequently exposed to pathogenic environments without
becoming infected. This approach led to the identification of a series of AmPs from the
skin of frogs, including the magainin class of compounds (Zasloff, Martin et al. 1988).
Other groups have discovered a variety of amphibian AmPs through similar searches
(Park, Jung et al. 1995; Conlon, Sonnevend et al. 2005). A related strategy has been
applied to marine animals to discover other groups of antibiotics (Silphaduang and Noga
2001; Shike, Lauth et al. 2002). Additional isolation studies have revealed two classes of
AmPs in humans: cathelicidin in neutrophils and defensins in Paneth cells (Zasloff 2002).
Fungi are a particularly rich source for screening, and Novozymes is developing a drug
candidate, Plectasin, which resulted from this screening (Mygind, Fischer et al. 2005).
Nevertheless, screening organisms is a painstaking method to produce drug candidates.
2.22 Unguided approaches to produce AmPs
The enormity of sequence space for 20 amino acids long peptides (10A26
sequences) is a formidable challenge if one attempts to experimentally create AmPs from
random sequences. Regardless of this, a few attempts have been made. One technique
enables the inducible expression of peptides within an E. coli host (Walker, Roth et al.
2001). A screen is undertaken with and without an inducer of peptide expression present,
and those colonies whose growth is inhibited by peptide are selected as leads. In a screen
of 20,000 colonies, 21 were found that had an inhibitory effect. In this screen, however,
the peptides are already within the target host cell. In order for a peptide to be effective
as a therapeutic, it must be able to disrupt or transverse the cell membrane, a trait for
which this screen does not select. Additionally, the peptides are over-expressed at high
concentration within the cell, which may not be practically achievable through delivery.
An improved method for screening utilized a heterologous system in which AmPs
are produced in one organism and excreted, with their activity measured as a zone of
inhibition created for a second organism. In this work, E. coli containing a plasmid
library is grown on solid media to produce colonies, and then transferred to a second
plate containing solid media and an inducer (Raventos, Taboureau et al. 2005). The E.
coli colonies are overlaid with a target indicator strain, and colonies are selected that
produce large zones of inhibition. This approach still relies on plasmids produced by
random mutagenesis, so the search space is limited to the neighborhood of the parent
sequence. Further, AmPs must not be toxic to the host strain, limiting their spectrum of
activity.
An alternative approach to unguided design focuses on the development of short
peptides through a greedy algorithm that establishes one position at a time along the
length of the peptide. In this work, all possible hexa-peptides were produced within
mixtures by allowing all but the left-most amino acids to be unspecified (Houghten,
Pinilla et al. 1991). To synthesize these, an equimolar mixture of all amino acids was
used at each unspecified position. In a step-wise process, one additional amino acid on
the left portion of the peptide was chosen by evaluating the activity of each of 20 amino
acids at the position being examined, with the remaining unspecified amino acids left as
mixtures. Ultimately, an "optimal" active 6-mer was produced. This unguided approach
places great weight on the first few amino acids in a sequence, and would not be expected
to converge to a global optimum peptide, particularly for longer sequences. In fact, no
peptides identified through combinatorial approaches have reached clinical trials
(Koczulla and Bals 2003). These methods have been adopted for anti-viral application
and to optimize a longer known peptide of 18-amino acids (Blondelle, Takahashi et al.
1996; Boggiano, Reixach et al. 2003). These applications, however, are tightly confined
to sequence space around the starting AmP.
2.3 Rational Design and Optimization of AmPs
As more information has been generated on natural AmPs, rational methods for
AmP design have been developed. As described in the following sections, promising
lead sequences may be optimized. Alternatively, computational designs may be executed
using 3-dimensional templates such as an alpha-helix. Finally, methods for the
computational analysis of highly conserved clusters of sequences have been invented to
improve activity.
2.3.1 Mutations around natural AmPs
A variety of heuristic techniques have been developed to improve the activity of
natural antimicrobial sequences. One of the more common approaches is to increase the
positive charge of the peptide to improve affinity for a bacterial membrane (Falla and
Hancock 1997). Increasing hydrophobicity may also enhance the ability of the peptide to
penetrate the lipid bilayer, and may further improve membrane affinity when positive
charge is increased as well (Wu and Hancock 1999; Park, Kim et al. 2004). The addition
of unnatural amino acids, fluorine atoms, and N-acylation have also been shown to
strengthen activity (Wakabayashi, Matsumoto et al. 1999; Gimenez, Andreu et al. 2006).
A methodical approach to improving activity was executed by systematically creating all
single amino acid mutations of a known AmP sequence (Hilpert, Volkmer-Engert et al.
2005). All of these techniques produce sequences that are tightly confined to sequence
space surrounding the starting AmP.
Strategies have also been created to address the developmental obstacles faced by
AmPs as drug candidates. First, the cost of manufacturing peptides limits the length of
peptide that may feasibly be created at a clinical scale. For this reason, researchers have
sought to identify short active regions of natural AmPs by creating truncations of natural
AmPs (Lupetti, Paulusma-Annema et al. 2000; Won, Jung et al. 2004; Rotem,
Radzishevsky et al. 2006). This approach has been extended by substituting a lipid tail
for a portion of the antimicrobial peptide, allowing further shortening (Makovitzki,
Avrahami et al. 2006). Another challenge for AmPs as systemic drugs is that high
selectivity is needed if therapeutic doses are to be given. Multiple strategies, including
limiting the hydrophobicity of the peptide, have been used to improve an AmP's
selectivity for bacterial over mammalian cells (Yan, Li et al. 2003; Asthana, Yadav et al.
2004; Chen, Mant et al. 2005). A third challenge for development is the stability of the
peptide to natural proteases. Single amino acid mutations may significantly improve
peptide stability (Owens and Heutte 1997). Modifications may also include the
introduction of non-natural amino acids (Ryge, Doisy et al. 2004). While these
techniques may improve the clinical characteristics of an AmP marginally, these efforts
do not significantly enhance the diversity of sequences available for evaluation.
2.3.2 Computational approaches to AmP design
One simple computational approach to design AmPs is to select members of an
antimicrobial database that have unique desirable properties and to create hybrid peptides
by linking the two peptides end to end. For instance, it was discovered that while
cecropin only has antimicrobial activity against gram-negative bacteria, adding a portion
of melittin, which has gram-positive activity, yields sequences which are active against
both (Boman, Wade et al. 1989; Andreu, Ubach et al. 1992). This strategy has been
applied to a series of peptide families (Hongbiao, Baolong et al. 2005; Ferre, Badosa et al.
2006).
Additionally, computational tools have been used to identify short active regions
of peptides as drug leads. Secondary structure prediction tools have been applied to
known peptides, such as CAP18 to determine helical regions, which were verified to have
activity (Tossi, Scocchi et al. 1994). Database scanning tools also have been used to find
regions of peptides which are highly charged and likely to adopt helical structures
(Zelezetsky, Pag et al. 2005). A helical propensity predictor, AGADIR, has been applied
to the human AmP, LL-37, to identify shorter linear regions that display antimicrobial
activity (Sigurdardottir, Andersson et al. 2006). While these tools help focus development
within a set of natural peptides, the do not create significantly novel sequences.
An alternative approach to AmP design is to start with a helical projection of a
peptide and place amino acids around the helix to give desired amphipathicity. In a de
novo study, an amphipathic 12-mer composed only of arginine and valine was used as a
base unit for design (Deslouches, Phadke et al. 2005). It was found that at least a 24
amino acid long helix was required for activity, with no improvement gained by using
longer sequences. This approach has been extended to allow the variation of sequence,
size, charge, structuring, amphipathicity, and hydrophobicity in controlled studies (Tossi,
Sandri et al. 2000; Giangaspero, Sandri et al. 2001). The de novo design of cyclic
sequences having improved stability was carried out using a similar strategy (Frecer, Ho
et al. 2004). While these approaches produce interesting leads, they are limited to purely
helical peptides. Many powerful, natural AmPs, however, are non-helical, and not all
helical peptides are active.
More sophisticated tools have been applied to design or optimize peptides based
on their structural properties or folds. Novozymes applied Quantitative Structure-
Activity Relationship (QSAR) analysis to a class of variants based on novispirin . They
discovered that the volume-surface ratio and charged partial surface area were key
descriptors to predict activity (Taboureau, Olsen et al. 2006). Nevertheless, this type of
analysis is most appropriate within a highly conserved set of sequences. An alternative
analysis was used to find conserved three dimensional structure across a diversity of
sequences (Yount and Yeaman 2004). This approach was also limited to a set of
disulfide containing peptides for which three dimensional structure was known. Each of
the computational methods focused on a known subset of natural peptides or limited to
one 3-dimensional motif.
2.4 AmPs as antibiotics
The broad spectrum activity of many antimicrobial peptides, coupled with their
reduced susceptibility to drug resistance, make them exciting drug candidates. In the
following sections, the progress to date on the development of AmPs as antibiotics is
discussed. Additionally, the remaining challenges which must be overcome before AmPs
enter clinical use are outlined.
2.4.1 AmPs in clinical development
AmPs are under development for a variety of topical and systemic applications.
The first peptide to undergo clinical trials was pexiganan, a derivative of magainin, for
the topical treatment of diabetic foot ulcers (Jacob and Zasloff 1994). This candidate
performed virtually identically to the oral antibiotic standard of care and had little
toxicity (Lamb and Wiseman 1998). Unfortunately, the drug was rejected due to a high
baseline of improvement based on debridement of the ulcer site alone. Nevertheless,
these clinical studies demonstrated the topical safety of an AmP and an efficacy that was
approximately equal to oral treatment.
Since the development of pexiganan, AmPs have entered development for a
variety of applications. Due to the ability of AmPs ability to bind lipopolysaccharide,
sequences are being studied for septic shock treatment (Kirikae, Hirata et al. 1998; Shu,
Shi et al. 2006). Additionally, AmPs have been created for the treatment of pneumonia
(Steinberg, Hurst et al. 1997). AmPs are also being developed for oral indications
including mucositis (Loury, Embree et al. 1999). One peptide, enfuvirtide, has been
approved for treating HIV (Holguin, Faudon et al. 2007). Finally, peptides are also being
studied because they have synergistic effects with traditional antibiotics (Giacometti,
Cirioni et al. 2000; Hancock and Patrzykat 2002; Cirioni, Silvestri et al. 2006). This
approach has the potential to extend the lifetimes of existing drugs for which drug
resistance has limited their potency. A summary of peptides undergoing clinical
development are shown in Table 2.1.
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Table 2.1: Antimicrobial peptides currently in development. A variety of AmPs are
in preclinical or clinical development for topical, oral, or systemic use. This Table is
reproduced from (Zasloff 2002).
2.4.2 Current difficulties in development
There are a number of clinical challenges facing antimicrobial peptide
development. First, all peptide therapeutics are subject to kidney clearance, which
reduces half-life (Lien and Lowman 2003). Strategies to improve circulation times
include the conjugation of PEG (Monkarsh, Ma et al. 1997). Peptides may also be
susceptible to proteases, but this may be averted by including D-amino acids (Hamamoto,
Kida et al. 2002). Peptides are also generally not stable for oral delivery, so most peptide
therapeutics require IV administration. However, improvements have been made in
transdermal delivery, with or without electrophoresis (Henry, McAllister et al. 1999;
Kanikkannan, Singh et al. 1999). Additionally, techniques for delivery via inhalation and
stabilized oral formulations are under development (Bot, Smith et al. 2001; Leone-Bay,
Sato et al. 2001).
Depending on the required dose, the cost of manufacture may limit drug
development (Zhang and Falla 2006). Chemical synthesis scales with the length of the
peptide being produced, and depending on the dose of drug required, is not feasible for
peptides longer than 35 amino acids (Latham 1999). Recombinant and transgenic
approaches represent economic alternatives for large scale production. In fact,
Novozymes has already developed recombinant means to produce plectasin, a promising
antimicrobial peptide drug candidate (Mygind, Fischer et al. 2005). Despite these
obstacles, peptide drugs have had success for a variety of applications. A sampling of
peptides that are approved or in clinical trials are shown in Table 2.2.
Drug Company Source IndIeations Phase'
Plenaxis" Praecis Pharmaceuticals Natural (naR) Prostate cancer NDA filed
(http://www.praecis.com)
Endometriosis 11411
Apan" Prascis Pharmaceuticals Natural $.amyloid) Alzheirnees disease I
Iseganan IntraBiotics (http'/iwww.intrabiotics.com) Natural (proterin) Respiratory infection in
Pneumonia 11411
Exubra* Inhale (http://www.nektarcom); Natural (insulin) Diabetes type I and 11 Ill
Pfizer (http:/wVww.pfizer.com);
Aventis Pharmaceuticals (http://ww.avents.comj
Oral insulin NOBEX (http'J/www.nobexcorp.com); Natural (insulin) Diabetes type land 11 it
GlaxoSmithKline (http://www.gsk.com)
Oratonin" NOBEX Natural (calcitonin) Osteoporosis
Oral calcitonin Emisphere (http://www.emisphere.com); Natural (calcitonin) Osteoporosis
Novartis (http://www.novartls.com)
Oralin" Generex (http://www.generex.com) Natural (insulin) Diabetes type I and 11 II11IC
HER-2/neu vaccine Corixa (http://www.corixa.com) Natural (HER-2neu) Breast and ovarian cancer I
FUZEON" Trimeris (http:/www.trimeris.com) Natural (gp4ll AIDS Approved
T-1249 Trimeris Natural (HIV2, SIV, gp4l) AIDS I/I
Symlin* Amylin (http://www.amyIin.com) Natural (amylin) Diabetes type land 11 lip
Exendin-4 Amylin Natural (glucagon-like peptide) Diabetes type It I
Lupron depot'* Takeda Abbott Pharmaceuticals Natural (GnRH, LH-RH) Prostate cancer Approved
(http/Mtww.takuda~co.plindex.e.html)
Endometriosis Approved
NAbbatvuaponr og nw dRug inetalonon.NCompa i nt p d
% Canada.
Table 2.2: Peptide therapeutics approved or in clinical trials. Peptides are
undergoing trials or approved for a variety of indications. Table reproduced from (Lien
and Lowman 2003).
In addition to the challenges faced by all peptide therapeutics, specific obstacles
exist for antimicrobial peptides. Antibiotics typically require large doses if used
systemically in order to maintain a therapeutic concentration throughout the body. This
exacerbates the cost of manufacturing obstacle for AmP development. Further, large
doses imply that a highly selective molecule is used in order to avoid toxicity. For these
reasons, the first successes for an AmP in the clinic may involve topical or localized
applications.
2.5 Summary
Their unique bactericidal mechanism of action gives AmPs great promise as
antibiotics. Existing approaches for screening for or optimizing natural peptides have not
produced candidates which have had clinical success. The barriers to this success,
however, are not overwhelming. Cost, activity, selectivity, and stability must each be
improved on the margin. Design tools that enhance the diversity of sequences from
which researchers may choose will be critical for finding sequences that have the
appropriate clinical properties. Further, creative solutions in drug delivery or localized
applications may sidestep some toxicity or stability barriers.
Chapter 3
In vitro Translation of AmPs
A number of methods exist for the production of peptides for research or
commercial purposes. These approaches vary in terms of their cost, yield, and purity of
peptide that can be produced. Some methods also allow the incorporation of unnatural
amino acids. Additionally, certain approaches are more easily adaptable to the high-
throughput production of a diversity of sequences. In this chapter, the available
production methods will be reviewed. Next, the selection criteria for the high-throughput
screen we are developing will be outlined. The improvements made to minimize costs
and optimize yield will be discussed. Finally, work towards an automatable high-
throughput platform will be described.
3.1 Approaches to peptide synthesis
Although a variety of approaches are available for the synthesis of peptides, there
are several drawbacks for making a great diversity of sequences or sequences longer than
30 amino acids. Chemical synthesis using Fmoc chemistry gives high yields and purity
(Amblard, Fehrentz et al. 2005). Nevertheless, chemical synthesis is quite costly
(Latham 1999). Also, the purity of chemically synthesized peptides falls as the sequence
length increases, and labor intensive HPLC is needed to remove undesired products that
are truncated or include deletions. Furthermore, the success of chemical synthesis is
highly sequence dependent and the purities of some peptides are very low (Carreno,
Mendez et al. 2000).
Existing in vivo approaches for peptide production are also not optimal for
activity measurement. Phage display libraries inexpensively produce an array of peptide
combinations, but they are better suited to biopanning screens than to structure or activity
determination (Hoess 2001). If measurements for rationally designed peptides are
desired, these screens are not appropriate. Alternatively, recombinant production can
give significant yields, but require cloning and fermentation steps (Latham 1999).
More attractive for drug discovery are in vitro translation methods, which may
quickly and cheaply produce a wide variety of peptides in parallel without cloning and
fermentation (Spirin, Baranov et al. 1988; Jewett and Swartz 2004). In vitro translation
allows the high-throughput production of many proteins or peptides, including those that
would be toxic to a host cell (Sawasaki, Ogasawara et al. 2002).
3.2 Overview of in vitro translation
In vitro (or cell-free) translation is a process in which all of the translational
machinery is purified from a cell so it can be used to create a specific protein of interest.
This can be accomplished by two methods. First, one can take a crude ribosomal extract
from cells, and add the appropriate amino acids and energy sources to produce a
functional system. Commercial kits have been established using both E. coli and wheat
germ. Additionally, the creators of the PURE system individually tagged and purified the
components involved in translation and can custom assemble them to give an active
translation mixture (Matsuura, Yanagida et al. 2007). While this system excludes
proteases and other cell products, it is more expensive than extract-based systems.
In vitro translation systems have a number of advantages relative to recombinant
production of desired proteins. First, DNA directly from a polymerase chain reaction
(PCR) can be expressed without a cloning or fermentation step. Additionally, the
purification of the product is simpler because cell lysis and separation of membrane from
internal components is not needed. In vitro translation is also well adapted for the high-
throughput production of custom sequences, assuming that the DNA encoding the desired
product may easily be obtained (Ozawa, Headlam et al. 2004; Spirin 2004). Individual
reactions may be run in separate wells of 96 well plates so the protein produced in each
well is known (Busso, Kim et al. 2004; Nakano, Kawarasaki et al. 2004). Since 96 well
plates may be used, an in vitro system may easily be integrated into an assay if a high-
throughput activity screen is available (Sawasaki, Ogasawara et al. 2002). Methods have
even been developed in which random mutagenesis yields a library of DNA which is
diluted to one strand per well, a PCR reaction is run in situ, and in vitro translation is
carried out (Rungpragayphan, Kawarasaki et al. 2002; Rungpragayphan, Nakano et al.
2003). Finally, products that would be toxic to a microbial host may be produced in a
cell-free system.
Recent advances have continued to address the shortcomings of in vitro
translation systems. Commercial products are now available for plasmid or linear
templates which may even be used for proteins with disulfide bonds (Roche Applied
Sciences, 4349741001). Additionally, extracts have been developed with altered genetic
codes so that unnatural amino acids can be incorporated (Josephson, Hartman et al. 2005).
Additional improvements have come from optimizing the energy sources for translation
or recycling energy sources. Much of the insight in this work has been to mimic the
environment of the cell (Jewett and Swartz 2004). In light of these improvements, in
vitro translation has become a viable option for the high-throughput screening of proteins
or peptides.
3.3 Desired properties for high-throughput screen
In order to create a cost-effective and efficient high-throughput screen, a number
of design criteria are desirable. First, a sufficient concentration of peptide must be
synthesized to test against a range of bacteria in clinically relevant concentrations. For
this application, we would like to test against 2 bacteria (one gram-positive and one
gram-negative) at up to 16 ug/ml. In vitro translation has the potential to fulfill these
requirements, but we will have to tailor it for the production of peptides and optimize
yield.
Ideally, methods for generating peptides should be suitable for automation using
robotics. This requires that synthesis is carried out in parallel, preferably in a 96-well
plate format. Using in vitro translation, individual oligos that are custom synthesized or
created through error prone PCR may be added to unique wells of a 96 well plate,
amplified, and used in situ for translation. This requires that the synthesis process is
robust, without delicate parts or procedures. For this reason, a batch translation process
is superior to popular semi-continuous methods in which translation is carried out within
a fragile dialysis membrane so that a reservoir of energy sources and amino acids may be
accessed in order to improve yield. A diagram of a semi-continuous in vitro translation
system is given in Figure 3.1. Ultimately, a robust batch system with high yields would
be desired for our platform.
Cell-free system
Dialysis Membrane
Figure 3.1: Semi-continuous in vitro translation. In semi-continuous translation, the in
vitro extract is placed within a vial with a dialysis membrane on the bottom. This vial is
floated within a larger bath containing additional amino acids and energy sources for
translation. The dialysis membrane cutoff is selected such that proteins in the extract are
retained, but undesired poisons that are produced during translation may exit, and fresh
translation resources may enter. This system typically gives higher yields than a batch
system, but is less suitable to 96 well plate automation.
3.4 Combinatorial DNA design and synthesis
In order to produce uniquely designed AmPs, custom oligonucleotides (oligos)
are required. Despite improvements in custom oligonucleotide synthesis, ordering
individual oligos for each peptides would constrain the number of sequences that may be
evaluated. In the following discussions, a method to produce oligonucleotides encoding
custom AmPs will be described, followed by a series of improvements that reduce the
cost of this approach by mimicking our design methodology in the construction of the
oligos.
3.4.1 Initial methods for DNA construction
Despite significant recent progress, challenges do remain in the production of
peptides by in vitro methods. Peptides translated on their own are typically degraded
(Pilon, Yost et al. 1997). In fact, most peptides expressed naturally are produced as part
of larger protein constructs, which are digested to release the free peptides after
translation, or are made using non-ribosomal peptide synthesis. This knowledge has led
researchers to express peptides as fusions with other proteins in order to achieve stable
production (Terpe 2003). In this Thesis, any protein or protein fragment that is co-
translated in frame with a peptide will be referred to as a fusion partner.
In our initial studies of antimicrobial peptide design, just a few peptides were
produced, and they were only assayed at concentrations up to 10 ug/ml to look for highly
active sequences. Thus, for these studies synthesis cost and yield were not critical factors.
An in vitro translation system was used in which the antimicrobial peptide of interest was
translated in frame with Green Fluorescent Protein (GFP). The GFP fusion partner was
used both to ensure stable protein accumulation and for quantification.
The DNA encoding the desired GFP-AmP constructs was created by removing
the GFP with T7 upstream region from the pQB 136 plasmid. A primer was used to add
an enterokinase recognition site between the GFP and AmP so the AmP could be freed
after translation. DNA encoding AmPs was created by designing overlapping sets of
primers that code for the desired peptide. The AmP and GFP sections were then
combined by a PCR reaction which takes advantage of homology designed into the two
pieces. After final purification and amplification, the DNA constructs were validated by
sequencing. This procedure is shown in Figure 3.2.
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Figure 3.2: Proof-of-concept scheme to create DNA templates for in vitro translation
of AmPs. A Green Fluorescent Protein (GFP) fusion partner used for quantification is
taken from the pQBI36 vector with a T7 promoter region. In order to minimize cost,
primers of 50 amino acids or less are linked together through a series of PCR reactions in
order to create DNA coding for a unique AmP, along with an enterokinase recognition
site (ERS) used to digest the AmP from the GFP following translation. The DNA
segments coding for the GFP and AmP are linked with PCR using overlapping portions
of the ERS to create the final template.
3.4.2 Drawbacks with prior methods
The above method has a number of shortcomings that limit its applicability for a
high-throughput screen of antimicrobials. First, the process is costly for each AmP
synthesized and would be prohibitively expensive to scale up. Multiple unique primers
must be designed for each AmP produced. At the beginning of this Thesis work, each
AmP would require more than two hundred dollars in primers. Additionally, overlapping
regions are required for the PCR process. Primers must painstakingly be designed for
each unique sequence to ensure that an appropriate melting temperature is achieved and
problems will not arise from misalignment or the formation of secondary mRNA
structure. It would not be practical to find individual conditions for each PCR step,
which would not produce undesired side-products. Additionally, during the construction,
DNA must be purified and amplified between each step.
3.4.3 Combinatorial DNA construction
In order to enable a more cost-effective screen, an improved method for
generating oligonucleotides was desirable. We devised a more efficient strategy based on
the insight that the pattern-based design method could be mimicked within DNA
synthesis. In the following section, this design approach is described, followed by two
sections providing experimental methods to construct these oligonucleotides.
3.4.3.1 Combinatorial oligonucleotide design
A critical goal for an in vitro translation based screen would be to reduce the cost
of the oligos used. A dramatic reduction in cost could be accomplished if oligos were
reused for multiple AmPs of interest. A combinatorial approach would be particularly
suited to our application: designing AmPs based on patterns associated with antimicrobial
activity. While a full description of the AmP design is given in Chapter 4, our approach
essentially consists of linking antimicrobial patterns in unique ways to create active
AmPs with novel profiles or to study the synergy of these patterns. Oligos could be
designed that code for individual patterns, which could be treated as substructures, that
could be combined using a variety of methods.
In order to accomplish this combinatorial production, the DNA coding for
antimicrobial peptides were designed in two substructures, A and B as shown in Figure
3.3. A number of unique DNA sequences were synthesized for piece A and a different
set of sequences were synthesized for piece B. The ends of the oligonucleotides for
pieces A and B have overlapping and complementary codes which allow any strand A to
be attached to any strand B through PCR. As mentioned above, antimicrobial patterns
cover the region of overlap between the substructures. Thus, in separate wells of a 96-
well plate, each A may be combined with each B to produce all possible A-B
combinations. From a total of N types of A or B substructures, this technique would
yield NA2 antimicrobial peptides, which would allow the exploration of a large portion of
sequence space.
Our peptides were initially designed to have a final length of 22 amino acids.
This is within the range of naturally occurring AmPs, which typically are 20-50 amino
acids long. Each A substructure was composed of nucleotides coding for 14 amino acids,
with the first 8 amino acids being allowed to vary in each unique A. The last 6 amino
acids overlap with B and were conserved between variations of A. Likewise, the first
portion of each B were the complement of the overlapping region of A, and the remaining
nucleotides code for 8 variable amino acids. An overlap of 6 amino acids, or 18
nucleotides, were long enough to ensure that when the PCR reaction is carried out to join
substructures A and B, misalignment between A and B was unlikely. This design
approach has the benefit that each unique DNA sequence could be constructed and
translated in an individual well, so no separations processes would be needed.
A potentially more powerful synthesis method could be explored which would
lead to a much larger set of peptides produced. Rather than creating just two
substructures per peptide, 3 or 4 units could be used so that the number of combinations
increases many orders of magnitude. As with the design using two substructures,
patterns would cover the length of the peptide, including the regions of overlap that
connect the substructures. A 3 or 4 unit methodology would allow us to accomplish our
goal of creating thousands of antimicrobial sequences from a small set of peptide
substructures. These peptides could also be synthesized in individual wells to eliminate
the need for separations.
Additionally, this approach would allow the exploration of synergistic behavior
between patterns and lead to an improved design methodology. Each of the substructures
used to create the longer peptides could be synthesized and tested for activity. The
substructures could be chosen to be varied in terms of their charge density,
hydrophobicity, and fold. The combinatorial design approach would allow us to
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investigate the cooperativity of antimicrobial sequences. This could lead to improved
design if patterns with certain characteristics are discovered to complement one another.
The length of the substructures could also be varied to see if there exists an optimal size
of peptide for antimicrobial activity. A diagram of the combinatorial design approach
used to economically create an array of AmPs of interest is shown in Figure 3.3.
A variable A conserved
B conserved B variable
A variable Conserved B variable
1 2 4 6 8 9
Patterns
A-1 Cons. B-1 A-1 Cons. B-N
A-2 Cons B-1 A-1 ConS. B-N
A-N Cons. B-1 A-N Cons. B-N
Figure 3.3: Combinatorial DNA design method mimicking pattern-based AmP
design approach. AmPs will be designed with two distinct variable regions, A and B,
both of which are entirely covered by antimicrobial patterns. A conserved region, used
for linking A and B, will also be covered by patterns. N variations of section A and N
variations of section B will designed, which may be linked through a conserved region to
give N2 unique combinations entirely covered by patterns. This approach will allow the
cost-effective synthesis of a large number of sequences and analysis of the synergy of
antimicrobial patterns.
3.4.3.2 Combinatorial oligonucleotide synthesis
The cost of synthesizing the nucleotide sequences for thousands of peptides in the
range of 20-50 amino acids would be prohibitively high if each sequence were made
individually. Nevertheless, most naturally occurring AmPs fall within this size range, so
a method to create peptides of this length with little expense would be very valuable. In
order to dramatically decrease costs for the production of novel peptides, combinatorial
methods may be used to synthesize large numbers of unique peptides, which are designed
to have antimicrobial activity.
As described in Section 3.4.3.1, the peptides may be designed in substructures,
which could be combined to produce longer sequences covered by antimicrobial patterns.
Details of the oligonucleotide synthesis procedure are shown in Figure 3.4. For peptides
composed of two substructures, part A consisted of 42 nucleotides. The first 24
nucleotides coded for the 8 amino acids that vary between peptides, while 18 nucleotides
overlapped with strand B and coded for 6 amino acids that were conserved in all peptides.
Similarly, part B was composed of the complement to these 18 nucleotides, followed by
24 nucleotides coding for unique amino acid sequences. Antimicrobial patterns covered
the entire 22 (8+6+8) amino acid sequence that were produced. Additionally, a T7
promoter, ribosome binding site, and start codon were attached on the upstream end of
each of the A strands for use during transcription. A stop codon and transcription
termination signal were placed downstream of each B strand. The oligonucleotides A
and B were short enough that they could be synthesized inexpensively.
The substructures were combined using individual polymerase chain reactions. In
separate microwells, each unique A substructure we designed was mixed with each
unique B substructure and run through 30 PCR temperature cycles (95-(Tm-10)-72 'C,
where Tm is the melting temperature of the overlapping region). An error-correcting pfu
enzyme was used for the reaction to minimize the number of misalignments that occurred.
The resulting DNA constructs were sequenced to ensure proper synthesis. This
combinatorial approach to creating oligonucleotides will be cost effective and amenable
to automation. A diagram of this process is shown in Figure 3.4.
Sample AmPs were designed using this combinatorial approach and synthesized
using the above methods. A combination of 3 unique part A's were combined with 2
unique Part B's as a proof of concept. Correct synthesis was validated by DNA
sequencing. The sequences used are shown in Figure 3.5.
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Figure 3.4: Combinatorial DNA synthesis method mimicking pattern-based AmP
design approach. AmPs designed using the strategy shown in Figure 3.3 will be
synthesized using PCR accomplished through a conserved 18 amino acid overlap region
between variable chains. A T7 promoter and ribosome binding site (RBS) will be ligated
upstream of all A regions, and a transcription terminator will be attached downstream of
all B regions. This approach yields a cost-effective synthesis of N2 unique peptides from
the creation of only 2*N antimicrobial segments.
Al - Bi
Cgateccgegaaattaatacgactcactataggggaattgtgagcggataacaattcccetetagaaataattttgtttaaetttaagaaggaattcaggagcc
cttcaccatgacgaatttaaaagcagttattcctgtagcgggtctcgggatgcat ATG GGT GGT CTG AAA AAA CTG GGT
AAA AAA CTG GAA GGT GTT GGT AAA CGT GTT TTT AAA GCG AGC GAA AAA GCC TTA
CCG GTG GCA GTT GGG ATT AAG GCG CTG GGC TAA TAG CGC TCG GTT GCC GCC GGG
CGT TTT TTA
Al -B2
Cgateccgegaaattaatacgactcactataggggaattgtgagcggataacaatteccetetagaaataattttgttaaetttaagaaggaattcaggagcc
cttcaccatgacgaatttaaaagcagttattcctgtagcgggtctcgggatgcat ATG GGT GGT CTG AAA AAA CTG GGT
AAA AAA CTG GAA GGT GTT GGT AAA CGT GTT TTT AAA GCG GCG GAA CTG AAG GCA
TTA CCG GTC GCG GCC TAA TAG CGC TCG GTT GCC GCC GGG CGT TTT TTA
Al - B3
Cgatccgcgaaattaatacgactcactataggggaattgtgageggataacaattcccetetagaaataattttgtttaaetttaagaaggaattcaggagcc
cttcaccatgacgaatttaaaagcagttattcctgtagcgggtctcgggatgcat ATG GGT GGT CTG AAA AAA CTG GGT
AAA AAA CTG GAA GGT GTT GGT AAA CGT GTT TTT AAA GCG ACC CTG GCG GAG AGC
GCC GTG TTA GAA ATT TAA TAG CGC TCG GiT GCC GCC GGG CGT TTT TTA
A2 - B1
Cgateccgegaaattaatacgactcactataggggaattgtgageggataacaattcccetetagaaataattttgtttaaetttaagaaggaattcaggagcc
cttcaccatgacgaatttaaaagcagttattcctgtagcgggtctcgggatgcat ATG CTG GTG GAG ATT AGC GAT GAA
GCG GCC GGT GTT GGT AAA CGT GTT TTT AAA GCG AGC GAA AAA GCC TTA CCG GTG
GCA GTT GGG ATT AAG GCG CTG GGC TAA TAG CGC TCG GTT GCC GCC GGG CGT TT
TTA
A2 - B2
Cgateccgegaaattaatacgactcactataggggaattgtgageggataacaattcccctetagaaataattttgtttaaetttaagaaggaattcaggagcc
cttcaccatgacgaatttaaaagcagttattcctgtagcgggtctcgggatgcat ATG CTG GTG GAG ATT AGC GAT GAA
GCG GCC GGT GTT GGT AAA CGT GTT TTT AAA GCG GCG GAA CTG AAG GCA TTA CCG
GTC GCG GCC TAA TAG CGC TCG GTT GCC GCC GGG CGT TMT TTA
A2 - B3
Cgateccgegaaattaatacgactcactataggggaattgtgageggataacaattcccetetagaaataattttgtttaaetttaagaaggaattcaggagcc
cttcaccatgacgaatttaaaagcagttattcctgtagcgggtctcgggatgcat ATG CTG GTG GAG ATT AGC GAT GAA
GCG GCC GGT GTT GGT AAA CGT GTT TTT AAA GCG ACC CTG GCG GAG AGC GCC GTG
TTA GAA ATT TAA TAG CGC TCG GTT GCC GCC GGG CGT Tf TTA
Figure 3.5: Example oligonucleotides designed and synthesized using combinatorial
approach. A set of 2-A regions were combinatorially attached to 3 B-regions using PCR.
The T7 promoter and RBS are shown in lower case, A-region in bold, B-region in
unbolded, and termination sequence in underlined text. A region used for PCR is
conserved in all sequences (GGTGTTGGTAAACGTGTTTTTAAAGCG). Optionally, a
fusion partner could be included with the T7 upstream region.
3.4.3.3 Improved combinatorial design using ligation
One drawback of a PCR approach to connect the unique A and B segments is that
it requires a long conserved region that limits the portion of the peptides that can be
varied. Furthermore, the conserved region must be carefully designed to have an
appropriate melting temperature for PCR and not to have self symmetry that could lead to
secondary structure that block annealing. A superior approach would have a shorter
conserved region, but would still ensure that the correct A-B construction occurred.
A method to accomplish this is to directly ligate the A and B segments. For this to work,
the primers for A and B were ordered along with their complementary strands.
Furthermore, two of the strands were ordered with phosphorylation, which allowed the
direct ligation of the double stranded A and B. A small overhang was designed on each
strand to encourage the proper ligation. The ligated A-B combinations were then
amplified by PCR from the ends. A T7 upstream region was added, and the final
construct was again amplified by PCR. The short 4 amino acid overlap required for
proper ligation allows almost complete freedom in designing the A and B sequences. A
diagram of this process is shown in Figure 3.6. This approach was also executed and
validated with DNA sequencing.
A B Transcr.
A____________ SP Term.
P
antA anti-B
44L Ligaton
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Figure 3.6: Alternative combinatorial DNA synthesis method requiring a shorter
conserved region. A revised strategy for combining variable A and B regions for pattern
based AmPs design. Rather than using PCR, which requires a longer conserved region, a
4-base pair overhang is designed so that double stranded oligos may be directly ligated
after they are annealed to their complementary strands. Two of the strands were
phosphorylated to enable direct ligation.
3.4.4 Summary
The first economic obstacle to developing a high-throughput in vitro translation
approach to AmP discovery was the cost of custom oligonucleotides. Multiple flexible
approaches were developed based on the insight that combinatorial DNA synthesis could
be used to reflect the pattern-based design scheme for antimicrobial peptides.
At the time of this work, an oligo of 50 base pairs, which would be used in this
work, cost -$50, and 3 custom oligos would be required for each peptide (including
overlapping segments for PCR, a transcription terminator, and an enterokinase site). For
an exploration of the interaction of 10 patterns in a 10 x 10 combination, this would cost:
100 sequences x 3 primers x $50 = $15,000. For a 40 x 40 combination, the price would
be $240,000. Using the combinatorial ligation approach outlined above, only 2 primers
would be needed for each part A and each part B. For the 10 x 10 experiment the cost
would be (2 x 10 part A's + 2 x 10 part B's) x $50 = $2,000 rather than $15,000. For the
40 x 40 experiment, which is the scale we would envision upon automating our system,
the price would be $8,000 rather than $240,000. In addition to making the study
affordable, the combinatorial approach allows the examination of the synergy of different
classes of patterns.
3.5 Initial AmP translation studies
Initial in vitro translation optimization studies were carried out using a GFP
control vector supplied with the Roche RTS 100 in vitro translation kit (3-186-148) in
order to determine parameters critical for a robust screening system. The first goal in
creating a more robust system was to switch from a semi-continuous to a batch system
while maintaining sufficient yield to test antimicrobial activity against 2 bacteria at up to
16 ug/ml. In vitro translation methods and yields in initial studies are described in the
following sections.
3.5.1 Methods for in vitro translation in the Roche system
The Roche RTS 100 translation kit was used to translate all truncated GFP vectors
because the upstream region of this vector is designed for the Roche system. The kit
comes in 5 vials, all of which were reconstituted according to the kit instructions. For
each 15 ul reaction, 3.6 ul of E coli Lysate, 3.0 ul of Reaction Mixture, 1.5 ul of Reaction
Buffer, 1.8 ul amino acid mix, and 0.16 ul of Methionine were used. Additionally, 3.13
uCi/ml of L-[U- 14C] leucine was used for protein quantification (Amersham CFB 183,
Buckinghamshire, England). Finally, 4 ul of template DNA at 60 ug/ml was used in all
reactions to give a total DNA concentration of 16 ug/ml, unless otherwise specified.
Adding additional DNA for both short and long constructs did not increase yield,
indicating that the amount of DNA was never limiting. The reaction was run for 6 hrs at
30'C, as suggested in kit instructions, with I hr and 2 hr time points taken in some
experiments. For all translations, duplicate reactions were carried out at 15 or 45 ul, with
two 5 ul samples taken from each reaction at each time point for protein quantification.
A modified version of a standard TCA precipitation was used for protein
quantification (Kim, Kigawa et al. 1996). Briefly, 5 ul of sample was quenched in 100 ul
of 0.1 N NaOH, with 20 ul of 0.2 mg/ml BSA as a coprecipitant. The samples were
spotted on filter paper and washed 3 times with ice cold 20% TCA for 15 min. each,
rinsed with EtOH, and quantified with a Liquid Scintillation Counter. In this Thesis, the
terms, "accumulated product," or, "molar yield," will refer to the concentration of intact
polypeptide measured with the 14C Leu quantification. When a fusion partner is linked
to a target peptide in a 1:1 ratio, the molar yields of the peptide and fusion partner are
identical.
3.5.2 Initial in vitro translation results
One primary objective for optimizing an in vitro system was to determine the
factors limiting yield. If the limiting reagents were DNA or amino acids, they could be
inexpensively supplemented to give more economical translation. First, we varied the
DNA concentration used in translation to ensure it was in excess. The translation
conditions described in Section 3.5.1 to translate GFP were used, with the exception that
the DNA concentration was varied from 2 to 15 ug/ml. As shown in Figure 3.7,
increasing DNA concentration only modestly increased yield.
Additionally, we assessed whether the elution buffer used to purify DNA from a
PCR reaction impacted translation, and whether agitation affected translation. Finally,
we evaluated molar yields for linear and plasmid templates for GFP. The results of these
studies are summarized in Table 3.1. None of these parameters had a significant impact
on yield.
In summary, these early studies provided familiarity with the parameters
important for successful translation. Further, it set a baseline yield using a control
sequence. It would be desirable to increase this yield in order to drive down translation
costs and increase the maximum concentration at which AmPs could be screened.
Improvements to achieve these goals are discussed in the following sections.
Figure 3.7: Effect of DNA concentration on GFP yield. Increasing DNA concentration
for a GFP template above 2 ug/ml gave only a modest increase in yield when using the
Roche in vitro translation system.
Conditions Molar Concentration
Plasmid GFP 4.72 uM
Linear GFP in EB 4.46 uM
Linear GFP in water 4.80 uM
Linear GFP with Shaker 4.98 uM
Table 3.1: Effect of template, buffer, and agitation on GFP yield. In vitro translation
was carried out using equivalent DNA concentrations of plasmid and linear DNA without
a significant change in yield. Further, the yield was not affected by the presence of PCR
elution buffer or agitation.
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3.6 Multimer AmPs
After reducing primer costs by developing a combinatorial approach described in
Section 3.4.3, the primary expense in the screening system is the in vitro translation
extract. The yield generated from the translation will dictate the expense of producing
the desired quantity of peptide for assay. Since we envision applying the screen to a
variety of bacteria for each AmP to generate an activity profile, as well as doing in vitro
hemolytic assays, achieving high yield is critical.
One technique used to improve peptide yield in fermentations is to translate a
series of copies of the same AmP sequence in tandem (Tian, Teng et al. 2007). These
strings of a repeating AmP, or multimer AmPs, can then be cleaved after translation to
produce a high molar yield of peptide. In order to limit the toxicity of the AmP to the host
cell, an anionic peptide may be co-expressed with the AmP in order to bind to and
neutralize the AmP before the multimer is cleaved (Lee, Kim et al. 2002).
Prior researchers have sought to produce one specific AmP at high yield. In order
to accomplish this, they created multimers within a plasmid. In our screen, inserting a
cloning step to create and amplify a plasmid would negate the advantages of an
automated in vitro approach. Therefore, we desired to create multimers from linear DNA.
A diagram of the synthetic process is shown in Figure 3.8, in which DNA encoding the
AmP has digestion sites that leave overhangs which may only reassemble with the AmP
in the proper orientation relative to an upstream and downstream region. Following
ligation with varying molar ratios of the AmP relative to the upstream region and
termination sequence, the multimer may be amplified from the ends using PCR.
Unfortunately, the large regions of homology in the linear template created significant
crossover sights, which led to the creation of multimers with fewer AmP incorporations
at each amplification cycle. As shown in Figure 3.9, as more amplification cycles occur,
the number of AmPs incorporated decreases, limiting the improvement in yield that could
be obtained for an AmP. Alternative strategies to improve yield were explored.
TAAT ITAAT
Upstream Region AmP 1Termination
ATTA ATTA
Upstream Region AmP AmP AmP AmP Termination
Figure 3.8: Construction strategy for multimer AmPs. DNA encoding an AMP is
created with Bbsl digestion sites that leave 4 base pair overhangs. The overhangs are
designed such that the AmP may only be incorporated in the correct orientation. An
upstream region and transcription termination sequence act as caps for this
polymerization. The AmP contains protease susceptible sites at either end of the peptide
so that the multimer may be digested after translation.
AmP
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4
3
2
1
0
Figure 3.9: DNA gel showing multimer AmPs. A series of oligonucleotides were
created coding for multimer AmPs. The number of amplification cycles in PCR was
increased from the far left lane through the neighboring 3 lanes. With greater
amplification, multimers that contained fewer AmP repetitions were created through
crossovers of longer multimers. Conditions which retained large numbers of multimers
as linear templates could not be found.
3.7 Fusion partner length optimization
As discussed in Section 3.5.2, limited yield made the high-throughput screening
of designed AmPs impractical. Because AmPs were initially translated as fusions with
GFP, there was a low molar AmP yield since most of the translational resources were
used to make the GFP fusion partner, which was more than an order of magnitude larger.
An attempt was made to increase the molar translation of AmPs per mass translated by
creating multimer AmPs, but this approach was problematic for linear templates.
Another approach to increasing yield would be to make the AmP a larger fraction
of the translated product by reducing the size of the fusion partner. In the following
study, peptide yield was maximized for in vitro translation by optimizing the length of
the translated product, which is composed of the fusion partner and the peptide. The
DNA encoding a standard GFP fusion partner was truncated to produce fusion partners of
many lengths, and the length that gave the maximum molar yield was found. This trend
was generalized to 2 fusion partner sequences. Protease inhibitors were used to confirm
that proteolysis was at least partially responsible for limiting accumulation of products
shorter than the optimal length.
3.7.1 Background on fusion partners
As described, fusion partners may be used to improve stability of translated
peptides. Fusion partner may also add functionality before the peptide is cleaved. The
characteristics of the fusion partner are often selected with the downstream processing of
the peptide in mind. For instance, a host of affinity tags are commonly used for one-step
purification (Terpe 2003). Fusion partners may also be designed to ensure the peptide
stays in solution at high expression levels (Davis, Elisee et al. 1999). Alternatively,
fusions designed for the formation of insoluble inclusion bodies allow product to be
isolated and resuspended (Lee, Kim et al. 2000). Additionally, fusions may neutralize the
charge or activity of the designed peptide until further processing (Lee, Minn et al. 1998).
Some fusion partners, such as ubiquitin, assist in proper folding of the co-expressed
molecule (Pilon, Yost et al. 1997). Finally, peptides may be detected and quantified
using luciferase or green fluorescent protein fusions (Su 2005).
While a great deal of attention has been paid to the functionality of fusion
partners, there has been little study of how the length of fusion partners influences the
peptide yields. The various functionalities mentioned previously may be achieved with
fusions of different lengths. Fusion partners for purification vary widely in length from
polyarginine and polyhistidine tags of 6 amino acids to maltose binding protein with 396
amino acids (Terpe 2003). Solubility partners range from the commonly used
thioredoxin at 109 residues to NusA at 495 residues (Tenno, Goda et al. 2004) (Davis,
Elisee et al. 1999). Insoluble partners of any length will cause the formation of inclusion
bodies. Fusion partners for detection may be as small as 15 amino acids (S-tags) and as
large as 250 (green fluorescent protein) or 550 amino acids (luciferase). Fusion partners
that span these ranges are widely used and reported throughout the literature.
Nevertheless, the effect of the length of the peptide fusion partner or total translated
product on yield has not been reported.
3.7.2 Optimizing length of GFP fusion partner
We desired to express Si, a 20 amino acid peptide of interest in our lab, at a high
level using an in vitro translation system in order to characterize its activity. We found
that SI did not stably accumulate when translated on its own, or with a 10 amino acid
HIS tag in the Roche Translation Kit. Therefore, we sought to translate SI with a fusion
partner to promote the stable accumulation of protein. We chose the Roche Translation
Kit control vector encoding Green Fluorescent Protein (GFP) as a fusion partner.
Because the GFP is significantly longer than Si, the majority of the translation
resources are used to make the GFP portion of the fusion. We sought to increase the
molar yield by shortening the amino acid length of the GFP fusion partner. To this end,
we created DNA encoding truncated versions of GFP, to be translated in the Roche
Translation Kit. In the following sections, the methods used to create the truncations and
the resulting yields are described.
3.7.2.1 Template construction for truncated GFP
Linear DNA was obtained from the Roche GFP control vector (supplied in kit 3-
186-148) through a PCR reaction. A primer was designed upstream of the T7 promoter
site in the control vector. Downstream primers were designed to add a Bbs 1 digestion
site after amino acids 35, 43, 57, 70, 82, 95, 139, 203, or 250 of the GFP. This site was
used to attach a transcription termination sequence for translation of the fusion partner
alone, or to add DNA coding for a peptide followed by the termination sequence. The
transcription termination sequence was also taken from the Roche GFP control vector.
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The attachment regions added 7 amino acids to the GFP truncations, giving lengths 42,
50, 64, 77, 89, 102, 146, 210, and 257 amino acids. Figure 3.10 shows a DNA gel for a
series of truncated GFP fusion partners with the transcription termination sequence
attached. DNA constructs were validated by sequencing. The full DNA sequences
encoding all of the truncated fusion partners created are given in the Appendix.
T7 RBS Start
T7 RBS Start
T7 RBS Start
G35 Stop Term
G95 Stop Term
G250 Stop Term
1500 bp
600 bp
100 bp
Figure 3.10: Diagram and gel showing DNA coding for truncated versions of GFP.
A schematic of 3 truncated versions of GFP containing 35, 95, and 250 amino acids with
identical upstream and termination regions is depicted. A DNA gel showing all of the
truncated GFP fusion partners is also given.
For some studies, it was desired to express SI in frame. The DNA encoding SI
was designed by reverse translating its amino acid sequence,
NKVKKPLTGAHRLLFTFLFV, in silico using an E. coli codon usage table
(www.entelechon.com). A Bbs 1 site was added on either end to allow the DNA for S 1 to
be ligated in frame with DNA encoding a promoter region and a truncated GFP fusion
partner on the 5' end, and a transcription termination sequence on the 3' end. The DNA
sequence for S1 with the Bbs 1 restriction sites is shown in Figure 1. All pieces were
digested with Bbs 1 (New England Biolabs, Ipswitch, MA) and ligated using T4 DNA
ligase (New England Biolabs, Ipswitch, MA). Once ligated, the correctly formed
construct was amplified with Forward Primer 1 from upstream of the promoter and
Reverse Primer 2 from downstream of the transcription termination sequence. The
addition of SI added 29 amino acids to the GFP truncations, resulting in constructs that
were 64, 72, 86, 99, 111, 124, 168, 232, and 279 amino acids. The full procedures with
primers are shown in Figure 3.11. The DNA sequences with Si fused in frame are given
in the Appendix.
Upstream region and first 35 amino acids of GFP
Forward Primer 1
5'- ATGCGTCCGGCGTAGAGGATC ->
Promoter, RBS, start, 35 AA of GFP 31 32 33 34 35
5'- ATGCGTCCGGCGTAGAGGATCOAG... TGGGCACAAATTTTCTOTCAGTGGAOAGGGTGAAGGT -3'
3'- TACGCAGGCCGCATCT CCTAGCTC... ACCCGTOTTTAAAA GACAGTCACCTCTCCCACTTCCA - 5'
<- GACAGTCACCTCTCCCACTTCCA AGTGTCTTAT TACCCAGAAGAGCTA -5'
Reverse Primer 1 overhang Bb
SI with oriented digestion sites on both ends
5'- TATOC GAAGAC GO TAAT GATGATGACGATAAG AAT AAA OTT AAG AAA CCA CTT ACA GGA GCA CAT AGA...
3'- ATACG CTTCTQ CC ATTA CTACTACTOCTATTC TTA TTT CAA TTC TTT GOT GAA TOT CCT COT GTA TCT...
Bbs overhang EK site Full SI sequence
... CTA TTG TTC ACT TTT TTA TTT GTA TAA TAG AA CCCC GTGTCTTC TCGAT - 3'
...GAT AAC AAG TGA AAA AAT AAA CAT ATT ATC TT GGGG CACAGAAG AGCTA -5'
SI sequence end Stop overhang Bbs1
Termination region
Forward Primer 2
5'-ATCG CCCC GOGTCTTC A TAATAG ATTCCAGCACACTOGCOOCCGTTAC ->
overhang Bj Termination sequence from GFP vector
5'- ATTCCAGCACACTGOCGGCCGTTAC... TCGCGTAGTCOATAGTGOCTCCAAGTAGCGAA-3'
3' - TAAGGTCGTGTGACCCCGGCAATG-.. AGCOCATCAGCTATCACCGAGGTTCATCGC TT -5'
<- CATCAGCTATCACCGAGGTTCATCGCTT - 5'
Reverse Primer 2
Figure 3.11: Procedure and primers to create a truncated GFP fusion partner.
Procedure for constructing DNA which encodes truncated versions of GFP (here 35 AA).
A Bbsl digestion site is added after 35 AA and used to attach a termination sequence, or
the peptide, Si, followed by a termination sequence.
3.7.2.2 Effect of translated product length of yield
With a series of truncated versions of GFP created, the effect of length of the
translated product on molar yield could be evaluated. A time course for translation was
carried out for all truncations in the Roche translation system. The translation and
quantification methods are described in Section 3.5.1. The molar yield, or accumulation
of translated product, at time points of 1, 2 and 6 hours are shown in Figure 3.12.
A three-fold increase in accumulation occurs as the length of the translated GFP
sequence is reduced from 257 to 102 amino acids (these lengths include 7 amino acids
added from restriction sites). The time course shows that the amount of accumulated
protein decreases between two and six hours after the start of translation for constructs of
77 amino acids and shorter.
Above the optimal translated product length, the molar yield of peptide falls
because excessive resources are consumed to produce the fusion partners rather than the
peptide of interest. If the construct is long enough to be stable, translation and
accumulation will continue until the energy sources or amino acids are depleted or
inhibitory agents build up in the system. For stable constructs, the total mass yield is
approximately constant, but the peptide of interest comprises a smaller portion of the
yield as the fusion partner length increases. The maximum molar yield of peptide occurs
at the minimum translated product length for which the product is stable.
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Figure 3.12: Dependence of molar yield on translated product length for truncated
GFP. There is an optimal length for the translated product at which peptide
accumulation is maximized. Truncated versions of GFP were translated in the Roche in
vitro translation system, and protein quantification was carried out using TCA
precipitation at 1, 2, and 6 hour time points. Yield peaks at roughly 100 amino acids by
the 6 hr time point, when translation has been completed. Below 80 amino acids, protein
accumulation falls between 2 and 6 hours, whereas at 80 amino acids or above,
accumulation increases between 2 and 6 hours (n=4, error bars = SD).
3.7.3 Effect of translation system on optimal length
In order to test the generality of this trend in molar yield, we studied three
additional translation systems. Two alternative extract sources for in vitro translation,
KC6 and NMR5, were used in the PANOx-SP system developed by researchers in the
Swartz lab (Michel-Reydellet, Calhoun et al. 2004; Calhoun and Swartz 2005). These
translation systems have the same energy source as the Roche system, but has a different
extract source. KC6 and NMR5 were used to translate DNA encoding the 64, 102, and
257 amino acid versions of truncated GFP.
3.7.3.1 Methods for translation in the KC6 and NMR5 extracts
The reaction mixture contains 10 mM ammonium glutamate, 20 mM magnesium
glutamate, 170 mM potassium glutamate, 1.2 mM ATP, 0.86 mM each of GTP, UTP, and
CTP, 34 ug/mL folinic acid, 170.6 ug/mL E. coli tRNAs, 2 mM of each of the 20 amino
acids, 0.03 M phosphoenolpyruvate, 0.33 mM NAD, 0.27 mM CoA, 2.7 mM oxalic acid,
1 mM putrescine, 1.5 mM spermidine, 5.25 uM L-[U- 14C] leucine, 0.1 mg/mL T7 RNA
polymerase, and 24% S30 E. coli cell extract in a 57.2 mM HEPES-KOH buffer at pH
7.5 (Spirin, Baranov et al. 1988). A total DNA concentration of 16 ug/ml was used along
with 1.67 uCi/ml of L-[U-14C] leucine. The reactions were run at 37'C for 4 hours as
described in Swartz et al., 2004 (Swartz, Jewett et al. 2004). The resulting yields are
shown in Figure 3.13.
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Figure 3.13: Molar yield of truncated GFP in alternate in vitro translation mixtures.
Truncated versions of GFP of lengths 64, 102, and 257 amino acids were translated in the
Roche, PANOx-SP KC6, and PANOx-SP NMR5 system and quantified using TCA
precipitation. A similar maximum in yield occurs at the same translated product length in
the PANOx-SP KC6 and NMR5 systems (n=2) as in the Roche translation system (n=4).
3.7.3.2 Optimal fusion partners in alternate in vitro systems
As seen in Figure 3.13, little accumulation occurred for the 64 amino acids
construct, whereas accumulation was threefold higher for the 102 amino acid construct
than for the 257 amino acid construct. The trend in these yields was similar to those
obtained in the Roche system, demonstrating that the presence of an optimal translated
product length occurs in multiple translations systems.
3.7.4 Effect of fusion partner sequence on optimal length
The same fusion partner truncation procedure was applied to luciferase to
determine whether the trend of molar yield versus translated product length was
sequence-dependent. To this end, a fourth translation system, the Promega S30 for
Linear Templates, was utilized because the luciferase vector was optimized for this kit.
3.7.4.1 Methods for creating and translating truncated luciferase
An identical procedure was used to produce truncated versions of the Promega
luciferase vector pBestLuc (Supplied in L1020). The DNA sequences for the truncated
versions of luciferase are included in the Supporting Information. The Promega S30 kit
for Linear Extracts was used to translate the truncated Luciferase constructs because it
has been designed for this kit. The reaction was composed of 4 ul S30 extract, 5.25 ul
S30 Premix, and 1.5 ul amino acid mix with 16 ug/ml DNA template, and 4.17 uCi/ml of
L-[U-14C] leucine. The reactions were run at 37'C for 6 hours. The resulting yields are
shown in Figure 3.14.
3.7.4.2 Optimal translated product length for truncated luciferase
The optimal product length does vary moderately with the identity of the fusion
partner being studied. In a series of truncated luciferase templates shown in Figure 3.14,
a three-fold increase in yield occurred as the translated product length was reduced to an
optimal length. The maximum molar yield for truncated GFP occurs at 102 amino acids,
whereas the optimum occurs at 136 amino acids for truncated Luciferase. This shift is to
be expected given the hypothesis that susceptibility to proteases causes places a lower
limit on the translated product length required for accumulation. Different amino acid
sequences will have different propensities for protease breakdown. Additionally, the
degree of tertiary folding for a given sequence length would vary with the sequence being
produced. The optimal truncated GFP does not clearly correspond with a subdomain of
the full GFP structure (Yang, Moss et al. 1996). This is not surprising given that the
truncated protein may fold differently than when it is a part of the full GFP protein.
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Figure 3.14: Dependence of molar yield on translated product length for truncated
Luciferase. Truncated versions of Luciferase were translated in the Promega translation
system for 6 hrs and quantified with TCA precipitation. The maximum yield for
truncated sequences from Luciferase in the Promega translation system occurs when 136
amino acids are translated. Lower yields are always seen in the Promega system than in
the Roche system (n=4, error bars = SD).
3.7.5 Translating with a desired AmP in frame
We then sought to confirm whether the optimal translated product length changed
when SI was attached to the fusion partner. DNA encoding Si was added in frame to the
DNA encoding each of the truncated GFP fusion partners along with a small attachment
region and enterokinase recognition site. The addition of SI lengthened the translated
product 29 amino acids. The effect of translated product length, composed of the fusion
partner plus the peptide, on the final molar yield of product is shown in Figure 3.15.
3.7.5.1 Yield with AmP translated in frame
The optimum in molar yield occurred at a similar translated product length when
SI was attached to fusion partners of different lengths. The fusion of SI and the 70
amino acid GFP truncation gave the maximum yield. The total length of the construct
was 99 amino acids, which is similar to the 102 amino acid optimal for GFP fusion
partners translated without S1. This indicates that for maximum yield, a fusion partner
should be selected such that the length of the peptide plus fusion partner is optimal.
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Figure 3.15: Dependence of molar yield on translated product length for truncated
GFP with AmP attached. Translation of GFP fusion partners alone or the fusion
partners plus S1I were carried out in the Roche system for 6 hrs at 30'C and quantified
with TCA precipitation. The maximum in molar yield occurs at the same translated
product length, which is composed of the peptide plus the fusion partner. A fusion
partner of 70 amino acids plus 29 amino acids to add Sl1 gave maximal yield.
3.7.5.2 Digestion from fusion partner
After translation, the peptide, S1, must be digested from its fusion partner if its
free activity is to be measured. Digestion was accomplished by adding 0.1 U/ul of
enterokinase to the translation mixture and incubating at 30'C overnight without adding
additional buffers (EMD Biosciences, Madison, WI). The digestions were visualized by
using the Promega Transcend Detection kit (L5080) using biotinylation. The Roche
Translation conditions mentioned above were used with the addition of 1.2 ul Transcend
tRNA per 15 ul reaction. Samples were diluted 1:1 with Tricine Sample Buffer (Bio-Rad
161-0739) and run on 16.5% Tris/ Tricine Peptide gels (Bio-Rad 161-1179). The gel was
blotted to PVDF and developed according to the Transcend Detection protocol. A
sample gel with S1 digested from GFP and a truncated GFP is shown in Figure 3.16. As
expected, the yield of Sl is visually greater when a truncated fusion partner is used.
Figure 3.16: Protein gel showing AmP digested from multiple fusion partners. An in
vitro translation reaction using biotinylation for detection was run for 95 and 250 amino
acid fusion partners with SI for 6 hours at 30'C. After translation, half of the samples
were digested with enterokinase, separated with gel electrophoresis, transferred to PVDF
and developed. Sample lanes are: 1- no DNA translated (control), background
biotinylation is seen, 2- no DNA translated, digested with EK, 3 - 95 aa fusion partner +
SI (hidden by background), 4 - 95 aa fusion partner + Sl digested, 5 - 250 aa fusion
partner (GFP) + S1, 6 - 250 aa fusion partner (GFP) + SI digested. A greater yield of
SI is seen when digested from a 95 amino acid fusion partner than from a 250 amino acid
fusion partner - lane 4 versus 6.
3.8 Exploration of protease activity
Below the optimal length, susceptibility to proteases may reduce yields. The in
vitro translation extracts used in this work are made from Escherichia coli, and thus
contain dozens of proteases (Gottesman 1996). These proteases range from narrow to
broad in their specificity, and may survive the extract preparation process. Genes
encoding some proteases may be deleted, as was done in labs of G. Georgiou to reduce
the degradation of products (Baneyx and Georgiou 1991; Jiang, Oohira et al. 2002).
Cell-free systems have been designed to reduce protease activity as described in Jiang et
al, 2002 (Jiang, Oohira et al. 2002). However, it may not be possible to remove many of
these proteases by deleting genes in Escherichia coli because some deletion strains are
not viable or robust (Gottesman 1996).
The enhanced degradation of fusions below 80 amino acids may be due to the fact
that shorter constructs are not sufficiently long to fold in a manner that protects them
from protease degradation. As shown in Figure 2, translated product appears in the first
hour of the reaction but is degraded away over time for truncations shorter than 77 amino
acids, as confirmed by protein precipitation using TCA. The degradation is more
extensive for the shorter constructs, with complete degradation of the 42 and 50 amino
acid constructs by 6 hours.
The activity of the proteases in the in vitro translation mixture falls over time.
The rate of disappearance of the 50 amino acid construct decreases after 2 hours in Figure
6. Additionally, the S 1 released from the 95 or 250 amino acid GFP constructs was
stable throughout the enterokinase digestion overnight, despite the fact that S1 is
degraded in fresh in vitro translation mixture. The digestion was carried out in the in
vitro translation mixture where proteases were still present, but the proteases did not
display activity in the spent mixture. The decrease in protease activity may be due to
wear on the proteases or the depletion of energy sources needed for activity. The loss of
protease activity over time is convenient for the translation of short peptides on fusion
partners since the translation can be run to completion and then the peptides may be
cleaved from the fusion partner after protease activity has decreased.
3.8.1 Translated product length defines optimal yield
We noted that when the peptide, Sl, is attached to a fusion partner, the optimal
yield still occurs at the same translated product length, which is composed of the fusion
partner plus the peptide. To test whether the length of the mRNA transcript or the amino
acid sequence of the fusion is critical in defining the optimal fusion length, a stop codon
was placed between the fusion partner and Si. Thus, the amino acid length of this
construct was the same as the length of the fusion partner alone, whereas the mRNA
length was equal to the length of the mRNA for the fusion partner with the peptide. If
proteases were responsible for defining the optimal length, one would expect the
optimum to be dependent on the length of the amino acid sequence translated, not the
length of the mRNA.
3.8.1.1 Methods for varying amino acid length independently of
mRNA length
In order to vary the translated amino acid length independently of the mRNA
length, two stop codons were inserted after the DNA for the truncated GFP fusion partner
but before the peptide Sl. A revised Reverse Primer 1 with the 5'-ATT CTG TGA-3'
segment replaced by 5'-ATT CTA TTA-3' was used in the first step of the procedure in
Figure 1 to create fusions with two stop codons before S 1. These constructs just had the
truncated GFP translated, so they were 35, 43, 57, 70, 82, 95, 139, 203, and 250 amino
acids. The DNA sequences for constructs with a stop codon before SI are included in
Supporting Information. Finally, constructs were created with Si attached directly to the
GFP upstream region or to an N-terminal HIS Tag (Roche 3-186-237). These constructs
were translated and quantified using methods given in Sections 3.5.1. The resulting
yields are shown in Figure 3.17.
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Figure 3.17: Dependence of molar yield on translated product length for GFP-AmP
fusion with stop codon between GFP and AmP. DNA coding for fusions of truncated
GFP and the peptide SI were translated with a stop codon between the truncated GFP and
the SI for 6 hrs at 30'C in the Roche system. The mRNA was the length of the truncated
GFP plus the S1, whereas the translated product was the length of the truncated GFP
alone. Optimal yield with stop codon inserted after GFP fusion partner and before SI has
a maximum yield of approximately 100 amino acids, which is similar to that of the
fusion partner alone. This indicates that the yield is a function of translated product
length and not DNA or mRNA length (n=4, error bars = SD).
3.8.1.2 Results of varying amino acid length independently of mRNA
length
As shown in Figure 3.17, the optimum occurred at the same translated amino acid
length as with the fusion partner alone, around 100 amino acids. This indicates that
amino acid length is critical for producing optimal yield. Additionally, this suggests that
the mechanisms responsible for the observed maximum in yield act post-translationally.
This observation supports the hypothesis that proteases limit the accumulation of peptides
below the optimal length.
3.8.2 Protease inhibitor studies
To further test this hypothesis, truncated GFP constructs of 50 and 102 amino
acids were translated with and without a protease inhibitor cocktail added to the Roche in
vitro translation mixture. In order to examine the rate of degradation only, tetracycline
(Tet) was added to halt translation one hour after translation was initiated.
3.8.2.1 Methods for investigating effect of protease inhibitors on
degradation rates
For time course experiments with protease inhibitors, GFP constructs of length
42, 50, and 102 amino acids were translated in the Roche Translation Kit with the
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composition described in Section 3.5.1, except that the 1.5 ul of Reaction buffer was
replaced with 1.5 ul of lOx Roche Complete Mini Protease Inhibitor Cocktail in water, or
1.5 ul water without inhibitor (11-836-153-001). After 1 hour of translation, tetracycline
hydrochloride (Sigma, St Louis, MO) was added to 100 ug/ml to stop translation, so the
rate of protein degradation could be quantified. Figure 3.18 shows the change in the
accumulation of translated product over a 3 hour period following Tet addition.
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Figure 3.18: Degradation profile for stable and unstable fusion partners with and
without protease inhibitors. Truncated GFP constructs of 50 and 102 amino acids were
translated in the Roche system at 30'C with and without protease inhibitors added. After
1 hour of translation, tetracycline was added to halt translation so that protease
degradation could be measured using TCA precipitation. The construct of 102 amino
acids did not show susceptibility to proteases with or without inhibitors. The yield of the
50 amino acid construct was twice as high in the first hour with inhibitors present, and
without inhibitors, the yield dropped below 1 uM within 30 minutes after translation
ceased (n=4, error bars = SD).
3.8.2.2 Methods for investigating effect of protease inhibitors on
degradation rates
As shown in Figure 3.18, no degradation of the 102 amino acid construct occurred
with or without protease inhibitors present, indicating that it is not susceptible to
proteases. While obtaining structures of each of the constructs is beyond the scope of this
work, the 102 amino acid construct may be long enough to be protected from degradation
by tertiary folding. However, degradation of the 50 amino acid truncation occurred and
was significantly reduced by protease inhibitors. In the first hour of translation, before
Tet is added in Figure 3.18, the accumulation of translated product is two times higher in
the presence of protease inhibitors. This accumulation, which is the net of translation
minus degradation, indicates that without protease inhibitors, more degradation occurred.
This assumes that protease inhibitors do not boost translation rate in the first hour. This
is a reasonable assumption because translation of the 102 amino acid construct, which
does not display protease susceptibility, is unaffected by the presence of protease
inhibitors. After Tet is added to translation of the 50 amino acid construct, samples
without protease inhibitors fall to below 1 uM within 30 minutes, but persist longer with
protease inhibitors. The fact that some degradation still occurs with protease inhibitors
present suggests that the proteases are not completely inhibited.
3.8.3 Application of fusion partner optimization
The optimal fusion partners for production in vitro may not remain the optimal
partners for production in vivo. Nevertheless, knowing the optimal length for in vitro
translation is useful for efficiently carrying out the parallel production of peptides for a
high-throughput screen. This platform would be particularly helpful for any activity
assay beyond the limitations of phage display screens. The DNA for leads found in this
screen may easily be cloned into a suitable host for recombinant production if a large
quantity of a given protein is desired for further research. Since not all components of
the protein translation and degradation machinery may function identically in in vivo and
in vitro systems, the optimal fusion partner for one system will not necessarily be the
optimal fusion partner in the other system.
In vitro translation may be useful for finding peptide structure or measuring
activity for a wide variety of applications. Our results demonstrate that molar yield may
be maximized by using the appropriate length fusion. A fusion partner based on GFP
truncations may not be optimal for all applications. However, a fusion partner that has
desirable properties for the downstream processing of a peptide be selected and its length
optimized to maximize product accumulation. We further suggest that the optimal length
should be approximately 100 amino acids. This knowledge is particularly important if
only a short HIS tag of 6-10 amino acids is needed, so that the construct may be designed
with the correct number of "buffer" codons between the fusion partner and peptide to
give the optimal total translated length. Purification, quantification, solubilization, or
inclusion body formation may be accomplished at maximal yields by selecting or
designing a fusion partner of the appropriate length.
3.9 Improving solubility
While insolubility or inclusion body formation would be desirable for some
applications, we desired soluble AmP fusions that could be cleaved by enterokinase and
used directly in an antimicrobial assay. Therefore we sought to assess the solubility of
the various fusion partners we had created.
3.9.1 Measuring solubility of existing templates
A variety of truncated GFP - AmP fusions were created and solubility evaluated.
Because we hope to synthesize a great variety of AmPs, the effect of the AmP sequence
on solubility was also evaluated. For these studies, the optimal truncated GFP fusion
partner (70 amino acid) was fused to the AmPs: human beta defensin-2, melittin, and Si.
The samples were translated using methods described in Section 3.5.1. In order to
measure soluble yield, the samples were centrifuged for 15 minutes at 15,000g. The
supernatant, which contains the soluble portion of the product, was removed and TCA
precipitation applied as in Section 3.5.1. As shown in Figure 3.19, all of the fusions,
along with the full GFP had solubilities between 20% and 60%. The economics of the
platform could be improved if the translated fusion had greater solubility.
Figure 3.19: Solubility of truncated GFP-AmP fusions. The solubility of various
AmPs on the optimal truncated GFP fusion partner vary from 20 to 60%. For our
application, it would be more desirable if higher solubility were achieved.
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3.9.2 Selection of appropriate partner
Fusion partner optimization studies indicated that optimal in vitro expression
could be achieved when the translated product was approximately 100 amino acids long.
In a search of known fusion partners with high solubilities, thioredoxin at 110 amino
acids most closely matched this criteria. In addition, recombinant thioredoxin could be
purchased in order to verify if it would toxic in an antimicrobial assay after being cleaved
from the AmP of interest. Methods given in 4.2.2.3 validated that thioredoxin was non-
toxic at 400 ug/ml. Thus, thioredoxin is the appropriate size to give high yields and will
not have to be purified after cleavage from the AmP before activity measurements.
3.9.2.1 Methods to create and translate a Trx fusion partner
The E. coli thioredoxin construct was obtained from the pET32a vector using
methods described in Section 3.7.2.1. The linear thioredoxin DNA was translating in the
Roche translation system as described in Section 3.5.1. A DNA concentration of 4 ug/ml
was used, which was sufficient to give maximal yield for GFP constructs of this size.
When the linear thioredoxin was translated the translation yield was only 4 uM. This is
significantly lower than the 16-20 uM that resulted from truncated GFP of this length.
We sought to determine the limiting factor in the thioredoxin concentration that was
lowering yields. The first hypothesis we sought to test was if the translation was DNA or
mRNA limited. This seemed unlikely since increasing DNA concentration above 4
ug/mI did not increase translation of truncated GFP constructs. Nevertheless, if the DNA
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or mRNA of the thioredoxin was less stable than that of the GFP constructs, degradation
could lead DNA or mRNA concentration to be limiting. In order to test this hypothesis, a
series of in vitro translation reactions were carried out in which the DNA concentration of
thioredoxin coding template was varied. Translation and quantification methods are
given in Section 3.5.1. The resulting yields are shown in Figure 3.20.
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Figure 3.20: Effect of DNA concentration on molar yield of Thioredoxin. The yield
of thioredoxin was approximately linear with DNA concentration during in vitro
translation. Further, at a DNA concentration of 4 ug/ml the yield was only 5 ug/mI,
whereas a yield of approximately 20 ug/ml would be expected for truncated GFP of this
length.
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3.9.2.2 Results of initial Trx translations
As seen in Figure 3.20, the yield of thioredoxin was directly proportional to the
concentration of DNA used. This indicated that the mRNA was unstable. If the mRNA
was sufficiently stable that its rate of production by translation exceeded its rate of
degradation, then the mRNA concentration would accumulate over time. This
accumulation would lead to an mRNA concentration that was not directly proportional to
the DNA concentration or the transcription rate. Since the translation seen in Figure 3.2
is strictly proportional to DNA concentration, accumulation of mRNA that would
decouple the translation rate from DNA concentration does not appear to be occurring.
Additionally, the DNA concentration could not simply be increased to improve
yield without increasing the cost of the high-throughput system. The goal of 4 ug/ml for
the desired volume of in vitro translations was chosen based on the amount of DNA
template for thioredoxin that can be produced in a single 50 ul PCR reaction. Increasing
DNA concentrations would increase the cost of polymerase enzyme and limit the
throughput that may be achieved with one PCR machine if multiple wells of 96 well PCR
plates were necessary for each construct produced.
3.9.3 Creating high-yield Trx translations from low DNA
template concentrations
In order to further test the hypothesis that mRNA stability was limiting yield from
the thioredoxin vector, we sought to translate the same thioredoxin vector with more
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stable mRNA. mRNA stability has been linked to the sequence of the untranslated
regions on either end of the mRNA construct. These regions, particularly the 5' region,
protect the mRNA from degradation and turnover in vivo (Mignone, Gissi et al. 2002).
The upstream region from the thioredoxin had been taken from the pet32a plasmid, which
was designed for translation in vivo. This upstream sequence may not have been well
designed to give high yields in vitro.
The hypothesis that the stability of the mRNA limited thioredoxin yield could be
tested if the thioredoxin coding region were ligated to an upstream region known to give
high protein yields at low DNA concentrations. As demonstrated with the shortened GFP
constructs, the upstream region of Roche-GFP vector gave translation that was
independent of DNA concentration down below 4 ug/ml. This indicated that the mRNA
had sufficient stability that the translation yield was independent of mRNA concentration.
3.9.3.1 Methods for creating Trx on GFP upstream region
The upstream region of the GFP control vector, along with the first 6 amino acids
after the start codon were obtained using PCR and a ligation site was added on the 3' end.
This segment was cut after the start codon because the base pairs from the ribosome
binding site to the start codon are known to be critical for in vitro translation. The
thioredoxin vector was obtained from pet32a using PCR with a matching ligation site on
the 5' end. After digesting, ligating, and amplifying, the resulting DNA template was
verified by sequencing.
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The revised thioredoxin vector was translated using the same conditions used
when translating the original thioredoxin vector shown in Figure 3.20. The same DNA
concentrations were used, with the expectation that a more stable mRNA would reach
saturation at a lower concentration, producing higher yields of thioredoxin. The results
are shown in Figure 3.21.
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Figure 3.21: Molar yield of thioredoxin versus DNA concentration for both a Pet32a
and a Roche upstream region. The yield of thioredoxin varies almost linearly with the
DNA concentration when a pet32a upstream region is used. This indicates that the
mRNA is not stably accumulating in the translation mixture. In order for a cost-effective
translation to be executed, a maximal yield is desired at a DNA concentration of
approximately 4 ug/ml. To address this instability, the thioredoxin vector was attached to
a Roche upstream region known to produce maximal yields independent of DNA
concentration down to 4 ug/ml. This solution produced thioredoxin yields equal to the
maximum expected from previous fusion partner optimization studies (18 ug/ml) at the
desired DNA concentration.
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3.9.3.2 Effect of upstream region on Trx yield at low DNA
concentrations
As shown in Figure 3.21, the yield of the thioredoxin on the revised upstream
region was decoupled from DNA concentration down to 4 ug/ml, as seen with the
original truncated GFP constructs. Further, the yields were similar to the yields with the
GFP constructs, with a yield of 18 uM for a translated product of length of approximately
110 amino acids. This yield met our goal for translation, and the low DNA concentration
necessary meant that sufficient DNA could be obtained for each desired AmP from a
single 50 ul PCR reaction, which reduces costs.
3.10 Developing purification scheme
A requirement of the high-throughput screening platform being developed is that
the synthesis portion of the system does not affect the antimicrobial measurements.
Interference could arise in the form of toxicity from the components of the synthesis
system or side products of the synthesis. In our case, we wanted to study the effect of the
in vitro translation mixture on a standardized antimicrobial assay. The toxicity of each
component was tested using methods given in Section 4.2.2.3. Toxicity to the bacteria
was seen from every component of the mixture, indicating that the reconstitution buffer,
used to resuspend all components of the kit, was the toxic agent. This was confirmed by
assessing the buffer on its own, and verifying that other components reconstituted in
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water were non-toxic. A variety of strategies to eliminate this toxicity while retaining
high peptide yield are presented below.
3.10.1 Protein precipitation to remove toxic in vitro translation
buffer component
A simple approach to removing the toxic agent would be to precipitate all proteins
following translation, including the antimicrobial peptide still attached to a fusion partner
of interest. Assuming the toxic agent remains soluble, the proteins can be resuspended
for use in an antimicrobial assay. A variety of standard techniques exist for protein
purification, including ethanol, acetone, and ammonium sulfate precipitation. For all
experiments, standard translation conditions given in Section 3.5.1 were used. For
precipitation, 90 vol% ethanol, 80 vol% acetone, or 80 vol% 4 M ammonium sulfate was
added. Samples were held for 5 minutes at -20'C (ethanol, acetone) or on ice for
ammonium sulfate. Mixtures were centrifuged for 15 minutes at 4'C at 15,000g,
supernatant was removed, and the pellet was dried and resuspended in Hepes KOH.
Fractional recovery was measured using TCA precipitation as described in Section 3.5.1.
Ammonium sulfate was chosen because it was easiest to resuspend the proteins after
precipitation, relative to ethanol and methanol. As shown in Figure 3.22, recoveries
ranged from 60 to 75%. Further, the resuspended mixture was non-toxic, indicating the
toxic component had been removed to a sufficient extent.
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Figure 3.22: Recovery of protein following various protein precipitation procedures
for purification. Because the in vitro translation mixture contains a component that kills
bacteria, precipitation procedures using 80% ammonium sulfate, ethanol, and acetone
were carried out. Recoveries varied from 60 to 80%, with the acetone procedure giving
the smallest reduction in yield. All purified samples did not display antimicrobial activity.
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3.10.2 Engineering toxicity out of in vitro system
A superior approach to avoiding toxicity from the in vitro translation system
would be to develop an alternative reaction mixture without toxicity, rather than adding a
protein precipitation work up. Each component of the Roche kit was tested for toxicity
using an antimicrobial assay described in Section 4.2.2.3. The reconstitution buffer was
determined to be the sole source of toxicity. Unfortunately, Roche would not divulge the
components of this buffer. Because the Roche system was based on a process developed
in Prof. James Swartz's lab in Stanford University, a series of salt solutions were
evaluated that were present in his published translation systems in the hopes of creating a
mixture with a high yield and no toxicity (Kim and Swartz 2001). Translations were
carried out using methods given in Section 3.5.1, with the exception that the reaction
buffer was replaced by pH 7.4 Hepes KOH supplemented with: 80 mM ammonium
acetate and 16 mM magnesium acetate, 230 mM potassium glutamate, all three, or no
supplemental salts. The resulting yields are given in Figure 3.23.
By supplementing a Hepes buffer with the appropriate complement of salts,
approximately 85% of the yield was achieved. Importantly, this buffer did not display
toxicity in the same antimicrobial assay for which the Roche buffer was toxic. For a
small reduction in yield, this alternate buffer eliminates the need for a protein
precipitation step.
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Figure 3.23: In vitro translation yields using non-toxic reaction buffers. It was
determined that the Roche translation buffer was responsible for the toxicity of the in
vitro mixture. An alternative approach was undertaken to eliminate this toxicity by
designing a replacement buffer. Yields were improved by supplementing a Hepes buffer
with potassium glutamate, magnesium acetate, and ammonium acetate, with the
combined buffer achieving 85% yield of the Roche buffer without having any toxicity.
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3.10.3 High-throughput isolation of AmPs
The toxicity of the in vitro system was eliminated through the development of an
alternate buffer for translation. This improvement enabled the testing of whether the
revised in vitro system would significantly influence the measurements of MICs, even if
the mixture was not toxic. Unfortunately, the in vitro translation mixture still affected
antimicrobial activity measurements using methods given in Section 4.2.2.3 even after
the toxic component had been removed. The cellular extract may alter the growth
resources for target bacteria or may bind to or otherwise inhibit the AmP. A strategy to
remove cellular components from the Fusion partner-AmP are described below.
3.10.3.1 His-tag purification
A desired purification scheme for an in vitro AmP production scheme would be
amenable to automation (preferably in 96 well plates), have little product loss, and would
be very selective for the desired product. To this end, a commercial 96-well plate HIS-
tag purification kit (Vivapure Cobalt Chelate) was utilized to purify the Trx-AmP.
Standard kit buffers were used, with product eluted in 500 mM Imidazole. Using this
approach, a recovery fraction of the Trx-AmP fusion 0.67 was achieved, with other
extract components removed.
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3.10.3.2 Dialysis to remove imidazole
While the purification scheme removed the components of the in vitro translation
mixture which impeded accurate MIC measurements, it introduced imidazole, which may
be toxic to bacteria. First, if imidazole was only mildly toxic, the elution conditions
could be adjusted to reduce imidazole at the expense of a portion of the protein recovery.
The MIC of imidazole was measured by using methods given in Section 4.2.2.3.
Additionally, the effect of imidazole on MIC quantification was assessed by measuring
the MIC of cecropin in the presence of a range of imidazole concentrations. The OD of
samples after incubation is given in Figure 3.24. Imidazole shows toxicity at 30 mM and
above, but has no effect on MIC determination at 10 mM or below. In order to reduce the
imidazole concentration below 10 mM, 96-well dialysis could be used. Dialysis was
carried out using a 2 kDa MW cutoff membrane and a pH 7.2 Hepes KOH buffer
overnight.
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Figure 3.24: Effect of imidazole on MIC determination for cecropin. Bacteria was
grown in the presence of various concentrations of imidazole and cecropin using methods
given in Section 4.2.2.3. Imidazole was toxic at 30 mM and above. Imidazole at 10 mM
and below was non-toxic, and furthermore, the presence of imidazole at 10 mM did not
affect the measured MIC for cecropin. The desired result for dialysis to remove
imidazole will be 10 mM or below.
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3.10.4 Activity of purified AmP
After all components of the in vitro translation and purification system were
removed apart from the AmP and its fusion partner, the activity of cecropin, a natural
AmP, was validated versus a recombinant standard. The fusion was translated using
methods in Section 3.5.1, and HIS-tag purification in Section 3.10.3.1. The eluted
sample was dialyzed for 16 hours in pH 7.2 Hepes buffer in a 2 kDa MW cutoff
membrane. Enterokinase was added to 0.34 units/ml for 20 hours at 30'C. To assess
antimicrobial activity, the standard MIC assay was adapted to allow a higher volume
fraction of the resuspended. Twelve ul of purified Trx or Trx-cecropin was added to 4 ul
of E. coli at OD -0.0125 in Mueller Hinton Broth (MHB) and 4 ul of 4x MHB. Samples
were incubated overnight at 37'C and assayed for growth inhibition visually. The Trx
and Trx-cecropin samples were tested in dilutions up to 8 ug/ml. An overview of the
synthesis and assay scheme, as well as the resulting MICs are given in Figure 3.25.
Thioredoxin translated on its own did not display antimicrobial activity. When
cecropin was translated in frame and digested from the thioredoxin, an MIC of 4 ug/ml
was measured. This is marginally less active than the 1-2 ug/ml measured for a
recombinant cecropin standard. Nevertheless, this degree of accuracy is suitable for a
screen, the results of which would be verified through chemical synthesis.
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Figure 3.25: Synthesis and purification of cecropin (CP) with resulting activity.
Following in vitro translation of thioredoxin-CP, HIS tag purification removes translation
components that affect MIC measurement. Next, dialysis removes toxic imidazole from
the HIS tag elution buffer. The AmP is digested from the fusion partner and available for
MIC measurement. When assayed for antimicrobial activity, thioredoxin without
cecropin did not have a measurable MIC, whereas cecropin translated with and digested
from thioredoxin inhibited growth at 4 ug/ml. This is marginally higher than a
recombinant cecropin standard with an MIC of 1-2 ug/ml.
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3.11 Summary
In vitro translation is an attractive approach to produce a diverse set of peptides
which could be toxic to host-cells in fermentations. Nevertheless, the cost of production
for this system had to be reduced for this method to become feasible. This was
accomplished through a series of innovations. First, we developed a cost-effective
strategy for constructing oligonucleotides which mimicked a pattern-based approach to
AmP design. Next, peptide yield was improved by optimized the size of a fusion partner
and solubility was improved. Finally, a purification scheme was created so that the
synthesis approach would not significantly impact MIC measurement. These
improvements, along with their impact on cost, are described in Table 3.2. Work on
fusion partner optimization was published as (Loose, Langer et al. 2007).
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Process Old New Changes
Oligo Cost $90 $7 Combinatorial,
Ligate Trans Term
Amplification $12 $3 Lower DNA Conc.
Needed
Improved Upstream
Translation $100 $3, Optimal Size Tag -
batch more robust Yield up 4x
Solubility up 2.5x
Cost down 4x per ul
reaction
Assay Prohibitively slow Automatable, Switch to NCCLS
clinically relevant microdilution,
luciferase
Table 3.2: Summary of improvement to a high-throughput in vitro translation and
assay scheme for AmPs. This table gives the cost per peptide for producing 100
peptides (1 Ox 10 combinations) at sufficient quantity to test against 2 bacteria at up to 16
ug/ml. Developing a combinatorial scheme reduces the cost of the oligonucleotides by
the square root of the number of sequences tested. Changing the upstream region of
thioredoxin reduced the required amount of DNA for maximal translation, reducing the
cost of amplifying DNA. Translation yield was maximized by optimizing the translation
partner, improving solubility, and switching to a lower cost, more robust batch system.
Finally, the assay was switched from a prohibitively slow plate counting technique to a
standardized microdilution assay.
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Chapter 4
AmP Design Based on Pattern
Discovery
Existing techniques for AmP design rely largely on screening organisms for new
AmPs or optimizing known sequences. In order to increase the diversity of known AmP
sequences, we generated a pattern-based approach in which semi-conserved rules are
derived by examining the set of all natural AmPs, and the rules are used to guide novel
designs. First, the methods of pattern discovery and their application to AmPs are
described. Next, approaches to filter patterns for significance and reassemble them in
non-homologous sequences are outlined. Finally, methods to synthesize and evaluate
designed sequences are given, along with the performance of the designed agents.
4.1 Pattern-based AmP design
More diverse natural AmPs could be designed if general rules about AmP
sequences could be deduced. Unlike full proteins, many AmPs do not depend on tertiary
structure for their activity (Boman 2003). Their activity is derived from the secondary
structure of the peptides, which is tightly tied to the primary sequence. It is our
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hypothesis that developing rules about the allowed primary sequence for AmPs may
generate useful design parameters for novel AmPs.
4.1.1 Patterns in natural AmPs
Our preliminary studies of natural AmPs indicated that their amphipathic structure
gives rise to a modularity among the different AmP amino acid sequences. The repeated
usage of sequence modules - which may be a relic of evolutionary divergence and
radiation - is reminiscent of phrases in a natural language, such as English. For
example, the pattern Q.EAG.L.K..K (the "." is a "wildcard", which indicates that any
amino acid will suffice at that position in the pattern) is present in over 90% of cecropins,
an AmP common in insects. This example instance of a motif is given in Figure 4.1.
Based on this observation we modelled the AmP sequences as a formal language - a set
of sentences using words from a fixed vocabulary. In this case, the vocabulary is the set
of naturally occurring amino acids, represented by their one-letter symbols. We
attempted to discover rules about the arrangement of amino acids by examining the broad
set of natural AmPs.
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QSEAGGLKKLGK
QSEAGWLKKIGK
QSEAGWLKKLGK
QSEAGWLRKAAK
QTEAGGLKKFGK
QTEAGGLKKLGK
Cecropins QTEAGRLKKLGK
li QTEAGWLKKIGK
kSEAO IMT FRVCH1RDA I !10 VA(4AANVAAF
QTEAGRLKKLGK r--? 'ro'
IT F AG rl KKI GKN -
1T-A'r KK: 'KW '
Q[ST]EAG.L[KR]K.[GA]K
Figure 4.1: Highly conserved motif from cecropins. Alignment of cecropins from a
variety of organisms reveals a highly conserved pattern, or motif. This motif can be
represented by the bottom sequence in which bracketed terms indicate a specific set of
amino acids may be selected at a position, and a period indicates that any amino acid may
be selected at a position. More loosely conserved motifs exist across AmP classes, and
will be utilized in our design algorithm. Figure reproduced from KL Jensen.
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We conjectured that the "language of AmPs" could be described by a set of
regular grammars. Regular grammars are, in essence, simple rules for describing the
allowed arrangements of words. These grammars, such as the cecropin pattern mentioned
previously, are commonly written as regular expressions and are widely used to describe
patterns in nucleotide and amino acid sequences (Falquet, Pagni et al. 2002; Searls 2002).
Previous approaches to the creation of synthetic AmPs have produced peptides
that are either closely related to naturally occurring peptides or composed of only a
handful of amino acids (Tiozzo, Rocco et al. 1998; Tossi, Sandri et al. 2000). Because of
the great similarity between the designed peptides and native sequences, they often have
similar efficacies against the same microbes as natural AmPs. In order to design peptide
that target novel diseases or were much more potent than known peptides, sequences with
little relation to the current database would be desired. As shown in our prior research,
AmPs with little overall homology to existing peptides could be designed as long as
underlying patterns for activity are retained.
In contrast to techniques in which single amino acids of existing peptides are
randomly changed, our synthetic AmPs may be designed with limited homology to
existing AmPs. Our peptides will populate a region of sequence space that is not
occupied by naturally occurring AmPs, as shown in Figure 4.2. While peptides that we
design in grammar space may not overlap perfectly with functioning AmPs, they will
contain many antimicrobials that are outside of the realm of known peptides. These
newly designed peptides may have activity against microbes with reduced susceptibility
to existing AmPs. Further, it has been suggested that using therapeutic agents highly
homologous to natural AmPs could compromise our natural defenses (Bell and Gouyon
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2003). In essence, our linguistic approach is a means to rationally expand the natural
sequence space without using structure-activity information or complex folding
simulations. Instead, we will rely upon the ability of sequence patterns to capture the
underlying function of the peptides.
sequence
space
known
AmPsA
grammar
space
functioning
AmPs
Figure 4.2: Representation of a grammar based search space. While sequence space
for 20 amino acid long peptides (typical for AmPs) contains approximately 10^26
sequences, only hundreds of AmPs are known. Our goal is to develop a grammar based
approach that generates a sequence space that overlaps well with the much larger space of
all possible functioning AmPs, while eliminating most other portions of sequence space
to give a high probability of predicting active sequences.
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4.1.2 Elucidation of grammars
In order to develop grammars based on natural AmPs, two criteria must be
defined:
1. Antimicrobial Peptide Database. A wide variety of collections of
natural AmPs exist. Additionally, many peptides in the Swiss-Prot
collection are annotated as having antimicrobial activity. These
databases vary in size and quality. Importantly, the database should be
curated to ensure that the entries are well justified and that only the
antimicrobial portion of a peptide or protein is included. Most AmPs
are translated within cells as part of a larger sequence including a non-
antimicrobial pro-region. Because these pro-regions are often highly
conserved, they would dominate pattern discovery attempts and result in
designs that do not have activity.
2. Pattern Discovery Tool. Many tools for discovering patterns in
sequential data exist. While some find only a portion of patterns
meeting defined criteria within a dataset, others are exhaustive. The
discovery tools also vary in their runtime for a given data set, and the
degree to which users may tune the parameters for the patterns being
discovered. Ideally, a discovery tool should be efficient, exhaustive,
and highly adaptable.
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4.1.2.1 Database selection
After comparing the available databases for natural AmPs, the University of
Nebraska Medical Center Antimicrobial Peptide Database was chosen
(http://aps.unmc.edu/AP/). This database includes 526 sequences, all of which have only
the active AmP included. The data may be subdivided based on length, nature of activity
(antimicrobial, antifungal, viral, cancer), structure, hydrophobic percentage, or net charge.
4.1.2.2 Teiresias
TEIRESIAS is an algorithm that discovers patterns in any database of sequential
data including DNA and peptides. A full discussion of TEIRESIAS is available in
(Rigoutsos and Floratos 1998). All patterns are discovered given the following
parameters:
1. Patterns must be at least L characters long.
2. Patterns must occur at least K times in the dataset to be considered significant.
3. Patterns will have a minimum fraction of L/W non-wild card characters over
any window of length W.
Example patterns discovered using these parameters are shown in Figure 4.3.
After pattern discovery is executed, resulting patterns should be filtered to ensure they are
statistically significant, and further data processing may be desired. A variety of methods
are available for this, and a sample methodology is shown in Figure 4.4.
ACGTCGCTAGCTCTC CAC ATCGA
GTACCGGCAT CTGACTCATACGTAG
CGACG ATGACTCGGCTAGTACTAC
G CAGAA CACATCGTGGGTGGCTTTT
TTTTTGATGAT GGCGCGAGTAGTAG
CTGCTACGTAGTGTT GCGTACCGGC
GTCAGCGATACGTAC ACAGT GATGC
ATGCATCGTACG TCGACACACGAGCA
CCAACAGTA CTATGTTCATGCTAGCT
CAGTAC GGTACCGCGCATGCTGCTAG
CT ACA ACTGCTGGTAACTGCAT
ACGATTGACGTAC GCTAGTCGATC
TAGCTCGTACGTTTTGGAT CTACG
TCGATCGTCGTACGATCGA CTG G
CGACATCGTACTAGCT CTAGCTCAGA
TCAGCTAGCTAGC CTGCAGTACCGCG
ATCT TCACC CGACTATCAGCTACGA
Wildcard ACACAA
A [AT G
Bracketed GGA.T. [CT ] CCA. GA
expression
A ___
Density = 6/6
Density = 4/7
Density = 9/13 or 4/7
Figure 4.3: Sample results of a TEIRESIAS search of a sample text. Sample patterns
which meet an L/W of 6/6, 4/7, and 9/13 are shown. An IJW of 4/7 means that in a
sliding window of 7 characters, at least 4 must be uniquely specified (not bracket or wild
card). Additional parameters in TEIRESIAS include L, the minimum length of a pattern
and K, the minimum number of times a pattern must appear in the training set to be
considered significant. Figure adapted from KL Jensen.
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thter 1
adddmonal filters
resuts
Figure 4.4: A generalized flowsheet for pattern discovery using TEIRESIAS. Input
sequences are exhaustively searched by TEIRESIAS for patterns meeting certain
parameter specifications. A filter for statistical overrepresentation is applied next, such
as a Markov model (filter 1), limiting the size of the candidate set. Additional filters
including a chi-squared test across defined subgroups or clique formation may also
applied until the candidate set. Figure reproduced from KL Jensen.
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4.1.2.3 Application of Teiresias to AmPs
Using the set of 526 AmP sequences from APD, we ran the Teiresias
pattern discovery tool with the following settings: L = 6, W = 6, and K = 2. The resulting
grammar set was masked from the input sequences and the process was repeated using L
= 7, W = 15, K = 5 with the following amino acid equivalency groups [[AG], [DE],
[FYW], [KR], [ILMV], [QN], [ST]]. (See Rigoutsos and Floratos (1998) for a
background on pattern discovery, masking, and terminology used in these methods.)
With Teiresias, we derived a set of 684 regular grammars that occur commonly in a set of
526 well-characterized eukaryotic AmP sequences from the Antimicrobial Peptide
Database (APD) (Wang and Wang 2004).
Together, these -700 grammars describe the "language" of the AmP sequences.
In this linguistic metaphor, the peptide sequences are analogous to sentences and the
individual amino acids are analogous to the words in a sentence. Each grammar describes
a common arrangement of amino acids, similar to popular phrases in English. For
example, the frog AmP brevinin-1E contains the amino acid sequence fragment
PKIFCKITRK, which matches the grammar
P[KAYS] [ILN] [FGI]C[KPSA] [IV] [TS] [RKC] [KR] from our database. (The bracketed
expression [KAYS] indicates that, at the second position in the grammar, either lysine,
alanine, tyrosine, or serine is equally acceptable.) Based on this match, we would say that
the brevinin- lE fragment is "grammatical".
The grammars were further processed for convenience in AmP design. Teiresias
outputs its grammars in regular expression format, using wildcards. To make the
grammars more selective, we de-referenced each wildcard in the grammars to a
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bracketed expression. That is, we replaced each wildcard with the set of amino acids
implied by the grammar's offset list. Finally, to allow partial matches as short as 10
amino acids, we divided each grammar into sub-grammars using a sliding-window of
size 10, resulting in 1551 grammars of length ten.
4.1.2.4 Filtering for selectivity
Using the set of 526 AmP sequences from APD, we ran the Teiresias pattern
discovery tool with the following settings: L = 6, W = 6, and K = 2 (a detailed description
of the Teiresias input parameters and associated tools is available elsewhere (Rigoutsos
and Floratos 1998)). The resulting grammar set was masked from the input sequences and
the process was repeated using L = 7, W = 15, K = 5 with the following amino acid
equivalency groups [[AG], [DE], [FYW], [KR], [ILMV], [QN], [ST]]. (See Rigoutsos
and Floratos (1998) for a background on pattern discovery, masking, and terminology
used in these methods.)
Teiresias outputs its grammars in regular expression format, using wildcards. To
make the grammars more selective, we de-referenced each wildcard in the grammars to a
bracketed expression. That is, we replaced each wildcard with the set of amino acids
implied by the grammar's offset list. Finally, to allow partial matches as short as 10
amino acids, we divided each grammar into sub-grammars using a sliding-window of
size 10, resulting in 1551 grammars of length ten.
By design, each grammar in this set of -700 grammars is ten amino acids
in length and is specific to AmPs -- at least 80% of the matches for each grammar in
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Swiss-Prot/TrEMBL are found in peptides annotated as AmPs (Bairoch and Apweiler
2000). APD is a subset of Swiss-Prot/TrEMBL.
Natural AmPs
Discover Motifs
10 Amino Acid Motifs
Filter for Specificity
Filtered 10 Amino Acid Motifs
Figure 4.5: Schematic of the discovery and filtering process for antimicrobial motifs.
TEIRESIAS was utilized to discover motifs from the approximately 500 natural AmPs.
These motifs were broken to 10 amino acid segments, which is long enough to have
relevant motifs, but short enough they could be manipulated and combined to produce the
desired design length of 20 amino acids. Additionally, the motifs were filtered to be
specific to AmPs by ensuring that 80% of the sequences matched in Swiss-Prot/TrEMBL
were annotated as antimicrobial.
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4.1.3 Designing novel AmPs from grammars
The grammars discovered using pattern discovery tools are rules to link function
with the primary sequence of a peptide. We would hypothesize that any sequence which
has significant homology to these grammars would be likely to be antimicrobial.
Therefore, a wide variety of approaches could be used to design novel peptide sequences
based on these grammars. An appealing strategy for reassembling the grammars into new
designs would have the following properties:
1. Sequences highly covered by grammars. Given the hypothesis that
the grammars are associated with antimicrobial activity, a sequence
which has a greater proportion of its length covered by antimicrobial
grammars will more likely exhibit antimicrobial activity. Further, the
likelihood for antimicrobial activity is expected to increase if at least
portions of the designed sequences are homologous to multiple
grammars.
2. Sequences diverse relative to each other. Because the set of
sequences that have homology to antimicrobial grammars is far too
large to synthesize exhaustively, it would be most efficient to sample a
very diverse subset of sequences from the grammar space. It may be
the case that sequences from similar regions of grammar space have
similar activity profiles or toxicity characteristics. In order to maximize
the probability of finding a sequence with a desirable activity spectrum
early in the screen, diverse sequences should be selected for validation.
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3. Sequences diverse relative to natural AmPs. A primary reason to use
a grammar-based approach to design is that it enables the design of
sequences which are only partially homologous to natural AmPs. Well
established techniques have been used to optimize known AmPs
through truncations or single mutations. The uniqueness and power of a
grammar based approach is best exploited through creating diverse
sequences. Furthermore, if therapeutics are developed that are highly
homologous to natural AmPs, they will be more likely to lead to cross
resistance in natural peptides.
4.1.3.1 In silico evolution
For initial studies in AmP design, an in silico evolution process was used to
generate designed sequences. This is a three step approach which involved the following:
1. Random sequence generation. On the order of one million random
amino acid sequences were generated on a computer in order to sample
a broad section of sequence space. While this is only a small portion of
all available sequences, it may be large enough to generate a subset of
sequences with moderate homology to antimicrobial grammars.
2. Scoring of sequences. The randomly generated sequences were then
scored based on their degree of homology with antimicrobial grammars.
Given that the random sequences are likely to have only limited
homology to the grammars, a scoring metric suitable for weak
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homology was devised. In this metric, the fraction of the random
sequence that are homologous to any grammar is determined through an
exhaustive homology search between all designs and grammars. This
scoring metric has a maximum score of 1.0 and will not differentiate
between sequences entirely covered by grammars based on the degree
of overlap of the grammars.
3. Mutate high-scoring sequences. A variety of methods can then be
used to create additional diversity from high-scoring sequences. One
suitable strategy is to perform single or multiple mutations, which may
be conservative or non-conservative. Alternatively, high scoring
sequences may be allowed to breed, meaning that portions of one
sequence is truncated and appended to a portion of another sequence to
further enhance diversity. Steps 2 and 3 of this process may be used in
an iterative process in which the minimum score for a sequence retained
in the mutation step is increased between each round of evolution. This
will create a rich set of highly scoring sequences.
A diagram of this in silico is shown in Figure 4.6.
mutated
children
(2)
//
reproduction& mutation
'* '*.,.,. 44K
""'|~] grammars
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sequences
Figure 4.6: In silico evolution procedure for designing AmPs. A random set of
sequences are generated in silico. Sequences are allowed to recombine with each other
and are mutated. Sequences are evaluated using a fitness function, which scores
sequences based on the fraction of the peptide that is covered by antimicrobial motifs.
High-scoring sequences are retained and iteratively allowed to recombine and mutate to
produce sequences highly covered by motifs. Figure reproduced from KL Jensen.
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An in silico evolution approach is attractive because it mimics the natural process
by which AmPs are designed. This assumes that the fitness function applied (homology
to antimicrobial grammars) is a reasonable proxy for a natural selection process for
antimicrobial defense. Additionally, the starting set of sequence is created without any
user bias, increasing the diversity of sequences that go through the scoring process.
Furthermore, because the process starts with a completely random set of sequences, this
process may be rerun indefinitely to continue generating novel leads for experimental
characterization. This could be used in a design scheme in which sequences that are
experimentally validated are added to a modified training set, and grammars are
rediscovered. The quality of the grammars, and thus the scoring metric, would continue
to improve after each iteration, improving the efficiency of the in silico design at creating
active sequences.
Nevertheless, there are drawbacks with an evolutionary approach. Most
importantly, the designed set is highly dependent on an initial random set. If only a small
portion of the random set has any homology to the grammars, a small set of sequences
may come to dominate the evolution. This may lead to a final set of sequences that are
not highly diverse relative to each other. The breadth of the initial training set is limited
by the computational expense of the exhaustive scoring and mutation process.
Additionally, the process is an inefficient way to develop high scoring sequences. If
parameters are set to retain diversity, the degree of antimicrobial coverage through each
round of evolution increases slowly. Further, a great deal of computational effort is spent
scoring sequences having little homology to the grammars. A more efficient approach to
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sequence design would incorporate knowledge of the grammars into the starting set of
candidates.
4.1.3.2 Combinatorial enumeration
As described above, an in silico evolution approach has a number of shortcomings,
including low efficiency at generating high-scoring sequences, and limited diversity in
the set of peptides designed. We sought a more rigorous and efficient approach to avoid
these problems. In order to accomplish this, the information contained in the grammar
set was used as a starting place for designing new sequences. To this end, we
combinatorially enumerated all sequences of a desired length that were entirely covered
by grammars. This addresses the 3 design criteria stated in Section 4.1.3 by
accomplishing the following:
1. Sequences highly covered by grammars. Inherently, all sequences we
created will be homologous over their entire length to at least one
grammar. This means that all designs would score a 1.0 using the
fractional coverage scoring metric developed for in silico evolution. A
modified scoring metric will be developed for highly covered sequences
and described below.
2. Sequences diverse relative to each other. While there will be less
diversity in the starting set than when using in silico evolution,
enumerating all heavily grammatical sequences will give much larger
set of high-scoring sequences. Sequence diversity may then be
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enforced by using clustering to select unique members from this high-
scoring set.
3. Sequences diverse relative to natural AmPs. As in the second criteria,
using combinatorial enumeration will create a rich set of high-scoring
sequences. Thereafter, a strict filter may be applied to remove
sequences that are too similar to natural peptides, and a large, highly
grammatical set will be left from which to select candidates for
characterization.
To design unnatural AmPs, we combinatorially enumerated all grammatical
sequences of length 20. A length of 20 amino acids was chosen because peptides of this
length may easily be chemically synthesized for validation, and it is near the median
length of natural linear AmPs. While it is advantageous to have shorter peptides for
therapeutic applications to reduce the cost of synthesis, peptides much below 12 amino
acids have reduced selectivity, and 20 amino acids gives a reasonable scale on which to
reassemble 10-amino acid motifs. An alternative approach using motifs shorter than 10-
amino acids would likely have less substantially justified motifs with some of the short
motifs based on chance.
First, for each grammar, we wrote out all possible grammatical amino acid
sequences. More than one 10-amino acid sequence is generated from each motif given
that wild-cards and bracketed expression allow multiple choices for amino acids at each
position. As an example, the grammar [IVL]K[TEGDK]V[GA]K[AELNH][VA][GA]K
has multiple acceptable amino acids at 6 positions, leading to 3*5*2*5*2*2 = 600 unique
sequences. There are roughly 3 million such 10-mers that correspond to antimicrobial
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patterns. Then we wrote out all possible 20 amino acid sequences for which each
window of 10 amino acids is found in the set of 3 million 10-mers. From this set, we
removed any 20-mers that had six or more amino acids in a row in common with a
naturally occurring AmP. There are roughly 12 million such 20-mers, each of which is a
"tiling" of ten 10-mers. An example of a 20-mer entirely covered by 10 amino acid
grammars is shown in Figure 4.7.
P5|
P4
P3 I
P2i
P1 I
FLGVVFKLASKVFPAVFGKV
P6
P7P 8 I
P9
pglo
P11
PHl
Figure 4.7: Example designed sequence covered by antimicrobial motifs. A 20-
amino acid designed sequence (D28) that is covered over each 10-amino acid window by
an antimicrobial pattern, P1-P 11 .
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4.1.3.3 Clustering and scoring of designs
In order to select designed AmPs to synthesize, a scoring metric is required. As
discussed in the text, if one of the AmP grammars matches a particular 10 residue stretch
of a 20-mer, we would call that 10 residue stretch "grammatical." Here, the 20-mers
were designed such that each window of 10 amino acids is grammatical. Obviously
though, some grammars are more common in the set of known AmPs than others. So,
rather than using a binary metric --- grammatical or not --- we developed a score S which
is the degree to which a given 20-mer is grammatical. This score is computed by making
a sequence dot plot matrix (Maizel and Lenk 1981). In the dot plot, the columns
represent the positions, 1-20, of the 20-mer and the rows represent the concatenated
sequences of the -1000 naturally occurring AmPs. A dot is placed in the matrix
wherever a grammar matches both a naturally occurring AmP and the 20-mer. Then
score S is then just the number of dots in the matrix.
First, we desired to create sequences that were diverse relative to natural AmPs. To
accomplish this, we removed any 20-mers that had six or more amino acids in a row in
common with a naturally occurring AmP. Next, we desired to ensure that our designs
were diverse relative to each other. To this end, we clustered these 12 million sequences
using the Mcd-hit software at 70% identity (Li, Jaroszewski et al. 2001). From these
clusters, we chose 42 high scoring sequences to test experimentally. This process is
illustrated in Figure 4.8.
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Figure 4.8: A schematic of the in silico peptide design strategy. Grammars are
induced from the set of natural AmP sequences using Teiresias. Overlapping grammars
are stitched together to create novel 20 amino acid sequences that correspond to the
antimicrobial syntax. Designed sequences are scored based on the prevalence of the
underlying grammar in natural peptides. After removing designs with 6 or more
consecutive amino acids in common with a natural peptide, a representative set of
sequences is selected for experimental validation.
natural
AmPs
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4.1.3.4 Designing negative controls
We sought to demonstrate that antimicrobial activity of designed sequences would
result from the grammars contained, rather than bulk physiochemical properties of the
peptide. While a reasonable negative control would be to use randomly generated
peptide sequences, a more rigorous approach would match the properties of the control to
the designed sequences with the exception of the presence of grammars.
To this end, for each of the 42 synthetic peptides, we also designed a shuffled
sequence, in which the order of amino acids was rearranged randomly such that the
sequence did not match any grammars. These shuffled peptides had the same amino acid
composition as their synthetic counterparts and thus, the same molecular weight, charge,
and pI: bulk physiochemical factors often correlated with antimicrobial activity. We
hypothesized that because the shuffled sequences were "ungrammatical" they would have
no antimicrobial activity, despite having the same bulk physiochemical characteristics. In
addition, we selected 8 peptides from the APD as positive controls and 6 20-mers from
non-antimicrobial proteins as negative controls.
It should be noted that one would expect that a portion of the shuffled controls
would have antimicrobial activity. Given the appropriate bulk physical properties, it is
reasonable to assume a random shuffling has the potential to produce new active
sequences even though it does not match grammars derived from AmPs found in nature,
which is a small set compared to the set of all sequences which have antimicrobial
activity. In fact, shuffling a strong natural AmP, cecropin-melittin hybrid, produced a
series of peptide with weaker, but measurable activity. Nevertheless, we hypothesize that
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non-grammatical sequences should be active less frequently than similar grammatical
sequences.
4.2 Experimental validation
After computational tools were used to generate 100 peptide sequences, including
positive and negative controls, a cost-effective and reliable method to synthesize and
assay the sequences was required. The methods must be appropriate for 20 amino acid
peptides and ideally should be automatable so that a broader set of predictions could be
validated in future work. First, methods.of peptide synthesis will be discussed, followed
by methods for evaluating antimicrobial activity.
4.2.1 Peptide synthesis
A variety of methods are possible for the synthesis of peptides. These methods
vary in cost, the amount and purity of peptide produced, and the ease to which they can
be adapted to a diversity of sequences. In the following sections the advantages and
disadvantages of recombinant production, in vitro translation, and chemical synthesis will
be discussed.
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4.2.1.1 Recombinant production
One method used for the creation of peptides is through recombinant synthesis.
Nevertheless, this approach has a series of undesirable properties for validating AmP
activity. First, the produced AmPs may be toxic to the host cells. Additionally, the
grammar based designs are greatly diverse, so there is not a cost-effective approach to
produce plasmids encoding each of these custom designed peptides. Further, in order to
create sufficient amounts of peptide for characterization against a series of bacteria,
fermentations and purifications would be required. For these reasons, recombinant
production for validating our predictions was infeasible. Recombinantly produced
peptides for well-studied AmPs were purchased and used as standards in this work.
4.2.1.2 In vitro translation
As discussed in Chapter 3, in vitro translation avoids some of the shortcomings of
recombinant production. There is no concern over toxicity to host cells and cells do not
have do be lysed and membranes removed before assaying the peptides. Through the
series of improvements in fusion partner optimization, the cost per peptide to synthesize
sufficient material to test against 2 bacteria at up to 16 ug/mI was reduced from around
$800 to $40, making this approach economically feasible. Additionally the synthesis and
purification was demonstrated entirely in 96-well plates, indicating the process could be
automated.
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There are, however, drawbacks associated with an in vitro translation platform.
First, the fact that the in vitro translation mixture impacts MIC measurements necessitates
a series of purification steps. While these are, in principle, automatable, the robotic
systems required are not available for our use, so they steps must be performed manually.
Additionally, while a combinatorial approach for producing oligos coding for
grammatical antimicrobial peptides was described, using this approach limits the
diversity of sequences that may be explored because it requires reuse of grammatical
subunits. There is not a cost-effective methods for producing oligos for completely
unique sequences that could emerge from some design approaches. Finally, the
concentrations produced are only sufficient to assay up to 16 ug/ml, so only highly active
peptides would be found. It would be advantageous to have information on peptides
which have moderate activity at 256 ug/mI or below, because one could have a fuller
picture of the landscape of activity. There are classes of peptide for which in vitro
translation would be the superior method. For instance sequences which are prohibitively
long to be chemically synthesized and are toxic to host cells would be ideal for in vitro
production. Nevertheless, for linear 20-mers, advances in automated small-scale
chemical synthesis were made during the time of this study so that it became a feasible
approach to validate our predictions.
4.2.1.3 Chemical synthesis
Chemical synthesis is carried out by adding amino acids one at a time through a
series of chemical reactions to produce a desired sequence on polymer resin beads. In
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order to add exactly one amino acid to each peptide being elongated at each synthesis
steps, blocked peptides are used (Fields and Noble 1990). For example, these peptides
may have an Fmoc group on the N-terminal of each amino acid being added. After a
single amino acid is added, the free amino acids are washed away, and the end of the
recently added amino acid is deprotected through the addition of 20% piperidine in DMF.
After a series of washes, the next amino acid is added to the reaction, which attaches to
the free end of the peptide chain which has been deprotected. Additionally, the side
chains of amine or acid containing amino acids are protected with a separate blocking
agent that remains attached throughout the entire peptide synthesis. After the entire
peptide has been synthesized stepwise, all deprotecting groups are removed by
trifluoroacetic acid and the peptide is cleaved from the resin beads. A diagram of the
procedure is given in Figure 4.9.
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Solid Phase Peptide Synthesis Scheme
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Figure 4.9: Schematic for Fmoc synthesis of peptides. Peptides are synthesized one
amino acid at with alternating coupling and deprotection steps. Figure reproduced from
http://www.sigmaaldrich.com/Brands/Sigma Genosys/Custom Peptides/Key Resources/
Solid Phase Synthesis.html.
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amino acid addition
146
While, at the outset of this work, custom synthesis of 20-mers cost in excess of
$500, costs fell to tens of dollars per peptide later in my work. This reduction was
enabled by advances in producing robotics to synthesize peptides at a small scale in
sufficient purity that they could be used without HPLC purification. Chemical synthesis
possesses a number of important attributes that made it ideal for validating our
predictions. First, the system is automated and can produce completely independent
sequences, allowing the evaluation of a diverse set of peptides. Additionally, the yield of
small-scale chemical synthesis is dramatically higher than in vitro translation, which
enables the testing of each peptide against multiple bacteria at up to 256 ug/ml, rather
than just 16 ug/ml. Finally, chemical synthesis allows the incorporation of unnatural
amino acids and chemical modification of the termini of the peptides.
For these reasons, Fmoc chemistry was used to synthesize peptides for validating
our grammar based designs by using the Intavis Multipep Synthesizer (Intavis LLC, San
Marcos, CA) at the MIT Biopolymers Lab. Mass spectrometry was used to confirm the
accuracy of the synthesis and typical purities obtained with the synthesizer were >85%.
Mass spectroscopy for a representative set of peptides is shown in Table 4.1.
Recombinantly produced standards for Cecropin P1, Cecropin Melittin Hybrid, Melittin,
Magainin 2, and Parasin were purchased from the American Peptide Company
(Sunnyvale, CA). In antimicrobial assays, four of the five recombinant peptides had
identical MICs to the chemically synthesized versions from MIT biopolymers, with the
last being one dilution different (Cecropin P1). Also, one designed peptide was
synthesized by MIT biopolymers 4 separate times and the resulting peptides had
consistent activities against both E. coli and B. cereus.
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Molecular Molecular
Peptide Sequence Weight Weight
(theoretical) (MALDI-TOF)
D28 FLGVVFKLASKVFPAVFGKV 2153.9 2154.0
S28 GVSVAGAKKVKVLFVFPFLF 2153.9 2153.6
D23 ALGKLASKVFPAVYCTISRK 2152.9 2153.1
S23 KYGPALVIAVKKSCSLTFRA 2152.9 2151.8
Magainin II GIGKFLHSAKKFGKAFVGEIMNS 2467.4 2467.1
Parasin KGRGKQGGKVRAKAKTRSS 2000.7 1999.4
Table 4.1: Molecular weight of selected peptides. Theoretical molecular weights of
peptides, and measured molecular weights using MALDI-TOF.
4.2.2 Antimicrobial assays
Researchers have used a host of different assays to evaluate antimicrobial activity.
While some assays measure the concentration at which AmPs kill bacteria (the minimum
bactericidal concentration, or MBC), other measure the minimum concentration at which
AmPs inhibit growth (the minimal inhibitory concentration, or MIC). The assays vary
greatly in the ease with which they may adapted to high-throughput evaluation and the
amount of labor required to test each peptide. While some assays are quantitative, others
are qualitative. Additionally, only some of the methods provide information on the
kinetics of the killing or inhibitory activity. Finally, the frequency with which each assay
is used and the degree to which clinicians believe the results of different assays varies.
Commonly used assays include plate counting, fluorescence, and microdilution methods
described below.
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4.2.2.1 Plate counting
As described in the National Center for Clinical Laboratory Standards (NCCLS)
guideline M-26A, the gold standard for evaluating the antibiotic activity of an agent is
through a plate counting technique. In this assay, the agent tested is incubated at desired
concentrations with a target bacteria at a given concentration (usually 5 x 10A5 cfu/ml) in
Cation-adjusted Mueller Hinton Broth (CMHB) for 16-20 hours. The optimal
temperatures for incubation varies by microbe (e.g. 37*C for E. coli and 30'C for B.
cereus). After that time, a sample of the mixture is diluted in Phosphate Buffered Saline
(PBS) to create a series of 10-fold dilutions. A 50 ul sample of each of these dilutions is
spread on a standard 150 mm agar plate and grown overnight at the optimal temperature,
and then enumerated. In order to obtain accurate counts, the dilution should be selected
which gives between 50 and 500 colonies per plate, and at least replicate plating should
be performed. An extension of this assay is a time-kill curve, in which dilution and
plating is carried out at specified times after the start of incubation of the AmPs and
bacteria in the 96-well plate. Time-kill curves demonstrate the rate at which the count of
viable bacteria decreases.
The advantages of this assay are that it is quantitative, and gives a measurement
of MBC as well as MIC. The major disadvantage of this method is that is ill-suited for a
screening assay because of the enormous effort that is required for each agent tested. If it
is desired to test 8 concentrations of an agent, with 5 dilutions required for each
concentration (since it is unknown what the order of magnitude of the resulting counts
will be), with triplicate plating, 120 plates must be created and counted for a single
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peptide. While automated methods are available for creating dilutions and even imaging
and plate counting, the spreading of plates is a significant bottleneck. Additionally, if a
number of agents are being tested together, the length of time required to make dilutions
and plate would likely introduce inconsistencies between the first sample evaluated and
the last sample evaluated. For these reasons, the plate counting method will only be used
as a validation tool to study leads that emerge from other screening methods.
4.2.2.2 Fluorescent reporting
The plate counting technique to find MICs would be prohibitively slow if
hundreds of peptides are to be tested. An alternative method is to use bioluminescence, a
technique developed in recent years to study microbial viability. A gene coding for
luciferase may be cloned into each target pathogen. Luciferase genes may be obtained
from insect and bacterial sources (Simon, Fremaux et al. 2001; Vesterlund, Paltta et al.
2004). Bacterial luciferases tend to have water-insoluble or volatile substrates and are
difficult to express in many hosts. Insect luciferases, on the other hand, catalyze the
breakdown of D-luciferin, which is available as a soluble sodium salt (Lehtinen, Virta et
al. 2003; Sakakibara, Murakami et al. 2003). Further, D-luciferin passes through cell
membranes, allowing fluorescence within intact cells. Finally, insect luciferases are
easily expressed in prokaryotes and mammalian cells. In the presence of ATP, insect
luciferase catalyzes the breakdown of D-luciferin in the presence of ATP and releases a
fluorescent signal, as shown in the following reaction:
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02 + D-luciferin + ATP => ADP + PP + oxyluciferin + H20 + light
Fluorescence is only observed in cells that are producing ATP, so the
fluorescence of a population of bacteria is proportional to the fraction of the cells that are
viable.
In order to use this assay, a luciferase encoding plasmid must be incorporated
either as a plasmid, as in (Lehtinen, Virta et al. 2003), or more stably into the genome of
the target bacteria (Hilpert, Volkmer-Engert et al. 2005). We obtained E. coli and B.
subtilis containing an existing plasmid (pCSS962) coding for luciferase, and appropriate
plasmids for other microbes may be made. Antibiotics are used to select only those
microbes that express this plasmid. For this plasmid, both chloramphenicol and
kanamycin resistance genes are used for selection. An antimicrobial assay may be
carried out by incubating the AmP and microbe for 16-20 hours at the desired incubation
temperature. At the end of incubation 500 uM D-luciferin is added at a 1:1 dilution and a
fluorescence plate reader is used to measure relative fluorescence by exciting at 485 nm
and reading emission at 530 nm in order to quantify the bacteria. Known dilutions of
viable bacteria may be used as a calibration curve for fluorescence versus viable bacterial
count. Plate counting may confirm the accuracy of the counts.
One concern with the use of a luciferase plasmid within target bacteria is that an
antibiotic may be necessary to ensure plasmid expression. If an antibiotic is required, it
may complicate the analysis of an AmP in a screen because the additive effect of the
AmP and antibiotic is measured. This may be particularly misleading for AmPs, which
are known to permeabilize membranes and may enhance the potency of the other
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antibiotic. An AmP which strongly encourages penetration of the other antibiotic without
any killing effect on its own would be mistakenly labeled a potent candidate. While
some error is acceptable for a screen since leads will be validated, clinicians may be
suspicious of this approach.
Fortunately, for this assay, an antibiotic may not be needed if the copy number of
the plasmid is sufficient that it is largely retained during the course of the assay. Cells
containing the plasmid could be grown to a high concentration in a selective medium
with the antibiotic, and then diluted to a fresh medium without the antibiotic for the AmP
assay. In order to test if the plasmid was retained, the specific fluorescence among a
population of viable cells was measured. First, the plasmid containing bacteria was
grown overnight in the presence of kanamycin (10 ug/ml) and chloramphenicol (68
ug/ml). The culture was then diluted 500-fold in the presence of chloramphenicol,
kanamycin, both, or neither and grown to an OD between 0.2 and 0.5. Dilutions of 3 and
10 fold were made, the sample was mixed 1:1 with 500 uM D-Luciferin, and relative
fluorescence read on a plate reader. The resulting fluorescence versus OD is shown in
Figure 4.10.
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Figure 4.10: Fluorescence versus cell density for luciferase containing E. coli with
various antibiotics. Viable E. coli was grown in the presence of Chloramphenicol (Cm),
Kanamycin (Kn), both, or neither. Both cultures with Cm showed reduced fluorescent
responses. For the duration of the assay, plasmid loss did not occur in the absence of
antibiotic, with equivalently strong fluorescence for samples with and without Kn.
Carrying out an antimicrobial assay without a second antibiotic would give clearer
measurement of AmP activity.
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As shown in Figure 4.10, no plasmid loss occurs over the course of the assay
since the specific fluorescence is identical with and without kanamycin present. This
would allow the AmP screen to be run without the presence of an extra antibiotic in the
mixture, simplifying the interpretation of the screening results. It was also noted that
chloramphenicol reduced the specific fluorescence of the plasmid containing bacteria.
A fluorescence assay is convenient because it may be run against multiple
dilutions of an AmP in a 96 well plate. Furthermore, the fluorescence reading reflects the
viable fraction of the cells over time, so both growth inhibition and killing kinetics may
be monitored. Nevertheless, these fluorescence methods are not widely accepted as
accurate measurements of antimicrobial activity within the clinical community.
Additionally, the burden of the luciferase production has the potential to affect MIC
measurements. It could also be possible that an AmP changes the specific fluorescence
of the target bacteria, as chloramphenicol did. Finally, D-Luciferin is an expensive
reagent required for all measurements.
An alternative method for quantifying a viable population is through the use of
LIVE/DEAD staining (Ramji, Baig et al. 2005). These commercially available stains
contain two dyes with selectively stain viable or non-viable cells. SYTO9 is a green dye
that stains all cells, including those with intact membranes. Propidium Iodide (PI) is a
red dye that may not penetrate intact cells, and thus stains the DNA only with disrupted
cell membranes. The fraction of red cells to green cells gives the percentage viability and
may be quantified using microscopy, or fluorescence plate readers. Additionally, flow
cytometry may be applied to quantify live and dead populations (Veal, Deere et al. 2000;
Budde and Rasch 2001). As with luciferase techniques, LIVE/DEAD quantification, is
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not broadly accepted in the clinical community. Further, LIVE/DEAD staining really is
an assay for membrane integrity, which is not equivalent to viability, especially for
membrane permeabilizing agents such as AmPs.
4.2.2.3 Microdilution assay
The most commonly accepted clinical method for screening antimicrobial agents
is a microdilution growth inhibition assay. This assay is describe in NCCLS M-26A, and
optimized for AmPs in the Hancock assay for cationic peptides (Wu and Hancock 1999).
The growth medium can have significant impact on the resulting MICs, particularly for
cationic peptides, and should be chosen to reflect the clinical environment (Schwab,
Gilligan et al. 1999; Dorschner, Lopez-Garcia et al. 2006). Serial dilutions of peptides in
0.2% Bovine Serum Albumin and 0.01% Acetic acid were made at lOx the desired
testing concentration. Target bacteria were grown in Mueller Hinton Broth (MHB, or
cation-adjusted CMHB) to an OD600 of 0.1 to 0.3 and diluted down to 2-7 x1OA5 cfu/ml
in fresh MHB, as confirmed by plating serial dilutions. Five ul of the peptide dilutions
was incubated with 45 ul of the target in sterile, capped, polypropylene strip tubes for 16-
20 hrs. The MIC was defined as the minimum concentration that prevented growth based
on visual inspection of OD. If verification of visual OD quantification is desired, dose
response curves may be created by taking OD600 measurements on a 96 well plate reader
after diluting 30 ul of the sample 1:3 in MHB. The 16-20 hour incubation may also be
carried out in a 96-well plate.
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A microdilution assay may be automated and does not require significant manual
manipulation, making it ideal for a screen. Its results are widely accepted by clinicians,
and any bacteria may be used. Finally, no additional antibiotics or dyes must be added
which could affect bacterial metabolism or viability. When desired, samples from an
overnight incubation may be streaked on MHB agar plates to assess the viability of the
bacteria, and thus determine an MBC. The shortcoming of the microdilution method is
that it does not measure time-kill kinetics. Nevertheless, microdilution is ideally suited
for a screen, and leads from the screen may be further characterized for killing
characterization. For these reasons, the Hancock assay for cationic peptides was used to
evaluate the AmPs designed with pattern-based methods. For more in depth studies in
complex environments such as biofilms, specialized assays may be applied to leads
(Zelver, Hamilton et al. 1999). A diagram of the microdilution assay is given in Figure
4.11 and a sample result is shown in Figure 4.12.
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Figure 4.11: Schematic of a microdilution assay. Within a 96-well plate, all wells are
inoculated with 5 x 10A5 cfu/ml target bacteria in Cation Adjusted Mueller Hinton Broth.
A series of 2-fold dilutions of an AmP is added along one axis at l0x the desired testing
concentration. Along the second axis, replicates of the AmP may be assayed, or different
AmPs. Figure reproduced from JF Moxley.
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Figure 4.12: Schematic of MIC results using a microdilution assay. Following 16-20
hour incubation of peptide with target bacteria, growth is observed (filled) for all
dilutions of peptide 2, whereas growth was inhibited at and above 16 ug/ml for peptide 1.
The MIC is 16 ug/ml for peptide 1 and is greater than 256 ug/ml for peptide 2.
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4.2.3 MICs of natural AmPs
We characterized the activity of each synthetic AmP using a broth microdilution
assay described in Section 4.2.2.3. This assay measures the Minimum Inhibitory
Concentration (MIC) at which the peptide inhibits growth of the target organism. It was
desirable to determine the spectrum of activity for each peptide, so Bacillus cereus and
Escherichia coli were used as representative gram-positive and gram-negative bacteria.
First, a selection of natural AmPs were evaluated to ensure that our results were
consistent with previous studies. A few strong, well-studied AmPs that are commercially
available through recombinant production were studied, including cecropin P1, cecropin
melittin, cecropin A magainin, magainin 2, and melittin. Additionally, a random
selection of peptides from the AmP database were selected including parasin, ranelexin,
and pyrrhocoricin. The MICs for each of these natural AmPs are shown in Table 4.2.
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Table 4.2: Representative MICs for natural AmPs. Powerful, well-studied, AmPs
including cecropin, melittin, magainin, and combinations thereof were tested against E.
coli and B. cereus. Some peptides, such as cecropin P1, are highly specific to Gram
negative bacteria. Others, such as cecropin-melittin hybrid, are broad spectrum. A
random selection of other natural peptides used in our training set including Parasin,
Ranelexin, and Pyrrhocoricin revealed that some AmPs were not active against our target
bacteria in the concentration range tested. This implies that designs drawn from these
peptides may not necessarily have activity.
Natural AmPs E. coli B. cereus
MIC (ug/ml) MIC (ug/ml)
Cecropin P1 2 >256
Cecropin 2 8
Melittin
Magainin 2 64 256
Melittin 16-32 8
Parasin >256 >256
Ranelexin 64 32
Cecropin A 32 >256
Magainin
Pyrrhocoricin >128 >128
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The activity of the natural peptides varies from narrow to broad spectrum. For
instance, cecropin P1 is highly active against E. coli, with no measurable activity against
B. cereus. Intriguingly, a number of the natural peptides such as parasin and
pyrrhocoricin are not active against either bacteria in the concentration range tested (note
that pyrrhocoricin was only tested to 128 ug/ml because of solubility limits). They may
have antimicrobial activity against other bacteria not tested, or may have been
documented as antimicrobial because they are evolutionarily related to other AmPs based
on an upstream or pro-region that is cleaved. This indicates that even if we create a
design tool that perfectly transmits antimicrobial information from the training set to a
designed set, not all of the designs would be expected to have activity. These MICs were
shared with Professor Robert Hancock who pioneered this antimicrobial assay and he
confirmed that the results matched his expectations. Finally, the MICs matched those
measured for recombinant standards for 4 of 5 natural AmPs for which recombinant
versions are available, with the MIC for last peptide being only one dilution different.
This indicates that the chemical synthesis is a reliable method for creating AmPs for
evaluation in this length range.
4.2.4 MICs of control sequences
We characterized the activity of each synthetic AmP using a broth microdilution
assay described in Section 4.2.2.3 against B. cereus and E. coli. Of the negative controls
- 6 peptides randomly selected from the middle of non-antimicrobial proteins from Swiss-
Prot/TrEMBL - none had activity. As shown in Table 4.3, six of the eight naturally-
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occurring AmPs in the positive control group show activity in the concentration range
tested against at least one of the bacteria. Even if our design tool were to perfectly
translate activity information from the training set to the designed set, activity in all
sequences would not be achieved.
162
NATURAL AMPs
Pegtide Sequence . gli B. cereus
Cec Mel Hyb KWKLFKKIGAVLKVL-NH2 2 8
Melittin GIGAVLKVLTTGLPALISWIKRKRQQ-NH2 16 8
Ranalexin FLGGLIKIVPAMICAVTKKC 64 32
Pyrrhocoricin VDKGSYLPRPTPPRPIYNRN ++ ++
NON-AMP SEQUENCES
Peptide
number Sequence E. eli B. cereus
19 RKRKSDVDFEAEFELFEDDD + +
50 PYSLKNGENWLLSEEIIRYP + +
86 HTGRSGPATGHSGHSSTHGS + +
+ = MIC greater than 256 ug/mL
++ = MIC greater than 128 ug/mL, not sufficiently soluble to test at 256 ug/mL
Table 4.3: Minimum inhibitory concentrations for natural peptides. Strong, natural
AmPs including cecropin, melittin, magainin, and combinations thereof have
antimicrobial activity that is either broad spectrum or specific. Randomly selected AmPs
including parasin, ranelexin, and pyrrhocoricin had weaker or no activity against these
target bacteria. This indicates that even if the design tool perfectly translates the activity
distribution from the natural set of peptides, not all designs will be active. Randomly
selected sequences from non-antimicrobial proteins did not display antimicrobial activity.
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4.2.5 MICs of designed sequences
Of 42 designed and 42 shuffled peptides, 2 of the designed were insoluble. Of the
40 soluble designed peptides, 18 had an MIC of 256 ug/mi or less against at least one of
the bacterial targets. This represents a design success rate of nearly 50 %. These results
were repeatable with variation of one dilution or less, which is regarded as the standard
error for MIC measurements. While more sequences are active against gram-negative
bacteria, many of the leads are broad spectrum.
Not only was the fraction of design peptides that were active significant, highly
active leads emerged from this screen of just 42 peptides. Two of the designed peptides,
D28 (FLGVVFKLASKVFPAVFGKV) and D51 (FLFRVASKVFPALIGKFKKK),
inhibited B. cereus growth at 16 ug/ml, which is close to the MICs of the strong positive
controls melittin and cecropin-melittin hybrid (8 ug/ml).
164
DESIGNED PEPTIDES
Peptide
number Seuence coi B. cereus
2 VVFRVASKVFPAVYCTVSKK 128 +
6 LSAVGKIASKVVPSVIGAFK + +
9 GLMSLVKDIAKLAAKQGAKQ 256 +
22 LGALFRVASKVFPAVISMVK 256 64
24 GFIGKLASKVVPSVYCKVTG 128 +
28 FLGVVFKLASKVFPAVFGKV 64 16
30 GALFGLASKVFPAVFGAFKK 256 +
33 VKDLAKFIAKTVAKQGGCYL ++ ++
35 LPVVFRVASKVFPALISKLT + 256
39 MKSIAKFIAKTVAKQGAKQG + +
43 SFVFKLASKVVPSVFSALTR 256 256
45 PVVGRVASKVFPAVIGLVKK + +
55 LSFVGRVASKVVPSLISMIK 256 +
57 LGVVGSLASKVVPAVISKVK + +
63 LPVLFKLASKVFPAVFSSLK 256 64
69 SVVFGVASKVVPSVIGKVKT + +
77 GKKLAKTIAKEVAKQGAKFA 64 +
82 FVGSLASKVVPSVFGAIKTK + +
84 GAVFGVASKVVPSVFSAIKK + +
88 VVFKLASKVVPSVYCTITKK 256 +
+ = MIC greater than 256 ug/mL
++ = MIC greater than 128 ug/mL, not sufficiently soluble to test at 256 ug/mL
Table 4.4: Minimum inhibitory concentrations for designed peptides. Of 42
designed peptides, 40 were soluble, and 18 had activity against either B. cereus and E.
coli at 256 ug/ml or below.
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4.2.6 MICs of shuffled sequences
As described in Section 4.1.3.4, a strict set of control peptides which had the same
overall charge, pI, and molecular weight were designed. Table 4.5 shows that only 2 of
the 38 soluble shuffled peptides displayed activity against B. cereus and E. coli.
Therefore, grammatical sequences are 10-fold more likely to have activity than similar,
non-grammatical sequences. This indicates that activity is not an artifact of bulk
physiochemical properties. Table 4.6 shows a summary of activity for designed,
shuffled, and control peptides against B. cereus and E. coli.
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SHUFFLED PEPTIDES
Peptide
number Seuence E. igi B. cereus
2 TAKVVVFVSFSYVVPKKRAC + +
6 GVSSPIVAVKFKGAVASLIK + +
9 GLKKDALQSIVKKALAAMG + +
22 SVPSVGAVLFFKRAAVMKLI + +
24 GGSTLGVFVKKSKACVIVPY Not soluble
28 GVSVAGAKKVKVLFVFPFLF + +
30 KVVLFGAAGAKLFKASFFGP Not enough material
33 ALVYAGIKKTAFLKVQKCDG + +
35 KVFIATLVVSSFLLAKPPRV + +
39 AKKAQKSGAQTIVKIFAKGM + +
43 ASPTVFRSSVFLSLFVVAKK + +
45 VKRAGKGVAVVPSPLFKIVV + +
55 SSSIPIKMVLVRALVFVKSG + +
57 PKVVGLSIVVVKAKVSSALG + +
63 VSVKKVLPFAPLKSLLSFAF 256 256
69 VFSVKGGKPSVVIKVVVAST + +
77 VIAFAKTKEAKAKLKGQAKG + +
82 KTVPVVLKASIKVSSAGFGF + +
84 SVKVAKSVIPSAVFAGGKVF + +
88 VKTKCSVPAVVYILVKTFKS + +
+ = MIC greater than 256 ug/mL
++ = MIC greater than 128 ug/mL, not sufficiently soluble to test at 256 ug/mL
Table 4.5: Minimum inhibitory concentrations for shuffled peptides. Of 42 designed
peptides, 38 were soluble, and only 2 had activity against either B. cereus and E. coli at
256 ug/ml or below. The fraction of sequences that had activity is almost 10-fold lower
than for the designed sequences.
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Table 4.6: Summary of activity of designed, shuffled, and natural AmPs. Of
peptides designed using antimicrobial motifs, nearly half were active against one of the
two target bacteria at 256 ug/ml or lower. Shuffled peptides, with the same
physiochemical properties, but no homology with antimicrobial motifs showed only 2
active sequences. Thus, the designed population is enriched by approximately 10-fold.
Further, only 6 of 8 natural peptides were active in the range tested, indicating that even
if our design tool perfectly translated activity from the training set, activity rates would
not approach 100%.
E.coli B. cereus Either E. coil
(gram-negative) (gram-positive) or B. cereus
MIC MIC MIC MIC MIC
s 256 ug/ml s 64 ug/ml s 256 ug/ml s 64 ug/ml : 256 ug/ml
Designed 16/40 4/40 8/40 4/40 18/40
Shuffled 1/38 0/38 2/38 1/38 2/38
atal 6/8 6/8 4/8 3/8 6/8
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4.2.7 Killing curves and bactericidal measurements
To validate MIC determinations, we measured optical density at varying
concentrations of a representative set of designed, shuffled, and natural peptides. The
microdilution assay described in Section 4.2.2.3 was carried out, and the degree of
growth was quantified by measuring the OD600 in a 96-well plate reader, rather than by
visual inspection. Figure 4.13 shows that peptides inhibit growth at the MICs determined
by visual inspection. The MBC was measured by dipping sterile toothpicks in wells from
an overnight incubation of the standard antimicrobial assay and streaking on MHB agar
plates. Incubating these samples overnight indicated that there were generally no viable
bacteria above the MIC, with the MBC within 2x of the MIC.
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Figure 4.13: Dose response curves for peptides against B. cereus and E. coli.
Designed peptides D28 and D23 are shown with their shuffled controls, S28 and S23.
Natural AmPs Magainin 2 (active against these bacteria) and Parasin (inactive) are also
shown. The visual determination of MIC corresponded with an OD600 below 0.1 for all
samples. No peptide is present at concentration N. Data is for 3 replicates, 4 OD
measurements each. Error bars = sd.
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Figure 4.14: Plating for viability following incubation with a lead design. Samples of
B. cereus incubated with varying concentrations of D28 and S28 overnight are streaked
on agar plates, which confirms that the bacteria are not viable at or above the MIC (16
ug/ml).
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4.3 High value targets
The prior section describes a proof of concept study for the use of pattern based
AmP design. Relative to shuffled controls, a 10-fold enrichment in the fraction of active
sequences was demonstrated along with a nearly 50% success rate in design. Both gram-
positive and gram-negative bacteria were evaluated and strong broad spectrum activity
was found for 2 leads. While E. coli, is an important hospital pathogen, the value of the
design work would be increased if efficacy was found against pathogens that are critical
in hospital infections or for national security.
4.3.1 Gram positive targets
Peptides with gram-positive activity are particularly exciting because of the
prevalence of drug-resistant, nosocomial Staphylococcal aureus and the threat of
bioterror agents such as B. anthracis, or anthrax. S. aureus is an aggressive pathogen and
the prevalence of drug-resistant S. aureus increased from 32% to 44% over just three
years ending in 1999 (Lowy 2003). This bacteria frequently colonizes a patient's skin or
nares and is often involved in catheter or bloodstream infections. The risk posed by
bioterror agents such as anthrax was brought to the forefront in 2001. These weapons
threaten both civilians and the military, and government has made the stockpiling of
existing antibiotics such as Ciprom a priority, along with supporting the development of
novel agents to fight anthrax. Therefore, we assayed seven designed peptides that had
gram-positive activity, including the highly active D28 and D51 peptides, against the
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Smith Diffuse strain of S. aureus and the Sterne strain of B. anthracis. The results are
shown in Table 4.7.
Table 4.7: Minimal inhibitory concentration of designed and shuffled sequences
against S. aureus and B. anthracis. All seven designed peptides that were active against
B. cereus, were active against both S. aureus and B. anthracis at 256 ug/ml or below.
Only one of the seven shuffled bacteria displayed antimicrobial activity.
MIC
(ugmi)S. aureus B. anthracis(ug/ml)
8 D28
16 D51 D28, D51
32
64 D22 D22
128 D63, S51 D4,D3
256 D5, D35, D43 S51
>256 S5, S22, S28 S5, S22, S28,
>S35,S43,S63 S35,S43,S63
D = Designed based on motifs;
S = Shuffled control
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4.3.2 Antimicrobial activity against S. aureus and B. anthracis
As shown in Table 4.7, all seven peptides had activity against both bacteria at 256
ug/ml or less, whereas only one of the seven shuffled controls had activity (the only
active shuffled peptide had MICs of 128 ug/mi against S. aureus and 256 ug/ml against B.
anthracis). Moreover, two designed peptides, D28 and D5 1, had MICs of 16 ug/ml
against Bacillus anthracis, which is equivalent to the activity of Cecropin-melittin hybrid,
a strong natural peptide. D28 also had an MIC of 8 ug/mi against S. aureus. Therefore,
our diversity generation tool produces leads against critical target bacteria for hospital
infections and national defense.
4.4 Diversity of designed sequences
One goal of our design approach was to create sequences which are diverse
relative to natural AmPs. This was enforced through the application of a filter that
removed any sequence that had more than 5 amino acids in a row in common with a
natural AmP. Nevertheless, our designed AmPs will, by design, show some degree of
homology with natural AmPs because the grammars are based on native sequences.
Peptide D28, for example, was matched by grammars derived from 11 natural AmPs
including brevinin, temporin, and ponericin. Smith-Waterman alignments of our
designed peptides against all natural AmPs in the Swiss-Prot/TrEMBL database reveal
that the degree of homology is limited. In particular, our two most active peptides, D51
and D28, have only 50 and 60% sequence identity with the nearest natural AmP,
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respectively. Our design tool maintains a high success rate for predicting activity while
accomplishing the goal of increasing diversity.
4.5 Summary
We have demonstrated a pattern-based design approach for AmPs. This tool
produced a high fraction of active sequences, which is significantly enriched relative to
shuffled controls with the same bulk physiochemical properties. We also demonstrated
the utility of the designed sequences against important bacterial targets including S.
aureus and B. anthracis.
Our linguistic approach to designing synthetic AmPs may be successful due to the
pronounced modular nature of naturally-occurring AmP amino acid sequences. As we
have shown, this approach can be used to rationally expand the AmP sequence space
without using structure-activity information or complex simulations of the interactions of
a peptide with a membrane. The peptides designed in this work are different from
previously designed synthetic AmPs in that they bear limited homology to any known
protein, which may be desirable for AmPs used in clinical settings (Tossi, Sandri et al.
2000). Some researchers argue that widespread clinical use of AmPs that are too similar
to human AmPs will inevitably elicit bacterial resistance, compromising our own natural
defenses and posing a threat to public health (Bell and Gouyon 2003). Additionally, using
our approach to develop an arsenal of highly diverse antimicrobials would further reduce
concerns about the development of antimicrobial resistance. We hope that this approach
175
will help to expand the diversity of known AmPs well beyond those found in nature,
possibly leading to new candidates for AmP-based antibiotic therapeutics.
Our linguistic design approach may be most valuable as a method for rationally
constraining a sequence-based search for novel AmPs. Diverse leads generated by our
algorithms may be optimized using approaches described in the literature (Hilpert,
Volkmer-Engert et al. 2005). But, the linguistic approach described here has a number of
limitations. First, sequence families that are poorly conserved on an amino acid level
would not benefit from this approach. Second, we suspect that the small size of AmPs is
helpful. Due to the simple nature of regular grammars, they would be less useful for
designing larger proteins and, in particular, proteins with complex tertiary or quaternary
structures. Nevertheless, AmPs are a class of therapeutic candidates whose size and
mechanism of action make them ideal for a pattern-based design approach. This AmP
design approached was published as (Loose, Jensen et al. 2006).
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Chapter 5
Refining AmP Design
In Chapter 4, a motif-based approach to designing novel AmPs was described that
predicted antimicrobial sequences with a high probability of success. Furthermore, two
leads emerged from just 42 designs that had broad spectrum activity at clinically relevant
concentrations. The motif-based tool may have great utility as the first step of a two-
stage design approach. In the first stage, diverse leads could be created using the strategy
described in Chapter 4. In the second stage, these leads are optimized using a variety of
heuristics. In the following sections, a proof-of-concept optimization is carried out for
one of the leads discovered. Additionally, strategies are presented to improve designs by
developing information on the toxicity and activity of natural AmPs used in our training
set.
5.1 Optimization of activity
Researchers have developed a variety of methods to improve the activity of
natural AmPs. Through structure-function studies, they have found that increasing
positive charge, hydrophobicity, and amphipathicity may increase activity (Hilpert,
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Volkmer-Engert et al. 2005). A number of these approaches involve the use of a helical
projection of a peptide, since many linear AmPs form alpha helices that segregate
hydrophobic from positively charged sidechains when they interact with a bacterial
membrane. A helical projection is created by placing the amino acids in order around an
alpha-helical template and viewing down the length of the helix to observe the manner in
which the amino acids are spatially separated.
5.1.1 Helical projection based optimization
In order to demonstrate that the leads we develop may be further improved using
these techniques, we optimized our best candidate, peptide D28. A helical projection of
this peptide is shown in Figure 5.1.
We created 44 variants of D28 by introducing mutations that were selected to
increase positive charge, increase hydrophobicity, and improve segregation of positive
and hydrophobic residues. Additionally, an interior proline residue was removed because
prolines typical create a break in helical structure. While a proline may be useful in
segregating the activity of two distinct domains of an AmP, they may limit the
cooperativity of two portions of the peptide. Each of the 44 variants was chemically
synthesized and tested using methods in Section 4.2.2.3. The resulting MICs are given in
Table 5.1.
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Figure 5.1: Helical projection of lead peptide used for optimization. Because linear
peptides often form alpha helices when interacting with bacteria, heuristic methods were
used based on this projection to increase positive charge, increase hydrophobicity,
improve amphipathicity, and remove a helix-breaking proline to create an optimized
sequence.
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Revised D28
Peptide
number Seauence LE.ggj B.cereus S.aureus
D28 FLGVVFKLASKVFPAVFGKV 64 16 4
R1 FLKVVFKLASKVFPAVFGKV 32 16 4
R3 FLGVVFKKASKVFPAVFGKV 256 256 *
R5 FLGVVFKLASKVFPAVFKKV 64 16 4
R7 FLGKVFKKASKVFPAVFGKV 32 *
R9 FLGKVFKLASKVFPKVFGKV 16 32 64
R11 FLKVVFKKASKVFPAVFGKV 128 * *
R13 FLGVVFKKASKVFPKVFGKV 128 * *
R15 FLGGVFKLASKVFPAVFGKV 64 32 64
R17 FLGVVFKGASKVFPAVFGKV 256
R19 FLGGVFKGASKVFPAVFGKV * *
R21 FLGVVVKLASKVFPAVFGKV 32 16
R23 FLGVVFKLAVKVFPAVFGKV*
R25 FLGVVFKLASKVFPAVVGKV 256 64 32
R27 FLGKVFKGVSKVFPAVFGKV 128
R29 FLGKVFKGASKVVPAVFGKV
R31 FLGKVVKKASKVFPAVFGKV 128 * *
R33 FLGKVFKKAVKVFPAVFGKV 32 * 256
R35 FLGKVFKKASKVFPAVVGKV 128 *
R37 FLGVVFKLASKVFGAVFGKV 16 8
R39 FLGKVFKLASKVFGAVFGKV 16 8 8
R41 FLGVVFKLASKVFGKVFGKV 64 8 8
R43 FLGKVFKGASKVFGAVFGKV 32 128
+ = MIC greater than 256 ug/mL
++ = MIC greater than 128 ug/mL, not sufficiently soluble to test at 256 ug/mL
Table 5.1: Minimum inhibitory concentrations for variants of a lead peptide. By
creating just 44 variants of a lead peptide, an optimized sequence was found with 2-4-
fold improved MICs (R8). This study demonstrates that diverse leads created with a
pattern-based approach may be optimized in a second stage of design.
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5.1.2 Antimicrobial activity of optimized sequences
As shown in Table 5.1, 18 of the 44 D28 variants showed improved activity
against E. coli, B. cereus, or S. aureus. Many of the D28 variants with improved activity
against B. cereus included a mutation at an internal proline, either to lysine or glycine.
These mutations removed the helix breaking proline and may allow the entire structure to
form an alpha helix. One variant (R8) had MICs of 16 ug/ml against E. coli and 8 ug/ml
against B. cereus and 4 ug/ml against S. aureus (relative to 64, 16, and 8 ug/ml,
respectively, for D28). This demonstrates that a lead may be quickly optimized to
improve its broad spectrum activity. If this process were automated, one would have the
opportunity to produce a much larger number of diverse leads, which could be more
thoroughly optimized.
Additionally, all of the work above was carried out using standard assays for
inhibitory activity. Because AmPs are known to work through a membrane
destabilization attack that is usually lethal, the minimum bactericidal concentrations
(MBCs) are frequently similar to the minimum inhibitory concentrations (MICs). In
order to measure MBCs, the standard MIC assay was carried out, and at the end of the
16-20 hour incubation, a sterile toothpick was dipped in each dilution of the 96 well plate
and streak on CMHB agar plates. These plates were grown overnight and all samples
were checked viable cells. As expected, D28 and all six of its variants that were assayed
for bactericidal activity had an MBC within a 2-fold dilution of their MIC.
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5.2 Evaluating mammalian toxicity
Antimicrobial peptides are known to discriminate between bacterial and
eukaryotic membranes based on charge, membrane potential, and presence of cholesterol,
among other characteristics. Nevertheless, systemic antibiotics require large doses to
maintain therapeutic concentrations throughout the body. In part, because AmPs have
not necessarily been designed by nature to be non-toxic to a human host in a systemic
setting, many sequences have significant toxicity at a therapeutic concentration.
A diversity generating design tool will help enable these toxicity barriers to be
overcome. First, a great variety of peptides may be assayed for toxicity in vitro, allowing
researchers to explore new regions of sequence space that may be populated by highly
selective AmPs. Additionally, this design tool will allow the generation of diverse AmPs
which may be tested for toxicity. This information could be used to create a filter that
could be used to eliminate future designs that are likely to be toxic.
5.2.1 Methods for assessing hemolytic activity
For the development of AmPs as systemic antibiotics, the first toxicity screen
typically carried out is for hemolytic activity. This screen is preferred because it does not
require cell culture and gives information on a critical toxicity that many AmPs display.
The hemolytic activity of the peptides may be quantified by measuring the concentration
at which 50% hemolysis of Human Red Blood Cells occurs (HC50) using standard high-
throughput methods (Hamuro et al., 1999). A stock of 10% washed pooled red blood
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cells is diluted to 0.25% with a buffer of 150 mM NaCl and 10 mM Tris at pH 7.0.
Twenty ul of peptide is diluted into 80 ul of the 0.25% red blood cell solution and
incubated for 1 hour at 37'C in a Costar round bottom polypropylene microtiter plate.
Cells are spun down at 6000g, the supernatant removed, and the OD414 measured on a
Fusion Microplate Reader. Total hemolysis will be defined by Melittin at 128 ug/ml or
sterile DI water. Using these methods, the hemolytic activity of lead AmPs D28 and D51
was assessed. While D28 had an HC50 of 64 ug/ml, D51 had an HC50 greater than 512
ug/ml.
5.3 Characterizing natural AmPs
The AmP design carried out in Section 4.1 was based on a list of sequences in a
database of natural AmPs. It was unknown which natural AmPs were active against the
targeted bacteria. Further, the strength and spectrum of activities of natural AmPs was
unknown. Also, no standardized toxicity data was available for the set of natural AmPs.
While publications exist that describe the activity and toxicity of many AmPs, the
methods for synthesizing or assaying are not standardized, and different strains of target
bacteria are used.
It is likely designs could be improved given information on the activity and
toxicity of sequences in the training set. This information could be used during the
pattern discovery phase by removing sequences that are not active against bacteria of
interest. Alternatively, the information could be incorporated during the reassembly of
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patterns or scoring phase. Significantly toxic members could be removed from the
training set or the score of any motifs derived from them could be penalized.
5.3.1 Screening for antimicrobial activity
In order to develop this information, we desired to characterize a diverse,
representative set of natural AmPs. The sequences were chosen from the University of
Nebraska Medical Center AmP database, the same set used for previous design. Only
linear sequences between 10 and 30 amino acids with no disulfide bonds were used
because they could be created using a chemical synthesizer with a high probability of
successful synthesis. The members of the database were clustered using k-means
clustering to select 100 natural AmPs for evaluation. Of these 100 peptides, 82 were
successfully synthesized and were soluble at sufficient concentration to measure their
MICs up to 256 ug/ml. Antimicrobial activities against E. coli ATCC 25922, S. aureus
ATCC 25923, and S. epidermidis ATCC 14990 were measured using standard techniques
given in 4.2.2.3. A distribution of the resulting activities are shown in Figure 5.2.
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Figure 5.2: Distribution of antimicrobial activity for natural AmPs. The MICs for 82
representative natural AmPs was evaluated E. coli, S. aureus, or S. epidennidis. Only
approximately 40% of the peptides had an MIC at or below 256 ug/mI against each
bacteria. Eliminating natural AmPs from the training set that are inactive against target
bacteria may improve the success rate for new designs.
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5.3.2 Antimicrobial activity of natural AmPs
In seen in Figure 5.2, for each target bacteria, approximately 40% of natural
AmPs are active at 256 ug/ml or below. This likely limited the fraction of AmPs that
were designed that had activity in this range and may explain why roughly half of our
designed sequences were not active against similar bacteria. The natural AmPs that were
not active in this screen may have been annotated as AmPs because they are active
against bacteria not tested or at higher concentrations than were tested. Alternatively,
they could have an evolutionary similarity to or share a conserved pro-region with other
AmPs. Narrowing the training set to AmPs active against target bacteria or developing a
scoring system that reflects natural AmPs activity would likely be more successful than
our initial design and is discussed in Future Work.
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5.4 Correlation of antimicrobial activity and toxicity
As described in Section 5.3, the antimicrobial activities of natural AmPs vary
widely. While incorporating MIC information for natural AmPs in our design may
improve activity, it would be even more advantageous if toxicity information were
simultaneously utilized. Ideally, the hemolytic activity of individual AmP sequences
would not be highly correlated with antimicrobial activity so that design tools could be
tuned to produce highly active and non-toxic sequences.
5.4.1 Screening for hemolytic activity
In order to examine this correlation, the hemolytic activities of the 82 natural
peptides screened in Section 5.3 were characterized using methods given in Section 5.2.1.
The resulting distribution of toxicity versus MIC is shown in Figure 5.3.
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Figure 5.3: Hemolytic activity versus antimicrobial activity for natural AmPs. The
hemolytic concentrations for 82 natural AmPs were plotted against the lowest MIC for
each peptide against E. coli, S. aureus, or S. epidermidis. Strong hemolytic activity is not
significantly correlated with strong antimicrobial activity, with some low MIC peptides
demonstrating little hemolysis. This indicates that a scoring approach could be designed
to enrich a population of highly active and non-toxic AmPs.
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5.4.2 Correlation of hemolytic and antimicrobial activity
As shown in Figure 5.3, hemolytic activity is not highly correlated with
antimicrobial activity. There are many AmPs with strong antimicrobial activity (low
MIC) that have low toxicity (a high concentration required for hemolytic activity).
Ideally, activity and toxicity and activity could be incorporated into a scoring algorithm
to enrich the desirable set of highly active and non-toxic AmPs, as discussed in Future
Work.
5.4.3 Distribution of therapeutic indices for natural AmPs
Figure 5.3 demonstrated that antimicrobial and hemolytic activity were not
strongly correlated. An important metric for the selectivity of AmPs for bacterial cells is
the therapeutic index. This is defined as:
Therapeutic Index = Hemolytic Concentration / Antimicrobial Concentration
For the purposes of our designs, the HC50, at which the peptide lyses 50% of red
blood cells is used for the hemolytic concentration and the minimal MIC for E. coli, S.
aureus, and S. epidermidis is used as the antimicrobial concentration. Figure 5.4 shows
the distribution of therapeutic indices for the set of 82 natural peptides described in
Section 5.3. The therapeutic indices vary widely, and AmPs with MICs of 32 ug/ml or
below tend to have a higher therapeutic index.
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Figure 5.4: Therapeutic index distribution for weak and strong natural AmPs. A
histogram of therapeutic indices for natural AmPs in solution (hemolytic concentration /
MIC). The MIC was defined as the smallest of MICs against E. coli, S. aureus, or, S.
epidermidis. The smaller outlined distribution is for strong AmPs which have MICs of
32 ug/ml or below. Because there is a wide distribution of MICs, the activity and toxicity
of peptides are not highly coupled, allowing highly active and non-toxic variants to be
designed. Figure reproduced from JF Moxley.
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5.5 Effect of c-terminal amidation
One of the advantages to a high-throughput design tool and assay is that it allows
users to deduce rules or test hypotheses for AmP design. One attractive question we
chose to explore is whether covering the negatively charged C-terminus of an AmP
would systematically improve activity for a diversity of AmPs. It has been reported for
individual AmPs that amidating the C-terminus, which eliminates the negative charge,
may increase activity (Machado, Sforca et al. 2007). Nevertheless, a systematic study of
the effect of amidation on activity has not been reported.
5.5.1 Effect of amidation of representative AmPs
In order to test the general effect of amidating AmPs, a representative set of designed,
shuffled, and natural peptides were chemically synthesized with and without amidation
and assayed against E. coli and B. cereus. The MICS are shown in Table 5.2.
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Table 5.2: Effect of C-terminal amidation on antimicrobial activity for
representative peptides. The MIC of free acid peptides was found to improve 2-4 fold
if the peptide was amidated. The improvement may result from the shielding of the
negatively charged C-terminus, which may inhibit interaction with a bacterial membrane.
E coli MIC ml B cereus m
'de Free Pep An*mated Free Pep Amidated
0 <4 <4 >256 >256
5 128 32 128 64
20 32 16 <4 <4
28 64 32 8 8
40 32 32 128 128
46 >256 64 >256 64
51 64 16 16 8
62 256 64 >256 256
72 <4 <4 16 <4
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As shown in Figure 5.2, amidated AmPs tend to have stronger activity than their
free acid counterparts. The improvement in activity in this sampling was encouraging,
but it was desired to see if this effect was consistent across a broader selection of natural
AmPs. If it were, this would enable us to improve the activity of all of our designs an
average of 2 to 4-fold.
5.5.2 Effect of amidation on a broader set of natural AmPs
In order to test the generality of the effect of amidation on activity, all of the
natural peptides characterized in Section 5.3 were synthesized with amidated c-termini.
MICs were measured against E. coli ATCC 25922, S. aureus ATCC 25923, and S.
epidermidis ATCC 14990. A histogram of MICs against each bacteria is shown in
Figures 5.5 through 5.7.
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Figure 5.5: Effect of amidation on the MIC against E. coli. The fraction of peptides
with MICs of 256 ug/ml or below increases from 31/82 for free acid peptides (FA) to
41/82 for amidated peptides (Amid), and results in a greater number of highly active (<16
ug/ml) peptides.
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Figure 5.6: Effect of amidation on the MIC against S. aureus. The fraction of
peptides with MICs of 256 ug/ml or below increases from 28/82 for free acid peptides
(FA) to 41/82 for amidated peptides (Amid), and results in a greater number of highly
active peptides.
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Figure 5.7: Effect of amidation on the MIC against S. epidermidis. The fraction of
peptides with MICs of 256 ug/ml or below increases from 30/82 for free acid peptides
(FA) to 51/82 for amidated peptides (Amid), and results in a greater number of highly
active peptides.
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5.5.3 Effect of amidation on hemolytic activity
In the previous section, it was demonstrated that amidating the C-terminus of
natural AmPs gives a broad spectrum improvement in antimicrobial activity, with the
most significant improvement against gram-positive bacteria. This result would be
particularly useful if there was not a concomitant increase in hemolytic activity. Even
without an improvement in therapeutic index, an equivalent increase in activity and
toxicity is desirable because it reduces the concentration of drug that would be required to
achieve a therapeutic effect, lowering the cost of the drug for each dose. To this end, the
hemolytic activities of the 82 natural AmPs screened in Section 5.3 were quantified for
the free acid and amidated versions of the peptides.
As seen in Table 5.3, while antimicrobial activity increases 2.3, 4.6, and 8.0 -fold
for E. coli ATCC 25922, S. aureus ATCC 25923, and S. epidermidis ATCC 14990,
respectively, the average hemolytic activity increases only 1.9 fold. Therefore the
average therapeutic index increases against all bacteria, with an 2.4-fold improvement
against S. aureus, and an 4.0-fold improvement against S. epidermidis. In future designs,
amidated versions of all leads should be tested in hopes of achieving this same
therapeutic index improvement.
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Avg improvement in MIC from
amidating 2.3x 4.6x 8.Ox
Avg improvement in therapeutic 1. 2x 2.4x 4.Oxindex from amidating I 
-
Table 5.3: Improvement in antimicrobial activity and therapeutic index from
amidation. Amidating the C-terminus of peptides increased hemolytic activity an
average of only 1.9x, whereas antimicrobial activities (MICs) improved 2.3-8.0x. This
resulted in improvement in the therapeutic index, defined as the hemolytic concentration
divided by the MIC.
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5.6 Summary
Ideally, a pattern-based AmP design approach would be used as the first step of a
two-stage design tool, with leads being optimized in the second step. Additionally, our
designs would likely improve if the members of the training set were better characterized.
For this reason, the antimicrobial activity and toxicity of a representative set of natural,
linear AmPs was evaluated. We found that antimicrobial activity was not highly
correlated with toxicity, indicating that highly active and non-toxic sequences maybe
designed. Further, we systematically showed that amidating the c-termini of AmPs
improves activity and therapeutic index. Suggestions for further improving a pattern-
based AmP design methodology are given in Section 7.2.1.
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Chapter 6
Medical Device Applications
As described in Section 2.4.2, the development of AmPs as systemic antibiotics
requires half-life, stability, and toxicity challenges to be overcome. Creating a localized
application for AmPs sidesteps many of these problems. Furthermore, hospital infections
are frequently associated with medical devices, so a dramatic clinical impact could be
achieved by creating AmPs localized on medical devices. In this Chapter, the role of
medical devices in infections is outlined. Existing antimicrobial technologies, along with
their shortcomings, are discussed. Finally, the potential of immobilized AmPs as
antimicrobial coatings is described, along with a series of formulations that have been
developed.
6.1 Infections associated with medical devices
The CDC estimates that hospital infections afflict 1.7 million patients and kill
99,000 people in the US each year (http://www.hhs.gov/asl/testify/t060329.html).
Medical devices such as catheters and implants are frequently involved in these infections.
In fact, the majority of hospital infections in critically ill patients are associated with
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medical devices (Darouiche 2001). In the following sections, the pathways for device
colonization, an analysis of devices susceptible to infection, and the problems posed by
biofilms are described.
6.1.1 Pathways for medical device infection
Medical devices provide a surface for bacterial growth and, when penetrating the
skin, a route for external bacteria to enter the bloodstream. Patients in a hospital setting
are particularly likely to be colonized by drug-resistant bacteria, which are particularly
difficult to treat. Figure 6.1 depicts the risks posed by these two classes of devices. If
these infections reach the bloodstream, they lengthen average hospital stays from 5.4 to
20 days and cost up to $50,000 to treat (US Antimicrobial Coatings Market, Frost and
Sullivan, 13 Feb 2006). Further, mortality from bloodstream infections have been
reported from 5 to 25% based on the health of the patient group (Pittet, Tarara et al.
1994).
Skin-Penetrang
Medical Device
Surface Bacteria
Biofilm Formation--
Cell Attachment
ration
Bloodstream
Infection
Implanted
Medical Device
(Artificial Knee)
Figure 6.1: Paths for infection of medical devices. Skin-penetrating medical devices,
such as venous catheters, allow a path for skin bacteria to enter the bloodstream. Fully
implanted devices are suitable surfaces for bacterial growth and biofilm formation.
Figure reproduced from M Hencke.
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6.1.2 Products associated with infection
As described in Section 6.1.1, both fully implanted and skin-penetrating devices
are susceptible to infection. The large infection costs and mortality associated with these
products provide drivers for the development of antimicrobial technology to prevent
these infections. The sizes of a number of medical device markets, along with the total
amount spent on treating infections associated with each of these devices, are given in
Table 6.1. Infection costs per device are also calculated.
For many of these devices, the cost of treating infections exceeds the cost of the
device itself. This is most dramatically evident for central venous catheters (CVCs),
whose infection cost per device used is ten-fold higher than device cost. Because central
venous catheters directly access the bloodstream, infections frequently become
bloodborne, leading to these high costs. If an effective technology were developed to
reduce the likelihood of infection by 50%, there would be a clear incentive for adoption
by hospital purchasers even with premium pricing. All of these markets offer either a
large potential premium or a large total market, and even the lowest achievable premium
($70 for urinary catheters) is high enough to justify market entry. Smaller markets such
as ventricular assist devices may be particularly rewarding. These devices have an
average associated infection cost of $20,000 per device, so a coating that reduces this rate
by 50% provides a savings of $10,000 per device. Ideally, a versatile technology could
be developed that addresses devices of all shapes, sizes, and materials.
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Fracture fixation (nails, rods) 1,498 1,500 750 750
Urinary catheters 283 1,900 10 70
Artificial heart valves 339 48 14,000 2,000
Vascular grafts 115 275 650 1,600
Ventricular assist devices 130 44 59,000 20,000
Central venous catheters 344 3,440 45 450
Table 6.1: Market sizes and infection costs for medical devices. A sampling of
medical devices are shown, many of which have average infection costs per devices
greater than the cost of each device. In addition to improving patient health, an economic
justification exists for an effective antimicrobial coating is added, even if a premium is
charged. (Veenstra, Saint et al. 1999; Darouiche 2004).
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6.1.3 Biofilm formation
Once bacteria colonize a device surface, they frequently form biofilms. These
biofilms are comprised of highly differentiated and complex regions in which interior
bacteria are sheltered from agents in the bloodstream (Costerton, Stewart et al. 1999).
Once a biofilm is formed, the bacteria have reduced susceptibility to both the immune
system and systemic antibiotics (Caraher, Reynolds et al. 2007). For many device
infections, the lack of systemic treatment options requires that physicians remove the
medical device, treat with antibiotics, and then insert a new device. For orthopedics such
as artificial hips and knees, which have been cemented in place, this operation is very
traumatic, especially given that many of the patients are elderly.
The details of biofilm formation and the biofilm environment have been a focus
of infectious disease researchers in recent years. The mechanism of lifestyle switching
have been elucidated for some bacteria, but the complex process of niche-formation
within biofilms is not fully understood (Kolter and Greenberg 2006). The factors which
induce biofilm formation vary, but it is often triggered by a quorum sensing process that
is activated once a sufficient local concentration of bacteria are present, and it may be
accelerated through stresses to the bacteria (Balaban, Gov et al. 2003). For instance,
systemic antibiotics have been shown to induce biofilm formation (Rachid, Ohlsen et al.
2000). Following biofilm formation, clumps of bacteria may detach and create infections
in a variety of tissues distant from the original infection site (Fux, Wilson et al. 2004).
Because treatment of fully formed biofilms is rarely successful, preventing colonization
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and biofilm formation in the first place may be a more effective strategy to block implant
infection.
6.2 Existing antimicrobial technology
Given the enormous impact of device-related infection, a variety of
antimicrobial products have been designed in an attempt to reduce colonization. These
devices use the slow-release of existing antibiotics such as silver other antibiotics to
attack bacteria in the neighborhood of the device. Technologies on the market and under
development are described in the following sections, followed by the shortcomings of
these approaches.
6.2.1 Coatings on the market and in development
Great attention has been paid to central venous catheters given the significant
infection cost. There are currently three antimicrobial CVCs with significant clinical use.
ARROWg+ard@ Blue catheters (Arrow International) are impregnated with a
combination of chlorhexidine (Kuyyakanond and Quesnel 1992) and silver sulfadiazine,
whose antimicrobial activity is primarily due to silver's disruption of the electron
transport chain and DNA replication (Silver, Phung le et al. 2006). These catheters have
been shown in clinical studies to reduce catheter colonization by 44% (Veenstra, Saint et
al. 1999). Cook Critical Care's Spectrum@ line of catheters utilizes the slow-release of
minocycline, which disrupts protein synthesis (Speer, Shoemaker et al. 1992) and
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rifampin, which inhibits RNA polymerase (Kim, Kim et al. 2005). These catheters have
been shown in clinical studies to reduce catheter colonization by 69% (Raad, Darouiche
et al. 1997). Edwards Lifesciences' Vantex@ catheters release silver, carbon, and
platinum ions, with most of the antimicrobial activity attributed to the silver ions. These
catheters have a demonstrated reduction in catheter colonization of approximately 35%,
which may be limited in part by the in vivo sequestration of silver ions by albumin in the
blood stream (Corral, Nolla-Salas et al. 2003). An alternative approach, using long,
cationic hydrophobic polymers has shown antimicrobial activity, but has yet to
demonstrate sufficient selectivity to enable use on an implanted device (Tiller, Liao et al.
2001; Lewis and Klibanov 2005).
6.2.2 Shortcomings of slow-release coatings
Inherently, slow-release formulations lose efficacy over time. Much of the
research to improve existing technologies has focused on extending lifespan by
increasing the loading of antibiotics. One strategy has been to increase the polymer
charge on the surface of the device to ionically bind a higher concentration of antibiotic
(Bassetti, Hu et al. 2001). For many applications, the lifespan remains insufficient.
Additionally, increasing drug load or directly impregnating a polymer with antibiotic may
impact the physical performance of the device. In the following sections, additional
concerns with existing slow-release technology, including the induction of drug
resistance and hypersensitivity, are described.
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6.2.2.1 Drug resistance
Drug resistance to antimicrobials used in existing slow-release formulations is
well documented. Furthermore, selection experiments using these antimicrobials or the
antimicrobial impregnated catheters creates bacterial strains with increased resistance in
vitro, particularly for rifampin (Sampath, Tambe et al. 2001; Tambe, Sampath et al. 2001).
Both chlorhexidine, silver sulfadiazine, and minocycline may also induce bacterial
resistance (Speer, Shoemaker et al. 1992; Silver, Phung le et al. 2006). Additionally, the
existing drug-resistant bacteria are less susceptible to these technologies. For instance,
rifampin-resistant staphylococcal strains, which are common, show reduced susceptibility
to rifampin impregnated catheters (Sampath, Tambe et al. 2001). Clinicians are hesitant
to preventively use antibiotic-impregnated catheters because of the risk of encouraging
the development of drug-resistance, and the knowledge that many resistant strains already
exist.
6.2.2.2 Systemic Toxicity and Hypersensitivity
Slow-release coating also pose a risk because the active agents may lead to
toxicity in the bloodstream or at a distant target in the body. For example, chlorhexidine
is known to result in hypersensitivity reactions (Terazawa, Shimonaka et al. 1998).
Additionally, toxicity has been reported for silver ions that enter circulation (Trop, Novak
et al. 2006). Inherently, a functional coating which does not release its active agent will
have reduced concerns over toxicity since the agent is permanently attached at the site of
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interest. Clinicians and the FDA may be more receptive to an immobilized approach
given these safety advantages.
6.3 AmPs as device coatings
AmPs have a number of advantageous properties for developing antimicrobial
coatings from them. First, they work through a mechanism that is unlikely to induce drug
resistance. This alleviates concerns from clinician about furthering this problem. Also,
they are membrane targeting, and may retain their function when permanently attached to
the surface of a device. By permanently attaching the AmPs, lifespan may be longer than
slow-release coatings and systemic toxicity risks reduced. In the following sections, data
that demonstrates the potential of an immobilized AmP coating for medical devices is
presented.
6.3.1 Immobilized AmPs retain activity
Some antimicrobial peptides maintain activity when permanently tethered to resin
beads. As shown in Haynie et al., some antimicrobial peptides retain activity when
synthesized on and permanently tethered to polymer surfaces (Haynie, Crum et al. 1995).
We sought to verify this activity for a variety of AmPs. To this end, we synthesized
peptides on polystyrene resin beads with permanent linkers.
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6.3.1.1 Methods to create permanently tethered AmPs on resin beads
Peptide synthesis described in Section 4.2.1.3 is frequently carried out on polymer
resin beads. These beads present amine groups on their surface upon which to synthesize
an amino acid stepwise from the C-terminus to the N-terminus. Typically, these beads
have a cleavable groups that allows one to free the peptide after synthesis for purification.
However, amine resins are available without cleavable groups, such as Anaspec tentagel
S-NH2. After synthesis, these 90 micron beads were washed and the peptide left
covalently attached to the beads by its C-terminus. For quality assurance, the same
synthesis procedures was used so the peptides could be cleaved from the resin and
analyzed using MALDI-TOF. A diagram of AmPs synthesized on and permanently
attached to resin beads is shown in Figure 6.2.
SAmP
-AmP
-AmP
Figure 6.2: Diagram of polymer resin beads with immobilized AmPs. A
diagram of a resin bead with peptide synthesized on the surface. These beads have
bactericidal activity when suspended with target bacteria.
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6.3.1.2 Antimicrobial activity of AmPs synthesized on resin beads
In order to evaluate the activity of tethered AmPs, an antimicrobial assay was
applied in which AmP-beads were suspended with target bacteria and the viability of the
bacteria was monitored over time. This resin was incubated at 4, 16, and 64 mg/ml with
a suspension of bacteria at 105 cfu/ml in CMHB for 1 hour and the concentration of
surviving bacteria quantified by plating serial dilutions. A broad spectrum of bacteria
most often associated with medical device infection was tested, including E. coli K12 and
S. aureus ATCC 25923. A polymer resin with a shuffled AmP was used to ensure the
resin itself does not affect cell viability.
As shown in Figure 6.3, cecropin melittin hybrid functionalized beads killed both
gram-positive and gram-negative bacteria. A shuffled peptide did not display activity.
Further, the supernatant from these samples was removed and tested using the same
incubation procedures described above. The supernatant did not display antimicrobial
activity, indicating that the killing does not result from a leached agent. Nevertheless, the
harsh conditions of peptide synthesis are not suitable for medical devices. A superior
approach would allow fully synthesized peptides to be covalently linked to designed
functional groups on the surface of a medical device. Ideally, only mild conditions would
be used.
Escherichia col Staphylococcus aureus
4 16 64 ~0 4 16
AmP-coated polymer conc. [mg/ml] AmP-coated polymer conc. [mg/ml]
Figure 6.3: Reduction in bacterial viability due to incubation with AmP covered
resin beads. We created a polymer resin that was covered with covalently tethered AmP.
This resin was incubated with a suspension of target bacteria, K12 E. coli or ATCC
25923 S. aureus, at ~105 cfu/ml in CMHB for 1 hour, and the concentration of surviving
bacteria was quantified with a standardized plating method. A non-antimicrobial control
was used to ensure the polymer resin itself did not affect cell viability. The supernatant
of the active beads did not show antimicrobial activity, indicating the AmP is not leached.
211
212
6.3.2 Chemistries for attaching AmPs to device surfaces
As discussed in Section 6.3.1.2, immobilized AmPs retain activity, but a mild
synthetic approach is required to attach fully synthesized AmPs to the surface of medical
devices. Amines are a convenient functional group for attachment because they can be
created on a variety of device surfaces. These amines can be converted to maleimide
using sulfo-GMBS. The maleimide created may be used to couple specifically to a
cysteine in the peptide. The remaining synthetic methods for creating immobilized AmPs
were developed and documented by L Ferreira and T Squier.
6.3.2.1 Coupling AmPs via sulfo-GMBS
First, we sought to couple AmPs to a surface similar to that used in Section
6.3.1.2. For this reason, we used the same NH2-microparticles (TentaGel S-NH2 resin).
Thus, reattached peptides could be compared to peptides synthesized on beads so that
similar bead sizes and surface density could be achieved. A single cysteine was
incorporated at the C-terminal of the cecropin-melittin peptide to produce a similar
orientation to the peptide synthesized on beads.
First, the number of free amino groups was quantified using the ninhydrin assay.
Approximately 6.7 mg of microparticles were suspended in 1 mL of 1 M acetate buffer
pH 5.0 containing 12.5 mg of ninhydrin (Sigma). The suspension was kept in boiling
water for 15 min. After 15 min the sample was removed and 15 mL of an ethanol/water
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mixture (1/1, v/v) was added. The reaction mixture was allowed to cool to room
temperature for 1 hour, away from light. Ninhydrin reacts with free amino groups and
creates a blue water-soluble compound. The amount of free amino groups in the beads
was spectrophotometrically determined by measuring the absorbance of the supernatant
at 570 nm, after the 1 hour cooling time. Glycine was used as a reference material.
Peptides were coupled using sulfo-GMBS chemistry. 3.4 mg of sulfo-GMBS was
reacted with 15 mg of NH2-microparticles suspended in 0.5 mL PBS buffer having a pH
of 7.4 at room temperature for two hours with mild agitation (vortex, 100 rpm). After
two hours, the beads were centrifuged for two minutes at 2500 rpm and washed five
times with 1 mL of PBS buffer. In the last wash, the beads were re-suspended in 0.5 mL
PBS buffer and reacted with 5 mg of a cysteine-incorporating Cecropin-Melittin hybrid
peptide, overnight, at room temperature with mild agitation (100 rpm). The beads were
again washed 5 times with 0.5 mL PBS buffer and then re-suspended in 1 mL of PBS and
kept at 4 "C overnight. The following morning the supernatant was removed, and the
beads were washed 5 times with lmL of PBS buffer. The beads were re-suspended in
lmL and stored at 4*C. The peptide immobilized in the beads was determined by BCA
assay (Sigma), using cecropin melittin as the standard. The amount of peptide bound to
beads was determined indirectly from the difference between the initial total peptide
exposed to the beads and the amount of peptide recovered in the several washes. The
concentration of peptide bound to the beads was approximately 0.91 mg per 15 mg of
beads, which corresponds to 0.060 mg of peptide per 72.7 mm2 of bead surface area,
assuming the bead is non-porous.
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6.3.2.2 Antimicrobial activity of AmPs attached via sulfo-GMBS
The peptide conjugated beads were tested against E. coli by incubating with 1 x
107 cfu/ml K12 E. coli in CMHB which had been stained with 30 pLM propidium iodide
and 6 pM SYTO9 stains from a standard Molecular Probes LIVE/DEAD kit. As
determined with a fluorescence microscope, 50% of the bacteria in solution were killed
after one hour, whereas no killing occurred with control beads that had shuffled peptides.
To assess whether the killing effect was due to the immobilized peptide, the medium that
was incubated with the beads was centrifuged at 3000g for 2 minutes, the supernatant
was removed, and the supernatant was inoculated with 1 x I07 cfu/ml stained E. coli in
CMHB for 1 hour. No killing was observed. This indicates that the immobilized peptide
is the effective component against bacteria.
6.3.3 Reattaching AmPs to membranes
While the experiments described in Section 6.3.2.2 demonstrated the
antimicrobial activity of an AmP attached via sulfo-GMBS, the assay is not well suited to
quantitative measurements. Different samples had various levels of bead agglomeration,
so the exposed surface area may not be consistent. A more appropriate model for the
interaction of a device surface with bacteria would be a flat functionalized membrane.
Additionally, standardized assays exist for non-leaching antimicrobial surfaces which
may be applied for a flat functionalized surface.
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6.3.3.1 Methods to attach AmPs to a cellulose membrane
Since the sulfo-GMBS chemistry reacts with an amine on the device surface, we
chose to immobilize on a membrane with terminal amine groups that is used for the solid
state synthesis of peptides (Intavis Product number 30.100). This surface presents 0.340
imoles of NH2 per cm2, as determined by a picric acid assay. The terminal amine
groups of the membrane were reacted with the succinimide groups of sulfo-GMBS and in
a subsequent step the maleimide groups of sulfo-GMBS was reacted with the thiol groups
of the cysteine containing cecropin melittin peptide. The amount of peptide bound to the
membrane was determined indirectly from the difference between the initial total peptide
exposed to the beads and the amount of peptide recovered in the several washes. The
quantity of immobilized peptide was approximately 2.0 mg per cm2 of membrane. This
peptide-conjugated membrane was tested for immobilized bactericidal activity against E.
coli ATCC 2592.
6.3.3.2 Antimicrobial activity of AmP functionalized membranes
The standardized method for evaluating a non-leaching antimicrobial surfaces is
described in ASTM 2149. Given materials constraints, we scaled this assay down to
smaller volumes. The modified assay used was as follows: an overnight culture of a
target bacteria in a growth medium such as Cation Adjusted Mueller Hinton Broth, is
diluted to approximately 1x105 cfu/ ml in pH 7.4 Phosphate Buffered Saline using a
predetermined calibration between OD600 and cell density. A 0.5 cm 2 sample of
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immobilized antimicrobial surface is added to 0.75 ml of the bacterial suspension. The
sample should be covered by the liquid and incubated at 37*C with a sufficient amount of
mixing that the solid surface is seen to rotate through the liquid. After 1 hour of
incubation, serial dilutions of the bacterial suspension are plated on agar plates and
allowed to grow overnight for quantifying the viable cell concentration. Using this
procedure, the cecropin melittin conjugated membrane produced a 4.2-log reduction of E.
coli in solution over 1 h. Testing the amine-functionalized membrane without an
antimicrobial peptide conjugated to it for immobilized bactericidal activity did not show a
significant reduction in viable bacteria (<0.1 log reduction).
6.3.4 Killing through multiple bacterial challenges
Samples identical to those generated in Section 6.3.3.1 were synthesized and
stored at 4' C in pH 7.4 PBS for more than three weeks. When this peptide-conjugated
membrane was tested against for immobilized bactericidal activity against E. coli using
methods given in Section 6.3.3.2, an average of a 1.8-log reduction of bacteria in solution
occurred over 1 h. The samples were then removed from the testing solution, and placed
in fresh PBS. Samples underwent 10 minutes of ultrasonication, were switched to fresh
PBS, and underwent an additional 30 minutes of sonication. They were then rinsed and
retested for bactericidal activity against E. coli ATCC 25922. The washed samples
produced an average of a 3.3-log reduction in viable bacteria over 1 hour. Therefore, the
active agent is not consumed during the one hour assay, and repeated killing is possible.
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6.3.5 Confirmation that activity results from non-leached
material
In order to convince clinicians and the FDA that activity results from the
immobilized agent, rather than a leached material, a variety of studies were undertaken.
As described in Section 6.3.1.2, direct observation of the interaction between the
antimicrobial surface and bacteria stained with LIVE/DEAD viability stain demonstrated
killing within minutes of bacteria contacting the surface. This could, however, result
from locally released AmPs. One reason this may be unlikely is that many of the samples
that demonstrate killing had been washed in PBS in excess of 10 times, well beyond the
point that leachable AmP could be detected using a BCA assay. Additionally, some
samples were stored for more than 3 weeks before use in an assay which lasted just one
hour. While bacteria were not present during this storage period, much of the non-
covalently attached material would have been released before the assay. Nevertheless, a
standardized test for leached agent from a permanently immobilized surface was carried
out, which is described below.
After performing the antimicrobial assay described in Section 6.3.3.2, the
supernatant was removed for characterization during both rounds of killing before and
after washing. At the end of the 1 hour incubation between the sample and a solution of
bacteria, 0.4 ml of bacterial solution was removed. The 0.4 ml was centrifuged at 3000g
for 5 minutes to remove remaining bacteria. A sample of 0.2 ml of supernatant was
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removed and added to 0.05 ml of E. coli ATCC 25922 at 5 x 105 cfu/ml, giving a final
concentration of 1 x 105 cfu/ml, as in the standard antibacterial assay. This mixture was
incubated at 37'C with the same degree of mixing as in the immobilized bactericidal
activity assay, and serial dilutions were plated at the end of 1 hour.
The supernatant from both the 1st and 2nd rounds of killing in Sections 6.3.4 did
not show a measurable amount of killing (< 0.1-log reduction in viable bacteria). Because
the surface demonstrated killing, but the supernatant above the surface does not
demonstrate any killing, the immobilized antimicrobial surface is substantially non-
leaching.
6.4 Improved device coatings
In the previous section, permanently immobilized AmPs as antimicrobial surfaces
were described. In addition to demonstrating broad spectrum activity, it would be
desirable to achieve the maximal activity per amount of peptide immobilized (specific
activity). This would reduce manufacturing costs and may lessen concerns over toxicity.
In the following sections, a strategy to optimize activity by controlling the orientation of
peptide during immobilization is described. Further, an alternative hydrogel formulation
is presented which may have superior properties in certain clinical settings. Finally, the
procedure for evaluating the hemolytic activity of the immobilized antimicrobial surface
is given, with the surface proving to be largely non-hemolytic.
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6.4.1 Effect of orientation on specific activity
In the two patent applications that describe reattachment of an AmP to a polymer
surface, the peptide is attached via any amine group (US Patent Applications
20040126409, 20050065072). AmPs tend to have multiple positively charged amines as
side chains, which contribute to their activity. Using a chemistry that links to any amine,
such as l-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) chemistry,
will tether an AmP with a random distribution of orientations, depending on which amine
is linked. Additionally, a given AmP may be tethered through multiple amines. Some
orientations of peptide, or peptides tethered by multiple sites may have reduced
bactericidal activity.
A superior strategy would be to immobilize the peptide on the surface of the
substrate in such a manner that the portion of the peptide presented to interact with
bacteria upon exposure is uniform for all immobilized molecules of a given peptide.
Ideally, the location of the single tethering site within the peptide should be controlled to
maximize activity. Alternatively, multiple attachment residues within the same region of
the peptide could yield a single orientation. Typically, the N-terminus of the peptide
should be presented to target cells for highest activity, although this may vary depending
on the peptide. The sulfo-GMBS described has the advantage that the orientation can be
controlled by placing only a single cysteine within the peptide being tethered. Since most
linear AmPs do not contain cysteines, allowing only one cysteine is not significantly
restrictive for peptide design.
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6.4.1.1 Methods to generated AmP surfaces without orientation
In order to assess the effect of orientation on activity, samples of membranes with
oriented and non-oriented peptide at similar surface densities would be desired. A
sample with non-oriented peptide tethered through any amine groups was created on the
same cellulose surface used in Section 6.3.3.1. The following protocol was followed: A
cellulose membrane (1xi cm ) containing terminal amine groups was incubated with a
solution of Methyl N-succinimidyl adipate (MSA, Pierce) (1.54 mg in 0.1 mL of a
solution of DMSO in PBS pH 7.4 (1:9, v/v)) for 2 h, at room temperature. The membrane
was then washed several times (5 x 1 mL) with PBS and incubated in phosphate buffer
pH 9.5 (2 mL) overnight. After that time, the membrane was washed with PBS pH 7.4 (5
x 1 mL) and 0. 1M citrate buffer pH 7.5 (5 x 1 mL). The majority of the terminal amine
groups of the cellulose membrane reacted with MSA. The content of amine groups was
0.340 pmol/cm2 and 0.039 gmol/cm2, before and after MSA reaction, respectively.
The terminal COOH groups of MSA were coupled with the terminal NH2 groups
of the antimicrobial peptide using EDC chemistry. The membrane was reacted with 0.5
mL of N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride (EDC) solution
(4.8 mg/mL in 0.1 M sodium citrate buffer pH 5.0) for 30 minutes and afterwards washed
with PBS (3 x 1 mL). The activated membrane was subsequently reacted with a cysteine-
incorporating Cecropin-Melittin hybrid peptide (5 mg in 1 mL of PBS), overnight, at
room temperature, with mild agitation (100 rpm), and finally washed with PBS (10 times,
1 mL washes) and kept in PBS, 4"C, until use. The peptide immobilized on the
membrane was determined by the BCA assay (Sigma), using free peptide as a standard.
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The amount of peptide bound to the membrane was calculated from the difference
between the initial total peptide exposed to the membrane and the amount of peptide
recovered in the several washes.
6.4.1.2 Methods to generate AmP surfaces without orientation
We sought to assess the specific activity for oriented versus non-oriented AmPs
immobilized on surfaces. To this end, samples were created with methods given in
Section in 6.3.3.1 and 6.4.1.1. For non-oriented AmP, the peptide content was 1.84
0.27 mg/cm2 (n=2). The content of peptide per surface area was similar to the one
immobilized using an oriented peptide (sulfo-GMBS chemistry) (1.75 ± 0.36 mg per cm2,
n=3). Both oriented and non-oriented peptides with similar surface densities were
evaluated for immobilized bactericidal activity against E. coli ATCC 25922 using
methods given in Section 6.3.3.2. The oriented peptide produced a 3.0-log reduction in
viable bacteria, whereas the non-oriented peptide produced only a 1.6-log reduction. This
shows that the immobilization of an antimicrobial peptide in an oriented way creates a
higher specific biological activity. A higher specific activity lowers costs and reduces
concern over toxicity.
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6.4.1.3 Activity of oriented AmP at lower concentrations
A cysteine-incorporating Cecropin-Melittin hybrid peptide was immobilized to
the amine presenting cellulose membrane with the sulfo-GMBS chemistry as described in
Section 6.3.3.1, with the exception that the concentration of peptide in solution during
immobilization was varied from 0.125 mg/ml to 5.0 mg/ml. Samples were assayed for
immobilized bactericidal activity as described in Section 6.3.3.2. When a concentration
of 5 mg/ml was used during immobilization, the resulting surface produced a 2.0-log
reduction of E. coli ATCC 25922 in 1 hour. However, when the concentration of peptide
during immobilization was reduced to 0.125 mg/ml, a 1.8-log reduction still occurred,
which is at a significantly lower density than the non-oriented peptide in Example 6.
Thus, a greater immobilized bactericidal activity is achieved per mass of peptide used
when the peptide is oriented (higher specific activity)
6.4.2 Hydrogel formula
Hydrogels have a number of appropriate properties for coating medical devices.
They can reduce biofouling and improve biocompatibility (Norton, Tegnell et al. 2005).
In addition, a wide variety of chemistries may be used to create hydrogels, which may be
designed to present attachment sites for AmPs. The design and evaluation of an AmP
functionalized dextran hydrogel is described below.
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6.4.2.1 Production of hydrogels
Dextran gels were prepared by the UV crosslinking of dextran acrylate
macromonomer. Dextran-acrylate with a degree of substitution of 23.3% (400 mg) (see
Ferreira et al., Biomaterials 2002, 23, 3957-3967 for details, in preparation) was
dissolved in PBS (1.8 ml) and Irgacure (5 mg/ml, 250 gL) was gently mixed into the
solution. Cross-linking of the solution was initiated by exposure UV-light over a 10
minute period. The resulting gel was cut into several disks (8 mm diameter) using a
biopsy punch, and washed overnight in water. Prior to the functionalization reaction, each
dextran disk was soaked in 95% ethanol for 20 minutes, shrinking the gel. Then, the
shrunken gel was soaked in a solution of sodium periodate (5.3 mg/ml, 1 ml) in PBS, for
1 hour with mild agitation (vortex, 100 rpm). After this time the disk was washed (5
times) in PBS to remove any un-reacted sodium periodate. The disk was then placed in a
solution of ethylene diamine dihydrochloride (66 mg/ml, 1 ml) and the reaction was
allowed to continue for 1 1/2 hours with mild agitation (vortex, 100 rpm). After this step
the disk was rinsed thoroughly (5 times) in PBS. A solution of sodium cyanoborohydride
(15 mg/mL, 1 ml) was prepared in PBS and allowed to cool to room temperature for 10
minutes after mixing. The disk was allowed to react, without agitation, in the sodium
cyanoborohydride solution for 30 minutes followed by thorough rinsing and overnight
soaking in PBS. The functionalized gel was soaked in 95% ethanol for 20 minutes
followed by soaking in a sulfo-GMBS (10 mg/ml, 0.4 ml) solution for 2 hours at room
temperature, with mild agitation (vortex, 100 rpm). Excess sulfo-GMBS was removed by
rinsing with PBS (5 times). The disk was then soaked again in 95% ethanol for 2 minutes
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followed by soaking in a cysteine-incorporating Cecropin-Melittin hybrid peptide
solution (5 mg/ml) overnight, at room temperature, with mild agitation (vortex, 100 rpm).
The disk was washed 10 times (0.5 ml, PBS), over a 2 day period, and the washings were
kept for the determination of peptide released. BCA assay showed 3.22 mg of peptide
was immobilized on the dextran disk.
6.4.2.2 Activity of hydrogels
The solid dextran gels were assayed for antimicrobial activity in Section 6.3.3.2.
Approximately 0.5 cm2 samples of gel were used at the same agitation as for the
cellulose samples, which was sufficient to suspend the gel throughout the assay. A gel
functionalized with a cysteine-incorporating Cecropin-Melittin hybrid peptide
demonstrated a 2.9-log reduction in E. coli ATCC 25922, whereas a gel without
Cecropin-Melittin hybrid peptide did not display a significant reduction in viable bacteria
(< 0.1-log).
6.5.3 Hemolytic activity
For blood contacting devices, a coating must be non-hemolytic. Neither cecropin
melittin nor the tethering approach have been optimized for hemocompatibility.
Nevertheless, a cysteine-incorporating Cecropin-Melittin hybrid peptide was immobilized
to the amine presenting cellulose membrane with the sulfo-GMBS chemistry as described
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in Section 6.3.3.1 was tested for hemolytic activity. A stock of 10% washed pooled red
blood cells (Rockland Immunochemicals Inc, Gilbertsville, PA) was diluted to 0.25%
with a hemolysis buffer of 150 mM NaCl and 10 mM Tris at pH 7.0. A 0.5 cm 2
antimicrobial sample was incubated with 0.75 ml of 0.25% red blood cell suspension for
1 hour at 37*C. The solid sample was removed and cells spun down at 6000 g, the
supernatant removed, and the OD414 measured on a spectrophotometer. Total hemolysis
was defined by diluting 10% of washed pooled red blood cells to 0.25% in sterile DI
water and incubating for 1 hour at 37*C, and 0% hemolysis was defined by a suspension
of 0.25% red blood cells in hemolysis buffer without a solid sample. The peptide
immobilized sample produced only 4.95% hemolysis using this assay, demonstrating that
the sample is a substantially non-hemolytic surface. With optimization of the AmP
sequence or coating parameters, it may be possible to further reduce hemolysis.
6.6 Commercial potential
A team was formed to evaluate the potential of immobilized AmPs as a
commercial coating for medical devices. Through extensive conversations with users and
industry, a business plan was developed. The societal impact and commercial
opportunities of our technology in addressing medical device infections has generated
excitement in the entrepreneurship and venture capital communities. In the previous year,
the following competitions recognized the potential of our technology:
e First Place, MIT lOOK Venture Capital Competition 2006 (164 entries)
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" First Place, Harvard GSAS Biotechnology Business Plan Competition
" First Place, Cambridge-MIT Pitch Competition
" First Place, Oxford University Business Plan Competition (117 entries from 10
countries)
In light of this success, we incorporated a company, SteriCoat, in July 2006 to
exploit this technology. Development work moving towards in vivo studies is described
in Future Work in Section 7.2.2.
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Chapter 7
Conclusions and recommendations
7.1 Summary and conclusions
A successful approach to create diverse AmPs was demonstrated. First, a high-
throughput method to produce AmPs was developed using in vitro translation. This
approach is automatable and may produce agents that would be toxic to recombinant
hosts. The cost of the system was reduced and yield optimized through a series of
improvements. An oligonucleotide synthesis scheme that mimicked pattern-based design
allowed the reuse of primers and the study of pattern synergy. Additionally, a robust
batch system was developed and yield maximized by optimizing the fusion partners co-
translated with the AmPs (Loose, Langer et al. 2007). Finally, an effective purification
scheme was developed so that components of the in vitro mixture would not impact MIC
measurements.
Methods to design AmPs based on semi-conserved patterns were evaluated.
Nearly 50% of the designed sequences were active against target bacteria tested at 256
ug/ml or below. This represents a 10-fold enrichment over shuffled control peptides
which had the same bulk physiochemical properties but were not homologous to
antimicrobial patterns. Further, two lead sequences were found which had MICs of 64
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ug/ml against E. coli and 16 ug/mI against B. cereus. This activity was extended to
critical targets including S. aureus and B. anthracis (Loose, Jensen et al. 2006).
We also demonstrated that AmP leads that emerged from pattern-based design
could be optimized through a variety of heuristic approaches. Broad spectrum activity
was improved, with an optimized sequence having MICs of 16 ug/mI against E. coli and
8 ug/ml against B. cereus and 4 ug/ml against S. aureus. Additionally, the groundwork
was laid for improved design by characterizing the antimicrobial activity and toxicity of a
representative set of natural, linear AmPs. This information may enable an improved
scoring metric, leading to more active designs, as described in Section 7.2.1. We also
systematically showed that amidated AmPs had stronger activities and higher therapeutic
indices than free acid peptides.
Finally, a series of immobilized AmP coatings were created for medical devices.
Through interactions with clinicians, it was found that infections were frequently
associated with catheters and implants. AmPs have suitable characteristics for medical
device coatings because they remain active when tethered to the device surface, potential
increasing active lifespan and lowering toxicity. Proof-of-concept surfaces we created
demonstrated broad spectrum activity through repeated bacterial challenges without
significant hemolytic activity.
Collectively, this work leads to the following conclusions:
* In vitro translation is a suitable platform for the creation of a diverse set of
peptides that may be toxic to a recombinant host.
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* Translation yield may be improved and functionality enhanced by the choice
of an appropriate fusion partner.
e Further, designing the fusion partner and peptide to be the optimal length,
approximately 100 amino acids, maximizes translation yield while providing
stability from proteases. This was demonstrated for multiple sequences and
translation systems.
" A high-throughput platform for the in vitro translation and evaluation of
AmPs may be enabled given an appropriate purification scheme.
" Natural AmPs contain hundreds of semi-conserved motifs in their sequences
that are specific to AmPs relative to other peptides and proteins in SWISS-
PROT.
* Further, these semi-conserved motifs may be assembled in novel
combinations to produce active AmPs with a high probability of success.
e Diverse leads emerging from a pattern based design approach may be
optimized to give broad spectrum agents.
* Amidation of natural peptides improves their antimicrobial activity and
therapeutic index.
e Immobilized AmPs retain broad-spectrum activity and are effective against
repeated bacterial challenges.
e While the clinical use of AmPs has been limited due to peptide cost, toxicity,
and instability, an improved design methodology may yield sequences that
have superior properties for development. Additionally, innovative strategies
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for the delivery or formulation of AmPs may also bypass obstacles to clinical
development.
7.2 Recommendations and future studies
The pattern-based design presented here was executed without any knowledge of
the antimicrobial activity and toxicity of members of the training set. Improved design
would likely be possible if this information was incorporated into the pattern discovery or
scoring portion of the AmP design. A portion of the data for natural peptides was created
as described in Section 5.3. This data should be supplement, and improved scoring
algorithms hypothesized and tested, as described below.
7.2.1 Iterative optimization of AmPs
In the work presented in this thesis, 50% of designs were active against E. coli or
B. cereus. Nevertheless, 70% of natural AmPs were found not to be active against each
target bacteria at 256 ug/ml or below. Given activity and toxicity data, a weighting
system could be developed for each motif based on the characteristics of the peptides
from which the motif is derived. These motif weights should provide a useful metric for
scoring designed sequences. An iterative approach could be used in which each set of
designed peptides is characterized and active peptides are added to the training set before
discovery and design are executed again. After many rounds of design and analysis, one
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would hope to enrich the space of highly active and non-toxic sequences. An overview
of this procedure is given in Figure 7.1.
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Figure 7: Proposed method for discovery and evaluation of antimicrobial peptides.
In our initial study, we applied pattern discovery to a sequence database of natural AmPs,
designed synthetic AmP leads, and demonstrated activity for 50% of these designed
sequences. However, preliminary experimental characterization of this sequence
database has shown only a small fraction of these AmPs as non-toxic and active against
clinical bacterial targets. To improve activity an upgraded database of experimentally
characterized peptides should be created. Furthermore, using this improved training set,
an iterative pattern discovery and design approach that leverages our accumulating
knowledge of peptide activity could produce highly active and non-toxic AMIN
customized for clinical needs. Figure designed with JF Moxley.
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7.2.2 In vivo activity and toxicity
In Chapter 6, a number of active and non-hemolytic medical device coatings
comprised of immobilized AmPs were presented. In order to further develop this
technology, animal biocompatibility of one of these active surfaces should be
characterized as soon as possible. Additionally, the activity should be improved by
optimizing the AmP sequence used and altering coating parameters including tethering
length and density. Finally, the in vivo antimicrobial activity should be quantified in
accepted models of medical device infection.
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Chapter 8
Appendix
8.1 Sequences for in vitro translation studies
Truncated GFP constructs
35 amino acid truncation of GFP (Bbsl linker underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTTCA
CAGAATAATGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTGGAT
CCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGCAA
TAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTIT TTGCTGAAA
GGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTC
GATAGTGGCTCCAAGTAGCGAA
43 amino acid truncation of GFP (Bbsl linker underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATrCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATITTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCTCACAGAATAATGGGTCTTCATAATAGATTCCAGCA
CACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAG
TTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCT7GGGGCCTCTAAACGG
GTCTTGAGGGGTTITTGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGG
TGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
57 amino acid truncation of GFP (Bbsl linker underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTITCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGTCACAGAATAATGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTAC
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TAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCG
CTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGT T
TGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATC
GCGTAGTCGATAGTGGCTCCAAGTAGCGAA
70 amino acid truncation of GFP (Bbsl linker underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAAC TTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTCACAGAATAATGG
GTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAA
CAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATA
ACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTITITGCTGAAAGGAGGAACTAT
ATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTC
CAAGTAGCGAA
82 amino acid truncation of GFP (Bbsl linker underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTTCAAGATACCC
GGATCATATGAAACGGCATGACTCACAGAATAATGGGTCTTCATAATAGATTCCAGC
ACACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGA
GTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACG
GGTCTTGAGGGGTITTGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGG
GTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
95 amino acid truncation of GFP (Bbsl linker underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATITGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTTCTCT7ATGGTGTTCAATGCTTTCAAGATACCC
GGATCATATGAAACGGCATGACTTTCAAGAGTGCCATGCCCGAAGGTTATGTACA
GGAATCACAGAATAATGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTACT
AGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGC
TGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGITIT
GCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATC
GCGTAGTCGATAGTGGCTCCAAGTAGCGAA
139 amino acid truncation of GFP (Bbsl linker underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
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GCAACATACGGAAAACTTACCCTJ7AAAYI1W1TrGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACYI17CTCTTATGGTGTI7CAATGCY1= CAAGATACCC
GGATCATATGAAACGGCATGACTF1= CAAGAGTGCCATGCCCGAAGGTTATGTACA
GGAAAGAACTATAT =TJCAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCA
AGYTrGAAGGTGATACCCYJ7GTTAATAGAATCGAGTTAAAAGGTAYJ7GATI=[AAAG
AAGATGGAAACATTCflGGACACTCACAGAATAATGGGTCTfCATAATAGATTCCAG
CACACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCG
AGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAAC
GGGTCYI7GAGGGGTIT[~wllGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACG
GGTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
203 amino acid truncation of GFP (Bbsl linker underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAAYJ7AATACGACTCACTA
TAGGGAGACCACAACGGTI1?CCCTCTAGAAATAAYLJGTTTAAC'JTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTThTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGYTAATGGGCACAAA = 1CTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACYJACCCTTAAAFITATT7GCACTACTGGAAAACTACCTGTfC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCY1TCAAGATACCC
GGATCATATGAAACGGCATGACT =rCAAGAGTGCCATGCCCGAAGGTrATGTACA
GGAAAGAACTATAFTTCAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCA
AGTTTGAAGGTGATACCCYTGTTAATAGAATCGAGTTAAAAGGTKFJ7GAT1AAAG
AAGATGGAAACATTCTTGGACACAAATTGGAATACAACTATAACTCACACAATGTAT
ACATCATGGCAGACAAACAAAAGAATGGAATCAAAGTTAACY7CAAAATTAGACAC
AACATTGAAGATGGAAGCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAAJ7
GGCGATGGCCCTGTCC=ITACCAGACAACCATACCTGTCCACATCACAGAATAATG
GGTCTI7CATAATAGATTCCAGCACACTGGCGGCCG7FTACTAGTGGATCCGGCTGCTA
ACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCAT
AACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGG1T1'I=GCTGAAAGGAGGAACTA
TATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCT
CCAAGTAGCGAA
250 amino acid truncation of GFP (Bbsl linker underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGG =[CCCTCTAGAAATAA =TJGTTTAACTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACT1=TCACTGGAGTJ7GTCCCAAT17CT7GTTGAA
UTAGATGGTGATGT7AATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTrACCCTrAAAYTTAYTTGCACTACTGGAAAACTACCTGrrC
CATGGCCAACACTTGTCACTAJTCTCTTATGGTGU7CAATGCTF=rCAAGATACCC
GGATCATATGAAACGGCATGACTTJCAAGAGTGCCATGCCCGAAGGUTATGTACA
GGAAAGAACTATAYI1=rCAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCA
AGTTrGAAGGTGATACCCTGTFJAATAGAATCGAGTTAAAAGGTAYJ7GA=IJAAAG
AAGATGGAAACATTCTTGGACACAAATTGGAATACAACTATAACTCACACAATGTAT
ACATCATGGCAGACAAACAAAAGAATGGAATCAAAGTTAACTTCAAAATTAGACAC
AACATTGAAGATGGAAc3CGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATT
GGCGATGGCCCTGTCC =TLACCAGACAACCATITACCTGTCCACACAATCTGCCCTTT
CGAAAGATCCCAACGAAAAGAGAGACCACATGGTCCTTCYJ7GAG1TTGTAACAGCTG
CTGGGAYTACACATGGCATGGATGAACTGTACCAACCCTCACAGAATAATGGGTCJ7C
ATAATAGATTCCAGCACACTGGCGGCCGTJIACTAGTGGATCCGGCTGCTAACAAAGC
CCGAAAGGAAGCGAGTTrGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTT
GGGGCCTCTAAACGGGTCTTGAGGGGT~fT =GCTGAAAGGAGGAACTATATCCGGA
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TATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAG
CGAA
Truncated GFP constructs with S1
35_S1 (Bbsl linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAA TTCTGTCAGTGGAGAGGGTGAAGGTTCA
CAGAATAATGATGATGACGATAAGAATAAAGTTAAGAAACCACTTACAGGAGCAC
ATAGACTATTGTTCACTTTTTTATTTGTATAATAGAACCCCGGGTCTTCATAATAG
ATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAG
GAAGCGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCT
CTAAACGGGTCTTGAGGGGTITITGCTGAAAGGAGGAACTATATCCGGATATCCAC
AGGACGGGTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
43_S1 (Bbs1 linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCTCACAGAATAATGATGATGACGATAAGAATAAAGT
TAAGAAACCACTTACAGGAGCACATAGACTATTGTTCACTTTTTTATTTGTATAA
TAGAACCCCGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTGGAT
CCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGCAA
TAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTITITGCTGAAA
GGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTC
GATAGTGGCTCCAAGTAGCGAA
57_S1 (Bbsl linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGTCACAGAATAATGATGATGACGATAAGAATAAAGTTAAGAAACCACTTAC
AGGAGCACATAGACTATTGTTCACTTTTTTATTTGTATAATAGAACCCCGGGTCTT
CATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAG
CCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCT
TGGGGCCTCTAAACGGGTCTTGAGGGGTITITGCTGAAAGGAGGAACTATATCCGG
ATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTA
GCGAA
70_- S1 (BbsI linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTCACTGGAGTFGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
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GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTCTCTATGGTGTTCAATGCTCACAGAATAATGA
TGATGACGATAAGAATAAAGTTAAGAAACCACTTACAGGAGCACATAGACTATT
GTTCACTTTTTTATTTGTATAATAGAACCCCGGGTCTTCATAATAGATTCCAGCAC
ACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGT
TGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGG
TCTTGAGGGGTTTGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGT
GTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
82_S1 (Bbsl linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTTCAAGATACCC
GGATCATATGAAACGGCATGACTCACAGAATAA TGATGATGACGATAAGAATAAAG
TTAAGAAACCACTTACAGGAGCACATAGACTATTGTTCACTTTTTTATTTGTATA
ATAGAACCCCGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTGGA
TCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGCA
ATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTITTGCTGAA
AGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGT
CGATAGTGGCTCCAAGTAGCGAA
95_S1 (Bbs1 linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTTTCAAGATACCC
GGATCATATGAAACGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACA
GGAATCACAGAATAATGATGATGACGATAAGAATAAAGTTAAGAAACCACTTACA
GGAGCACATAGACTATTGTTCACTTTTTTATTTGTATAATAGAACCCCGGGTCTTC
ATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGC
CCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTT
GGGGCCTCTAAACGGGTCTTGAGGGGTITTTGCTGAAAGGAGGAACTATATCCGGA
TATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAG
CGAA
139_S1 (Bbsl linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTT7CTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTTTTCAAGATACCC
GGATCATATGAAACGGCATGACT=ITTCAAGAGTGCCATGCCCGAAGGTTATGTACA
GGAAAGAACTATATTCAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCA
AGTTTGAAGGTGATACCCTTGTTAATAGAATCGAGTTAAAAGGTATTGATTTTAAAG
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AAGATGGAAACATTCTTGGACACTCACAGAATAATGATGATGACGATAAGAATAAA
GTTAAGAAACCACTTACAGGAGCACATAGACTATTGTTCACTTTTTTATTTGTAT
AATAGAACCCCGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTGG
ATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGC
AATAACTAGCATAACCCCYJ'GGGGCCTCTAAACGGGTCT[GAGGGGTT =GCTGA
AAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTA
GTCGATAGTGGCTCCAAGTAGCGAA
203-Sl (Bbsl linker underlined, Si bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTI17CCCTCTAGAAATAAY=ITT~ITAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTYI17CACTGGAGTfGTCCCAATTCTTGYTGAA
YrAGATGGTGATGTrAATGGGCACAAAYI=fCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAAYLTATITGCACTACTGGAAAACTACCTGFTC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCYP= CAAGATACCC
GGATCATATGAAACGGCATGACTIT=TCAAGAGTGCCATGCCCGAAGGT7ATGTACA
GGAAAGAACTATATIT=TCAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCA
AGTITGAAGGTGATACCCTTGYTAATAGAATCGAGTTAAAAGGTAYTGAYI=fAAAG
AAGATGGAAACATTCTTGGACACAAATTGGAATACAACTATAACTCACACAATGTAT
ACATCATGGCAGACAAACAAAAGAATGGAATCAAAGTTAACTrCAAAATrAGACAC
AAGATTGAAGATGGAAGCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATr
GGCGATGGCCCTGTCCT1TACCAGACAACCATACCTGTCCACATCACAGAATAATG
ATGATGACGATAAGAATAAAGTTAAGAAACCACTTACAGGAGCACATAGACTAT
TGTTCACTTTTTTATTTGTATAATAGAACCCCGGGTCTTCATAATAGATrCCAGCA
CACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAG
TrGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGG
GTCTrGAGGGGTrF1=rGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGG
TGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
250 -S1 (Bbsl linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTCCCTCTAGAAATAA = TTITAACYITAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTCACTGGAGTGTCCCAACTGUTGAA
TTJAGATGGTGATGTTAATGGGCACAAAT = CTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGUTC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCFF=rCAAGATACCC
GGATCATATGAAACGGCATGACYTL=TCAAGAGTGCCATGCCCGAAGGT7ATGTACA
GGAAAGAACTATATJT=TCAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCA
AGTTrGAAGGTGATACCCTTGTTAATAGAATCGAGTTAAAAGGTAGAmI'pwAAA
AAGATGGAAACATTCTTGGACACAAATTGGAATACAACTATAACTCACACAATGTAT
ACATCATGGCAGACAAACAAAGAATGGAATCAAAGTTAACTrCAAAATTAGACAC
AACATTGAAGATGGAAGCGTTCAACTAGCAGACCATrATCAACAAAATACTCCAATI7
GGCGATGGCCCTGTCCTTTACCAGACAACCATTACCTGTCCACACAATCTGCCCyfl'
CGAAAGATCCCAACGAAAAGAGAGACCACATGGTCCTrCTGAGFJTGTAACAJCTG
CTGGGATTACACATGOCATGGATGAACTGTACCAACCCTCACAGAATAATGATGATG
ACGATAAGAATAAAGTTAAGAAACCACTTACAGGAGCACATAGACTATTGTTCA
CTTTTTTATTTGTATAATAGAACCCCGGGTCTTCATAATAGATTCCAGCACACTGGC
GGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTrGGCTG
CTGCCACCGCTGAGCAATAACTAGCATAACCCCTGGGGCCTCTAAACGGGTyj'GA
240
GGGGITITITGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTC
GCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
Truncated GFP constructs with stop codons inserted before Si
35_S1_stopjns (Bbsl linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAAT1TTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAAYTTCTGTCAGTGGAGAGGGTGAAGGTTAA
TAGAATAATGATGATGACGATAAGAATAAAGTTAAGAAACCACTTACAGGAGCA
CATAGACTATTGTTCACTTTTTTATTTGTATAATAGAACCCCGGGTCTTCATAATA
GATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAA
GGAAGCGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCC
TCTAAACGGGTCTTGAGGGGITT =TGCTGAAAGGAGGAACTATATCCGGATATCCA
CAGGACGGGTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
43_S1_stopjns (Bbsl linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTGTTTAACTITAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACYTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCTAATAGAATAATGATGATGACGATAAGAATAAAGT
TAAGAAACCACTTACAGGAGCACATAGACTATTGTTCACTTTTTTATTTGTATAA
TAGAACCCCGGGTCTTCATAATAGAT7CCAGCACACTGGCGGCCGTTACTAGTGGAT
CCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGCAA
TAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGITITITGCTGAAA
GGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTC
GATAGTGGCTCCAAGTAGCGAA
57_S1_stopjns (Bbs1 linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGTAATAGAATAATGATGATGACGATAAGAATAAAGTTAAGAAACCACTTAC
AGGAGCACATAGACTATTGTTCACTTTTTTATTTGTATAATAGAACCCCGGGTCTT
CATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAG
CCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCT
TGGGGCCTCTAAACGGGTCTTGAGGGGTTTIGCTGAAAGGAGGAACTATATCCGG
ATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTA
GCGAA
70_Slstopins (Bbsl linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATFTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
241
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTAATAGAATAATGA
TGATGA CGATAAGAATAAAGTTAAGAAACCACTTACAGGAGCACATAGACTATT
GTTCACTTTTTTATTTGTATAATAGAACCCCGGGTCTTCATAATAGATTCCAGCAC
ACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGT
TGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCT7GGGGCCTCTAAACGGG
TCTTGAGGGGTThJTTGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGT
GTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
82_S1_stop-ins (Bbsl linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTTTTCAAGATACCC
GGATCATATGAAACGGCATGACTAATAGAATAATGATGATGACGATAAGAATAAA
GTTAAGAAACCACTTACAGGAGCACATAGACTATTGTTCACTTTTTTATTTGTAT
AATAGAACCCCGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTGG
ATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGC
AATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGA
AAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTA
GTCGATAGTGGCTCCAAGTAGCGAA
95_S1_stop-ins (Bbs1 linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTT7TCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTTTTCAAGATACCC
GGATCATATGAAACGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACA
GGAATAA TAGAATAATGATGATGACGATAAGAATAAAGTTAAGAAACCACTTACA
GGAGCACATAGACTATTGTTCACTTTTTTATTTGTATAATAGAACCCCGGGTCTTC
ATAATAGA'TTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGC
CCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTT
GGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGA
TATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAG
CGAA
139_Sistop-ins (Bbsl linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTTTTCAAGATACCC
GGATCATATGAAACGGCATGACTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACA
GGAAAGAACTATATTTTTCAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCA
AGTTTGAAGGTGATACCCTTGTTAATAGAATCGAGTTAAAAGGTATTGATTTTAAAG
242
AAGATGGAAACATTCTTGGACACTAATAGAATAATGATGATGACGATAAGAATAAA
GTTAAGAAACCACTTACAGGAGCACATAGACTATTGTTCACTTTTTTATTTGTAT
AATAGAACCCCGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTGG
ATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGC
AATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTITITGCTGA
AAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTA
GTCGATAGTGGCTCCAAGTAGCGAA
203_S1_stop-ins (Bbs1 linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCT=TTCAAGATACCC
GGATCATATGAAACGGCATGACTTCAAGAGTGCCATGCCCGAAGGTTATGTACA
GGAAAGAACTATATTTTCAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCA
AGTTTGAAGGTGATACCCTTGTTAATAGAATCGAGTTAAAAGGTATTGATTAAAG
AAGATGGAAACATTCTTGGACACAAATTGGAATACAACTATAACTCACACAATGTAT
ACATCATGGCAGACAAACAAAAGAATGGAATCAAAGTTAACTTCAAAATTAGACAC
AACATTGAAGATGGAAGCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATT
GGCGATGGCCCTGTCCTTACCAGACAACCATTACCTGTCCACATAATAGAATAATG
ATGATGACGATAAGAATAAAGTTAAGAAACCACTTACAGGAGCACATAGACTAT
TGTTCACTTTTTTATTTGTATAATAGAACCCCGGGTCTTCATAATAGATTCCAGCA
CACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAG
TTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGG
GTCTTGAGGGG.ITITTGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGG
TGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
250_S1_stopins (Bbsl linker underlined, S1 bold and underlined)
ATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAG
ATATACCATGACTAAAGGTGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAA
TTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGAT
GCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTC
CATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTTTTCAAGATACCC
GGATCATATGAAACGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACA
GGAAAGAACTATATTTTTCAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCA
AGTTTGAAGGTGATACCCTTGTTAATAGAATCGAGTTAAAAGGTATTGATJTAAAG
AAGATGGAAACATTCTTGGACACAAATTGGAATACAACTATAACTCACACAATGTAT
ACATCATGGCAGACAAACAAAAGAATGGAATCAAAGTTAACTTCAAAATTAGACAC
AACATTGAAGATGGAAGCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATT
GGCGATGGCCCTGTCCTTTACCAGACAACCATTACCTGTCCACACAATCTGCCCTTT
CGAAAGATCCCAACGAAAAGAGAGACCACATGGTCCT7CTTGAGTTTGTAACAGCTG
CTGGGATTACACATGGCATGGATGAACTGTACCAACCCTAATAGAATAATGATGATG
ACGATAAGAATAAAGTTAAGAAACCACTTACAGGAGCACATAGACTATTGTTCA
CTTTTTTATTTGTATAATAGAACCCCGGGTCTTCATAATAGATTCCAGCACACTGGC
GGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTG
CTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGA
243
GGGGTIT TGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTC
GCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
Truncated Luciferase constructs
36 amino acid truncation of Luciferase (Bbsl linker underlined)
TGGTCCGGTAACGTGCTGAGCCCGGCCAAGCTTACTCCCCATCCCCCTGTTGACAATT
AATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAA
ACAGGATCCAAATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTAT
CCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGC
CCTGGTTTCACAGAATAATGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTA
CTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACC
GCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTT
TTGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGAT
CGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
51 amino acid truncation of Luciferase (Bbsl linker underlined)
TGGTCCGGTAACGTGCTGAGCCCGGCCAAGCTTACTCCCCATCCCCCTGTTGACAATT
AATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAA
ACAGGATCCAAATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTAT
CCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGC
CCTGGTTCCTGGAACAATTGCTTTACAGATGCACATATCGAGGTGAACATCTCACA
GAATAATUGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTGGATCC
GGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGCAATA
ACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTlTITGCTGAAAGG
AGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTCGA
TAGTGGCTCCAAGTAGCGAA
69 amino acid truncation of Luciferase (Bbsl linker underlined)
TGGTCCGGTAACGTGCTGAGCCCGGCCAAGCTTACTCCCCATCCCCCTGT7GACAATT
AATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAA
ACAGGATCCAAATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTAT
CCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGC
CCTGGTTCCTGGAACAATTGCTTTTACAGATGCACATATCGAGGTGAACATCACGTA
CGCGGAATACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATCACAGAA
TAATGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGGCT
GCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGCAATAACTA
GCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGT= IGCTGAAAGGAGGA
ACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTCGATAGT
GGCTCCAAGTAGCGAA
83 amino acid truncation of Luciferase (Bbsl linker underlined)
TGGTCCGGTAACGTGCTGAGCCCGGCCAAGCTTACTCCCCATCCCCCTGTTGACAATT
AATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAA
ACAGGATCCAAATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTAT
CCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGC
CCTGGTTCCTGGAACAATTGCTTTTACAGATGCACATATCGAGGTGAACATCACGTA
CGCGGAATACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCT
244
GAATACAAATCACAGAATCGTCGTATGCAGTGAATCACAGAATAATGGGTCTTCATA
ATAGATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCG
AAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGG
GCCTCTAAACGGGTCTTGAGGGGTITITGCTGAAAGGAGGAACTATATCCGGATAT
CCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGA
A
101 amino acid truncation of Luciferase (Bbsl linker underlined)
TGGTCCGGTAACGTGCTGAGCCCGGCCAAGCTTACTCCCCATCCCCCTGTTGACAATT
AATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAA
ACAGGATCCAAATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTAT
CCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGC
CCTGGTTCCTGGAACAATTGCTTTACAGATGCACATATCGAGGTGAACATCACGTA
CGCGGAATACTTCGAAATGTCCGTTCGGT7GGCAGAAGCTATGAAACGATATGGGCT
GAATACAAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGCC
GGTGTTGGGCGCGTTATTFATCGGAGTTGCATCACAGAATAATGGGTCTTCATAATAG
ATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAG
GAAGCGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCT
CTAAACGGGTCTTGAGGGGTTITIGCTGAAAGGAGGAACTATATCCGGATATCCAC
AGGACGGGTGTGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
129 amino acid truncation of Luciferase (Bbsl linker underlined)
TGGTCCGGTAACGTGCTGAGCCCGGCCAAGCTTACTCCCCATCCCCCTGTTGACAATT
AATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAA
ACAGGATCCAAATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTAT
CCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGC
CCTGGTTCCTGGAACAATFGCTTTACAGATGCACATATCGAGGTGAACATCACGTA
CGCGGAATACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCT
GAATACAAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGCC
GGTGTTGGGCGCGTTATTTATCGGAGTTGCAGT7GCGCCCGCGAACGACATTTATAA
TGAACGTGAATTGCTCAACAGTATGAACATTTCGCAGCCTACCGTAGTGTTTGTTTCC
TCACAGAATAATGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTG
GATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCTGAG
CAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTITITUCTG
AAAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGT
AGTCGATAGTGGCTCCAAGTAGCGAA
169 amino acid truncation of Luciferase (Bbsl linker underlined)
TGGTCCGGTAACGTGCTGAGCCCGGCCAAGCTTACTCCCCATCCCCCTGTTGACAATT
AATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAA
ACAGGATCCAAATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTAT
CCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGC
CCTGGTTCCTGGAACAATTGCTTTTACAGATGCACATATCGAGGTGAACATCACGTA
CGCGGAATACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCT
GAATACAAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGCC
GGTGTTGGGCGCGTTATTTATCGGAGTTGCAGTTGCGCCCGCGAACGACATTTATAA
TGAACGTGAATTGCTCAACAGTATGAACATTTCGCAGCCTACCGTAGTGTTTGTTTCC
AAAAAGGGGTTGCAAAAAATTTGAACGTGCAAAAAAAATTACCAATAATCCAGAA
AATTATTATCATGGATTCTAAAACGGATTACCAGGGATTTCAGTCGATGTACACGTTC
245
GTCACATCACAGAATAATGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTA
CTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACG
GCTGAGCAATAACTAGCATAACCCCTrGGGGCCTCTAAACGGGTCTTGAGGGG =L
YL'GCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGAT
CGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
211 amino acid truncation of Luciferase (Bbsl linker underlined)
TGGTCCGGTAACGTGCTGAGCCCGGCCAAGCTTACTCCCCATCCCCCTGYJ7GACAAYT
AATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAA
ACAGGATCCAAATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTAT
CCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGC
CCTGGTJ7CCTGGAACAATTGC =TJACAGATGCACATATCGAGGTGAACATCACGTA
CGCGGAATACTTCGAAATGTCCcrTrCGGYrGGCAGAAGCTATGAAACGATATGGGCT
GAATACAAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTrCAATrCTTrATGCC
GGGTGCCTATACGGTCGTCCCCACAATAA
TGAACGTGAATTGCTCAACAGTATGAACATTTCGCAGCCTACCGTAGTGTITGTLTCC
AAAAAGGGGTTGCAAAAAAT =rGAACGTGCAAAAAAAATTACCAATAATCCAGAA
AATTATATCATGGATTCTAAAACGGATTACCAGGGATTTCAGTCGATGTACACGTTC
GTCACATCTCATCTACCTCCCGG =ITAATGAATACGAT= GTACCAGAGTCCYI'TG
ATCGTGACAAAACAAYJ7GCACTGATAATGAATTCCTCTGGATCTACTGGGTTACCTA
AGGGTGTGGCCCTI7CCGTCACAGAATAATGGGTCTTCATAATAGATTCCAGCACACT
GGCGGCCGTTACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGG
CTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCT
TGAGGGGY'i1rr11GCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTG
GTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
339 amino acid truncation of Luciferase (Bbsl linker underlined)
TGGTCCGGTAACGTGCTGAGCCCGGCCAAGCTTACTCCCCATCCCCCTGTTGACAATr
AATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAA
ACAGGATCCAAATGGAAGACGCCAAAAACATAAAGAAAGcJCCCGGCGCCATTCTAT
CCTCTAGAGGATGGAACGGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGC
CCTGGT7CCTGGAACAArrGCFI=rACAGATGCACATATCGAGGTGAACATCACGTA
CGCGGAATACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCT
GAATACAAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTLTATGCC
GGTGTTGGGCGCGTTAYITATCGGAGTFGCAGTrGCGCCC3CGAACcIACA1TTATAA
TGAACGTGAATTGCTCAACAGTATGAACATTTCGCAGCCTACCGTAGTGTGYI1CC
AAAAAGGGGTTGCAAAAAAYI=FGAACGTGCAAAAAAAATrACCAATAATCCAGAA
AATJ7ATTATCATGGATTCTAAAACGGATTACCAGGGATTTCAGTCGATGTACACGTTC
GTCACATCTCATCTACCTCCCGGYI=rAATGAATACGATI=rGTACCAGAGTCCTLTG
ATCGTGACAAAACAATrGCACTGATAATGAATI'CCTCTGGATCTACTGGGTTACCTA
AGGGTGTGGCCCTTCCGCATAGAACTGCCTGCGTCAGArrCTCGCATGCCAGAGATC
CTAT = rGGCAATCAAATCATrCCGGATACTGCGAFI=IAAGTGTTGTTCCATTCCA
TCACGGTTTGGAATGTJ7ACTACACTCGGATATTrGATATGTGGArrrCGAGTCGTC
TTAATGTATAGATTTGAAGAAGAGCTGTI =rACGATCCCTTCAGGATACAAATTFC
AAAGTGCGTrGCTAGTACCAACCCTATTTTCATTCTTCGCCAAAAGCACTCTGATrGA
CAAATACGATTTATCTAATI-rACACGAAATTGCTTCTGGGGGCGCACCTC1TTCGAAA
GAAGTCGGGGAAGCGGFJ7GCAAAACGCTTCCATCYJ7CCAGGGATACGACAAGGATC
ACAGAATAATGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTTACTAGTGGA
TCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCACCGCT3AGCA
ATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTT =GCTGAA
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AGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGT
CGATAGTGGCTCCAAGTAGCGAA
437 amino acid truncation of Luciferase (Bbsl linker underlined)
TGGTCCGGTAACGTGCTGAGCCCGGCCAAGCTTACTCCCCATCCCCCTGTTGACAATT
AATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAA
ACAGGATCCAAATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTAT
CCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGC
CCTGGTTCCTGGAACAATTGCTTTTACAGATGCACATATCGAGGTGAACATCACGTA
CGCGGAATACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCT
GAATACAAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGCC
GGTGTTGGGCGCGTTATTTATCGGAGTTGCAGTTGCGCCCGCGAACGACATTTATAA
TGAACGTGAATTGCTCAACAGTATGAACATTCGCAGCCTACCGTAGTGTTTGTTTCC
AAAAAGGGGTTGCAAAAAATTTTGAACGTGCAAAAAAAATTACCAATAATCCAGAA
AATTATTATCATGGATTCTAAAACGGATTACCAGGGATTTCAGTCGATGTACACGTTC
GTCACATCTCATCTACCTCCCGGTTAATGAATACGATTTTGTACCAGAGTCCTTTG
ATCGTGACAAAACAATTGCACTGATAATGAATTCCTCTGGATCTACTGGGTTACCTA
AGGGTGTGGCCCTTCCGCATAGAACTGCCTGCGTCAGATTCTCGCATGCCAGAGATC
CTATT GGCAATCAAATCATTCCGGATACTGCGATTTTAAGTGTTGTTCCATTCCA
TCACGGTITrGGAATGTTTACTACACTCGGATATTTGATATGTGGATTCGAGTCGTC
TTAATGTATAGATTTGAAGAAGAGCTGTTTACGATCCCTTCAGGATTACAAAATTC
AAAGTGCGTTGCTAGTACCAACCCTATTTTCATTCTTCGCCAAAAGCACTCTGATTGA
CAAATACGATTTATCTAATTTACACGAAATTGCTTCTGGGGGCGCACCTCTTCGAAA
GAAGTCGGGGAAGCGGTTGCAAAACGCTTCCATCTTCCAGGGATACGACAAGGATA
TGGGCTCACTGAGACTACATCAGCTATTCTGATTACACCCGAGGGGGATGATAAACC
GGGCGCGGTCGGTAAAGTTGTTCCATTITITGAAGCGAAGGTTGTGGATCTGGATAC
CGGGAAAACGCTGGGCGTTAATCAGAGAGGCGAATTATGTGTCAGAGGACCTATGA
TTATGTCCGGTTATGTAAACAATCCGGAAGCGACCAACGCCTTGATTGACAAGGATG
GATGGCTACATTCTGGAGACATAGCTTACTGGGACGAAGACGAACACTTCTTCATAG
TTGACCGCTCACAGAATAATGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGTT
ACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCAC
CGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTT
TTTGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGA
TCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
550 amino acid truncation of Luciferase (Bbsl linker underlined)
TGGTCCGGTAACGTGCTGAGCCCGGCCAAGCTTACTCCCCATCCCCCTGTTGACAATT
AATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAA
ACAGGATCCAAATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTAT
CCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGC
CCTGGTTCCTGGAACAATTGCYTTACAGATGCACATATCGAGGTGAACATCACGTA
CGCGGAATACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCT
GAATACAAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGCC
GGTGTTGGGCGCGTTATTTATCGGAGTTGCAGTTGCGCCCGCGAACGACATTTATAA
TGAACGTGAATTGCTCAACAGTATGAACATTCGCAGCCTACCGTAGTGTTTGTITCC
AAAAAGGGGTTGCAAAAAATTTTGAACGTGCAAAAAAAATTACCAATAATCCAGAA
AATTATTATCATGGATTCTAAAACGGATTACCAGGGATTTCAGTCGATGTACACGTTC
GTCACATCTCATCTACCTCCCGGTTTTAATGAATACGATTTTGTACCAGAGTCCTTTG
ATCGTGACAAAACAATTGCACTGATAATGAATTCCTCTGGATCTACTGGGTTACCTA
AGGGTGTGGCCCTTCCGCATAGAACTGCCTGCGTCAGATTCTCGCATGCCAGAGATC
247
CTAT=GGCAATCAAATCATTCCGGATACTGCGATTTTAAGTGTTGTTCCATTCCA
TCACGGT=GGAATGTTTACTACACTCGGATATTTGATATGTGGATTTCGAGTCGTC
TTAATGTATAGATTTGAAGAAGAGCTGT = ACGATCCCTTCAGGATTACAAAATTC
AAAGTGCGTTGCTAGTACCAACCCTATTTTCATTCTTCGCCAAAAGCACTCTGATTGA
CAAATACGATTTATCTAATTTACACGAAATTGCTTCTGGGGGCGCACCTCTTTCGAAA
GAAGTCGGGGAAGCGGTTGCAAAACGCTTCCATCTTCCAGGGATACGACAAGGATA
TGGGCTCACTGAGACTACATCAGCTATTCTGATTACACCCGAGGGGGATGATAAACC
GGGCGCGGTCGGTAAAGTTGTTCCATT = GAAGCGAAGGTFGTGGATCTGGATAC
CGGGAAAACGCTGGGCGTTAATCAGAGAGGCGAATTATGTGTCAGAGGACCTATGA
TTATGTCCGGTTATGTAAACAATCCGGAAGCGACCAACGCCTTGATTGACAAGGATG
GATGGCTACATrCTGGAGACATAGCTTACTGGGACGAAGACGAACACTTCTrCATAG
TTGACCGCTTGAAGTCTTTAATrAAATACAAAGGATATCAGGTGGCCCCCGCTGAAT
TGGAATCGATATTGTTACAACACCCCAACATCTTCGACGCGGGCGTGGCAGGTCTTC
CCGACGATGACGCCGGTGAACTTCCCGCCGCCGTTGTTGTTTTGGAGCACGGAAAGA
CGATGACGGAAAAAGAGATCGTGGATTACGTGGCCAGTCAAGTAACAACCGCGAAA
AAGTTGCGCGGAGGAGTTGTGTTTGTGGACGAAGTACCGAAAGGTCTTACCGGAAA
ACTCGACGCAAGAAAAATCAGAGAGATCCTCATAAAGGCCAAGAAGGGCGGAAAGT
CCAAATTGTCACAGAATAATGGGTCTTCATAATAGATTCCAGCACACTGGCGGCCGT
TACTAGTGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCGAGTTGGCTGCTGCCAC
CGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTT
TTrGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGA
TCGCGTAGTCGATAGTGGCTCCAAGTAGCGAA
248
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